US20060235204A1 - BMP-2 variants with improved properties - Google Patents

BMP-2 variants with improved properties Download PDF

Info

Publication number
US20060235204A1
US20060235204A1 US11/471,893 US47189306A US2006235204A1 US 20060235204 A1 US20060235204 A1 US 20060235204A1 US 47189306 A US47189306 A US 47189306A US 2006235204 A1 US2006235204 A1 US 2006235204A1
Authority
US
United States
Prior art keywords
bmp
variants
yield
protein
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/471,893
Inventor
John Desjarlais
Shannon Marshall
Jonathan Zalevsky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xencor Inc
Original Assignee
Xencor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc filed Critical Xencor Inc
Priority to US11/471,893 priority Critical patent/US20060235204A1/en
Publication of US20060235204A1 publication Critical patent/US20060235204A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the invention relates to variants of bone morphogenetic proteins and other cysteine knot growth factors with improved properties, and to methods of making and using compositions utilizing these variants.
  • Bone morphogenetic proteins are a well-known family of growth factors that contribute to developmental processes such as pattern formation and tissue specification as well as promoting wound healing and repair processes in adult tissues. BMPs were initially isolated by their ability to induce bone and cartilage formation and are now known to regulate cell proliferation, migration, differentiation, and apoptosis in a number of tissues and organs.
  • BMPs include a number of related human proteins, such as BMP-2, BMP-3 (osteogenin), BMP-3b (GDF-10), BMP-4 (BMP-2b), BMP-5, BMP-6, BMP-7 (osteogenic protein-1 or OP-1), BMP-8 (OP-2), BMP-8B (OP-3), BMP-9 (GDF-2), BMP-10, BMP-11 (GDF-11), BMP-12 (GDF-7), BMP-13 (GDF-6, CDMP-2), BMP-15 (GDF-9), BMP-16, GDF-1, GDF-3, GDF-5 (CDMP-1), and GDF-8 (myostatin).
  • BMPs may be grouped into subfamilies.
  • BMP-2 and BMP-4 are closely related, as are BMP-5, BMP-6, BMP-7, BMP-8, and BMP-8B.
  • BMP-13, BMP-14, and BMP-12 also constitute a subfamily.
  • BMPs are also present in other animal species.
  • allelic variation in BMP sequences among different members of the human population is also considered.
  • BMPs are a subset of the transforming growth factor- ⁇ (TGF- ⁇ ) family, which also includes TGFs (TGF- ⁇ 1, TGF- ⁇ 2, and TGF- ⁇ 3), activins (activin A) and inhibins, macrophage inhibitory cytokine-1 (MIC-1), Mullerian inhibiting substance, anti-Mullerian hormone, and glial cell line derived neurotrophic factor (GDNF).
  • TGF- ⁇ family is in turn a subset of the cysteine knot cytokine superfamily.
  • cysteine knot cytokine superfamily include, but are not limited to, platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), placenta growth factor (PIGF), noggin, neurotrophins (BDNF, NT3, NT4, and ⁇ NGF), gonadotropin, follitropin, lutropin, interleukin-17, and coagulogen.
  • PDGF platelet derived growth factor
  • VEGF vascular endothelial growth factor
  • PIGF placenta growth factor
  • noggin neurotrophins
  • BDNF neurotrophins
  • NT3, NT4, and ⁇ NGF neurotrophins
  • gonadotropin gonadotropin
  • follitropin lutropin
  • interleukin-17 interleukin-17
  • coagulogen coagulogen.
  • BMPs have demonstrated utility in the treatment of a variety of conditions and diseases.
  • BMP-2 and BMP-7 have been used to promote bone formation, bone fracture healing, and spinal fusion.
  • BMP-4 Redet. al. (2003) Bone 32: 591-601
  • BMP-5 Adrena and Collins (2003) Arch. Otolaryngol. Head Neck Surg. 129: 1125-1130
  • BMP-6 Helm (2003) Gene Ther. 10: 1735-1743
  • BMP-9 Li et. al. (2003) J. Gene Med. 5: 748-756
  • Animal studies indicate that BMP-7 may be used to treat renal fibrosis and renal failure (Wang et. al.
  • BMPs are dimeric cysteine knot proteins. Each BMP monomer comprises multiple intramolecular disulfide bonds. An additional intermolecular disulfide bond mediates dimerization in most BMPs. BMPs may form homodimers; furthermore some BMPs may form heterodimers. BMPs are expressed as pro-proteins comprising a long pro-domain, one or more cleavage sites, and a mature domain. The pro-domain is believed to aid in the correct folding and processing of BMPs. Furthermore, in some but not all BMPs, the pro-domain may noncovalently bind the mature domain and may act as an inhibitor (eg. Thies et. al. (2001) Growth Factors 18: 251-259).
  • Type I receptors include but are not limited to ALK-1, ALK-2 (also called ActRIa or ActRI), ALK-3 (also called BMPRIa), and ALK-6 (also called BMPRIb) and type II receptors include but are not limited to ActRIIa (also called ActRII), ActRIIb, and BMPRII.
  • the type II receptors phosphorylate the type I receptors, the type I receptors phosphorylate members of the Smad family of transcription factors, and the Smads translocate to the nucleus and activate the expression of a number of genes.
  • BMPs also interact with inhibitors, soluble receptors, and decoy receptors, including BAMBI (BMP and activin membrane bound inhibitor), BMPER (BMP-binding endothelial cell precursor-derived regulator), Cerberus, cordin, cordin-like, Dan, Dante, follistatin, follistatin-related protein (FSRP), ectodin, gremlin, noggin, protein related to Dan and cerberus (PRDC), sclerostin, sclerostin-like, and uterine sensitization-associated gene-1 (USAG-1).
  • BAMBI BMP and activin membrane bound inhibitor
  • BMPER BMP-binding endothelial cell precursor-derived regulator
  • Cerberus cordin, cordin-like, Dan, Dante, follistatin, follistatin-related protein (FSRP), ectodin, gremlin, noggin, protein related to Dan and cerberus (PRDC), sclerost
  • BMPs may interact with co-receptors, for example BMP-2 and BMP-4 bind the co-receptor DRAGON (Samad et. al. (2005) J. Biol. Chem.), and extracellular matrix components such as heparin sulfate and heparin (Irie et. al. (2003) Biochem. Biophys. Res. Commun. 308: 858-865)
  • BMP expression yields are typically poor and suitable expression hosts are limited, hindering development and production.
  • BMPs often possess multiple biological effects, including unwanted side effects.
  • Many BMPs are poorly soluble, reducing storage stability and bioavailability.
  • BMPs may induce unwanted immune responses.
  • BMP variants with improved yield in the context of E. coli expression and subsequent refolding from inclusion bodies have been disclosed (U.S. Pat. No. 5,399,677; U.S. Pat. No. 5,804,416; and U.S. Pat. No. 6,677,432).
  • Consensus BMP variants with BMP-like activity have also been described (U.S. Pat. No. 5,011,691; U.S. Pat. No. 6,395,883; U.S. Pat. No. 6,531,445).
  • a BMP-2 point mutant, L51P has been described that does not bind type I receptors but binds type II receptors normally (Keller et. al.
  • the present invention is related to variants of human bone morphogenetic proteins and other cysteine knot cytokine proteins with improved properties, including increased expression yield, expression in the absence of a pro-domain, increased solubility, increased specific activity, altered receptor, co-receptor, and inhibitor specificity, and decreased immunogenicity.
  • the invention provides variant BMP-7 protein comprising the sequence: Fx(1-20)-Vb(21)-Fx(22-38)-Vb(39)-Fx(40-64)-Vb(65)-Fx(66-71)-Vb(72)-Fx(73-77)-Vb(78)-Fx(79-92)-Vb(93)-Fx(94-119)-Vb(120)-Fx(121-134)-Vb(135)
  • the invention provides variant BMP-7 proteins comprising a substitution as compared to human BMP-7 (SEQ ID NO:5) selected from the group consisting of: L21G, K39A, K39S, Y65N, A72D, Y78H, F93H, F93S, F93T, SI 20D and A135E.
  • substitutions include, L21G, K39A, K39S, Y65N, A72D, Y78H, F93H, F93S, F93T, S120D and A135E.
  • substitutions include, K39S-F93S; K39S-S120D; K39S-S120D-Y65N; K39S-S120D-A72D; K39S-S120D-Y78H; K39S-S120D-F93H; K39S-S120D-F93S; Y65N-L21G; Y65N-L21R; Y65N-K39S; Y65N-Y78H; Y65N-S120D; Y78H-A72D; Y78H-F93H-Y65N; Y78H-F93H-A72D; Y78H-F93H-S120D; Y78H-S120D and F93H-K39S.
  • the invention provides variant BMP-7 proteins having altered receptor binding affinity compared to wild-type BMP-7 (SEQ ID NO:5), the variant BMP-7 protein comprising one or more substitutions selected from the group consisting of: M23N, Q53G, Q53H and I86D.
  • FIG. 1 shows sequence alignments of the mature domains of human BMP and GDF proteins (Residues 14-114 of SEQ ID NO:1, residues 16-116 of SEQ ID NO:2, residues 37-138 of SEQ ID NO:3, residues 38-139 of SEQ ID NO:4, residues 38-139 of SEQ ID NO:5, residues 38-139 of SEQ ID NO:6 and SEQ ID NOS:71-83).
  • the consensus BMP sequence and the MIC-1 sequence are shown for reference.
  • the N-terminal most residues of the mature domain, which are significantly less well aligned, are not shown.
  • FIG. 2 shows the hexameric structure comprising BMP-7 dimer bound to two type I receptors and two type II receptors.
  • the structure was generated by superimposing BMP-2 (white) bound to ALK-3 (gray, upper right and lower left) and BMP-7 (black) bound to ActRIIa (gray, upper left and lower right).
  • FIG. 3 shows alignments of human type I BMP receptors and human type II BMP receptors used for homology modeling (SEQ ID NOS:7-12).
  • FIG. 4 shows 12-point binding curves for wild-type BMP-7 (Image clone) binding to ActRIIa, BMPRII, BMPRIa, and BMPRIb.
  • FIG. 5 shows 12-point binding curves for (A) BMPRIa (ALK-3), (B) BMPRIb (ALK-6), (C) ActRIIa, and (D) BMPRII.
  • the thick black lines are wild type BMP-7 (Image clone).
  • the thin gray lines correspond to variants.
  • FIG. 6 shows dose-response C2C12 biassay data for selected Library 1 variants.
  • Highlighted variants in (A) include: F93Q (black hollow circles), F93S (gray filled diamonds), N110D (gray filled squares), S120D (black hollow squares), A135E (black hollow triangles), A135S (black filled circles) and wild type (thick black line, no markers). Additional variants are shown in (A) and (B)
  • FIG. 7 shows 12-point binding curves for (A) BMPRIa (ALK-3), (B) BMPRIb (ALK-6), (C) ActRIIa, and (D) BMPRII.
  • A BMPRIa
  • B BMPRIb
  • C ActRIIa
  • D BMPRII
  • FIG. 8 shows a summary of 12-point receptor binding curves for wild type human BMP-7 (Image clone) and variants.
  • FIG. 9 shows dose-response C2C12 biassay data for selected Library 2 variants.
  • FIG. 10 shows dose-response C2C12 biassay data for selected Library 3 variants, Library 1 variants (thick gray lines, no markers), and wild type (thick black line, no markers).
  • FIG. 11 shows (A) ELISA quantitation of the expression yield of the best single, double, and triple variants in 293T cells (black bars) and CHO cells (white bars) and (B) that enhanced expression yield of the best-expressing single, double, and triple mutant variants results in increased C2C12 bioactivity from serially diluted conditioned media.
  • FIG. 12 shows appropriate correction factors when using a commercial ELISA (R&D Systems) to determine the concentration of selected BMP-7 variants.
  • FIG. 13 shows purification of selected BMP-7 variants.
  • FIG. 14 shows fluorescence images of SDS-PAGE gels showing (A) Alexa 568 labeling of BMP-7 variant Y65N/S120D as a function of dye concentration; and (B) scale-up of Alexa-568 labeled Y65N/S120D BMP-7.
  • FIG. 15 shows fluorescence anisotropy as a function of receptor concentration.
  • FIG. 16 shows that binding of Alexa568-labeled Y65N/S120D BMP-7 to the receptor ActRIIa can be competed with unlabeled BMP-7.
  • FIG. 17 shows competitive binding of (A) recombinant human BMP-7 (R&D Systems), (B) BMP-7 variant 565 (Y65N/F93T/R129D), (C) BMP-7 variant 526 (K39S/S120D/R134E), and (D) BMP-7 variant 504 (Y65N/S120D) to the BMP receptors and inhibitors BMPRIb (open circles), ActRIIa (closed diamonds), BMPRII (closed triangles), and Noggin (stars) determined using AlphaScreen.
  • BMPRIb open circles
  • ActRIIa closed diamonds
  • BMPRII closed triangles
  • Noggin stars
  • FIG. 18 shows a bar graph indicating the EC50 of binding for four BMP-7 variants to three receptors and one inhibitor.
  • BMP responsive disorders diseases, disorders, and conditions that may benefit from treatment with one or more BMPs.
  • BMP responsive disorders include, but are not limited to, cartilage, bone, and tooth disorders or conditions including but not limited to bone fractures, bone degeneration, osteoporosis, spinal fusion, spinal degenerative disc disease, osteotomy, orthopedic and reconstructive surgery, and periodontal disease; repair of tendons and ligaments; renal disease including but not limited to chronic or acute renal failure, renal injury due to reperfusion, drug-induced renal toxicity, renal fibrosis, renal osteodystrophy, and vascular complications resulting from kidney disease; liver disease including but not limited to cirrhosis and hepatic fibrosis; lung disease including but not limited to asthma, emphysema, and pulmonary fibrosis; wound healing; cancers including but not limited to prostate cancer; inflammatory bowel disease; conditions that would benefit from a neuroprotective agent including but not limited to stroke, Parkinson's disease
  • exposed residues and grammatical equivalents herein are meant those residues whose side chains have at least 50 ⁇ 2 (square Angstroms) of solvent accessible surface area in the context of a specified protein structure, preferably an x-ray crystal structure.
  • ⁇ 2 square Angstroms
  • other values such as 75 ⁇ 2 (square Angstroms) or fractional values such as 50% could be used instead.
  • alternative methods such as contact models, among others, may be used to identify exposed residues.
  • expression yield and grammatical equivalents herein is meant the amount of protein, preferably in mg/L or PCD (picograms per cell per day) that is produced or secreted under a given expression protocol (that is, a specific expression host, transfection method, media, time, etc.).
  • improved expression yield and grammatical equivalents herein is meant an increase in expression yield, relative to a wild type or parent protein, under a given set of expression conditions. In a preferred embodiment, at least a 50% improvement is achieved, with improvements of at least 100%, 5-fold, 10-fold, or more being especially preferred.
  • the expression yield is improved to yields of at least 1 ⁇ g/ml, with at least 10 ⁇ g/ml or 100 ⁇ g/ml being especially preferred.
  • hydrophobic residues and grammatical equivalents are meant valine, isoleucine, leucine, methionine, phenylalanine, tyrosine, and tryptophan.
  • interface residues and grammatical equivalents herein are meant those residues located within 8 ⁇ (Angstroms) of a protein-protein contact. Distances of less than 5 ⁇ (Angstroms) are especially preferred. Distances may be measured in the context of any structure, with high-resolution crystal structures being especially preferred.
  • library as used herein is meant a collection of protein sequences that are likely to take on a particular fold or have particular protein properties.
  • the library preferably comprises a set of sequences resulting from computation, which may include energy calculations or statistical or knowledge based approaches. Libraries that range in size from about 5 to about 10 13 sequences are preferred. Libraries are generally generated experimentally and analyzed for the presence of members possessing desired protein properties.
  • mature domain herein is meant, in the context of BMP-7, a domain substantially comprising residues 1-137 of BMP-7. In wild type BMP-7, the mature domain is cleaved from the pro-domain by furin or a furin-like proprotein convertase.
  • modification and grammatical equivalents is meant one or more insertions, deletions, or substitutions to a protein or nucleic acid sequence.
  • naturally occurring or “wild type” or “wt” and grammatical equivalents thereof herein is meant an amino acid sequence or a nucleotide sequence that is found in nature, including allelic variations. In a preferred embodiment, the wild type sequence is the most prevalent human sequence.
  • the wild type BMP nucleic acids and proteins may be a less prevalent human allele or BMP nucleic acids and proteins from any number of organisms, including but not limited to rodents (rats, mice, hamsters, guinea pigs, etc.), primates, and farm animals (including sheep, goats, pigs, cows, horses, etc).
  • rodents rats, mice, hamsters, guinea pigs, etc.
  • primates including sheep, goats, pigs, cows, horses, etc.
  • farm animals including sheep, goats, pigs, cows, horses, etc.
  • Nucleic acids include genomic DNA, cDNA and oligonucleotides including sense and anti-sense nucleic acids.
  • Nucleic acids may also contain modifications, such as modifications in the ribose-phosphate backbone that confer increased stability and half-life.
  • modifications such as modifications in the ribose-phosphate backbone that confer increased stability and half-life.
  • polar residues and grammatical equivalents herein are meant aspartic acid, asparagine, glutamic acid, glutamine, lysine, arginine, histidine, serine, and threonine.
  • pro-domain herein is meant, in the context of a BMP or other TGF- ⁇ family member, the N-terminal domain that is removed following cleavage by furin or a furin-like proprotein convertase. The presence of the pro-domain may promote proper folding and processing.
  • protein herein is meant a molecule comprising at least two covalently attached amino acids, which includes proteins, polypeptides, oligopeptides and peptides.
  • the protein may be made up of naturally occurring amino acids and peptide bonds, or synthetic peptidomimetic structures such as peptoids (see Simon et al. (1992) Proc. Natl. Acad. Sci. USA 89: 9367-9371).
  • peptoids see Simon et al. (1992) Proc. Natl. Acad. Sci. USA 89: 9367-9371).
  • homo-phenylalanine, citrulline, and noreleucine are considered amino acids for the purposes of the invention, and both D- and L-amino acids may be utilized.
  • protein properties herein are meant physical, chemical, and biological properties including but not limited to physical properties (including molecular weight, hydrodynamic properties such as radius of gyration, net charge, isoelectric point, and spectral properties such as extinction coefficient), structural properties (including secondary, tertiary, and quaternary structural elements) stability (including thermal stability, stability as a function of pH or solution conditions, storage stability, and resistance or susceptibility to ubiquitination, proteolytic degradation, or chemical modifications such as methionine oxidation, asparagine and glutamine deamidation, sidechain racemerization or epimerization, and hydrolysis of peptide bonds), solubility (including susceptibility to aggregation under various conditions, oligomerization state, and crystallizability), kinetic and dynamic properties (including flexibility, rigidity, folding rate, folding mechanism, allostery, and the ability to undergo conformational changes and correlated motions), binding affinity and specificity (to one or more molecules including proteins, nucleic acids, polysaccharides,
  • solubility and grammatical equivalents herein is meant the maximum possible concentration of protein, in the desired or physiologically appropriate oligomerization state, in a solution of specified condition (i.e. pH, temperature, concentration of any buffer components, salts, detergents, osmolytes, etc.). Unless otherwise noted, dimeric BMPs are the desired species.
  • soluble expression and grammatical equivalents herein is meant that the protein is able to be produced at least partially in soluble form rather than in inclusion bodies when expressed in a prokaryotic host. It is preferred that at least 1 ⁇ g soluble protein is produced per 100 mL culture, with at least 10 ⁇ g or 100 ⁇ g being especially preferred.
  • solubility and grammatical equivalents herein is meant an increase in the maximum possible concentration of protein, in the desired or physiologically appropriate oligomerization state, in solution.
  • solubility is increased by at least a factor of 2, with increases of at least 5-fold or 10-fold being especially preferred.
  • solubility is a function of solution conditions. For the purposes of this invention, solubility should be assessed under solution conditions that are pharmaceutically acceptable.
  • variant BMP nucleic acids and grammatical equivalents herein is meant nucleic acids that encode variant BMPs. Due to the degeneracy of the genetic code, an extremely large number of nucleic acids may be made, all of which encode the variant BMPs of the present invention, by simply modifying the sequence of one or more codons in a way that does not change the amino acid sequence of the variant BMP.
  • variant BMPs or “non-naturally occurring BMPs” and grammatical equivalents thereof herein is meant non-naturally occurring BMPs which differ from a wild type or parent BMP by at least one (1) amino acid insertion, deletion, or substitution. It should be noted that unless otherwise stated, all positional numbering of variant BMPs and variant BMP nucleic acids is based on these sequences. BMP variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the BMP sequence. BMP variants must retain at least 50% of wild type BMP activity in one or more cell types, as determined using an appropriate assay described below.
  • variants that retain at least 75% or 90% of wild type activity are more preferred, and variants that are more active than wild type are especially preferred.
  • BMP variants may be engineered to have different activities than a wild type BMP.
  • competitive inhibitors may be designed.
  • a variant BMP may contain insertions, deletions, and/or substitutions at the N-terminus, C-terminus, or internally.
  • variant BMPs have at least 1 residue that differs from the most similar human BMP sequence, with at least 2, 3, 4, or 5 different residues being more preferred.
  • Variant BMPs may contain further modifications, for instance mutations that alter additional protein properties such as stability or immunogenicity or which enable or prevent posttranslational modifications such as PEGylation or glycosylation.
  • Variant BMPs may be subjected to co- or post-translational modifications, including but not limited to synthetic derivatization of one or more side chains or termini, glycosylation, PEGylation, circular permutation, cyclization, fusion to proteins or protein domains, and addition of peptide tags or labels.
  • naturally occurring BMPs are difficult to produce in large amounts, are sparingly soluble, exhibit pleiotropic activities, and may induce unwanted immune responses.
  • novel variants of human BMPs comprise one or more modifications that were selected to improve biophysical properties and clinical performance.
  • Reported expression yields for BMPs are typically very low. Reported yields range from 2-6 ng/mL for transiently transfected COS-1 cells in roller bottle culture to 100-200 ng/mL in DHFR-amplified stably transfected CHO cells, see U.S. Pat. No. 6,048,964 to John C. Lee, et al. To facilitate the development and therapeutic use of BMPs, it would be desirable to increase the expression yield to at least 10 ⁇ g/ml, with at least 100 ⁇ g/ml being more preferred and at least 1000 ⁇ g/ml being especially preferred.
  • a number of nucleic acid properties and protein properties may influence expression yields; furthermore the expression host and expression protocol contribute to yields. Any of these parameters may be optimized to improve expression yields. Also, expression yield may be improved by the incorporation of one or mutations that confer improved stability and/or solubility, as discussed further below. Furthermore, interactions between the pro-domain and the mature domain may influence folding efficiency, and so the pro-domain may also be targeted for modification.
  • nucleic acid properties are optimized to improve expression yields using one or more of the following strategies: 1) replace imperfect Kozak sequence, 2) reduce 5′ GC content and secondary structure of the RNA, 3) optimize codon usage, 4) use an alternate leader sequence, 5) include a chimeric intron, or 6) add an optimized poly-A tail to the C-terminus of the message.
  • protein properties are optimized to improve expression yields using one or more of the following strategies: 1) optimize the signal sequence, 2) optimize the proteolytic processing site, 3) replace one or more cysteine residues in order to minimize formation of improper disulfide bonds, 4) improve the rate or efficiency of protein folding, or 5) increase protein stability, especially proteolytic stability.
  • alternate pro-domain sequences are used.
  • the pro-domain from BMP-2 may be used to aid in the expression of BMP-4 (Wozney et. al. (1988) Science 242: 1528-1534).
  • Pro-domains that may be used include but are not limited to the pro-domains from any BMP sequence and the MIC-1 pro-domain.
  • the pro-domain may be expressed in cis or in trans.
  • transfection or expression conditions are optimized to increase expression yields.
  • furin and other pro-protein convertase enzymes require calcium
  • the addition of calcium to the media during expression may increase the yield of properly processed protein.
  • proteosome inhibitors may be added to minimize proteosomal degradation. Fetal calf serum or heparin may also be used.
  • the expression host is selected to optimize expression yields. Folding and processing of BMPs is relatively complex and may be assisted by appropriate chaperones. These chaperones may not be expressed equally in all mammalian cell lines.
  • BMP-7 is naturally produced in the kidney and several well-established expression lines are derived from the kidney; in a preferred embodiment BMP-7 is expressed in a kidney cell line including but not limited to 293T, 239-EBNA, COS, and BHK.
  • the cleavage site in BMP-7 is optimized to promote more efficient proteolytic processing by furin and related subtilisin-like proprotein convertase enzymes. Substrate preferences for furin have been well-characterized (Henrich et. al. (2003) Nat. Struct. Biol. 10: 520-526; Holyoak et. al. (2004) Biochem. 43: 2412-2421; and Duckert et. al.
  • BMP-7 is expressed in a cell line that is co-transfected with one or more chaperone or processing proteins, including but not limited to furin.
  • BMPs are typically expressed in mammalian cells.
  • alternate expression systems including but not limited to yeast expression systems, it would be desirable to 1) eliminate the N-linked glycosylation site, 2) eliminate potential O-linked glycosylation sites, 3) enable expression in the absence of the pro-domain, and 4) enable processing by an alternate protease present in the desired expression host.
  • one or more N- or O-linked glycosylation sites is removed.
  • Removal of glycosylation sites from variant BMP polypeptides may be accomplished, for example, by the elimination of one or more serine or threonine residues to the native sequence or variant BMP polypeptide (for O-linked glycosylation sites) or by the modification of a canonical N-linked glycosylation site, N-X-Y-X, where X is any amino acid except for proline and Y is threonine, serine or cysteine.
  • pro-domain dependence is reduced or eliminated by 1) introducing mutations that stabilize the folded state of the BMP; 2) reducing the exposed hydrophobic surface area of BMP; 3) stabilizing one or more intermediates along the folding pathway of BMP; or 4) replacing one or more pairs of cysteine residues forming a disulfide bond.
  • the furin cleavage site is modified to allow recognition by an alternate protease that is present in the desired expression host.
  • the furin cleavage site may be changed to a kexin cleavage site to facilitate yeast expression. Kexin cleavage sites have been well characterized; see for example Holyoak et. al. (2004) Biochem. 43: 2412-2421.
  • the BMPs are expressed using in vitro translation.
  • a number of factors may be added to the reaction to improve the yield of total protein and of correctly folded protein, including but not limited to 1) pro-domains from any TGF- ⁇ family member, including but not limited to BMP-2, BMP-4, BMP-7, and MIC-1; 2) accessory factors and chaperones including but not limited to cysteine isomerases, proline isomerases, BiP, heat shock proteins, furin, and other proprotein convertases; 3) redox agents including but not limited to glutathione; 4) monovalent and divalent cations including but not limited to sodium, potassium, calcium, zinc, and magnesium; and 5) microsomes.
  • a variety of strategies may be utilized to design BMP variants with improved solubility and expression yield.
  • one or more of the following strategies are used: 1) reduce hydrophobicity by substituting one or more solvent-exposed hydrophobic residues with suitable polar residues, 2) increase polar character by substituting one or more neutral polar residues with charged polar residues, 3) increase protein stability, for example by one or more modifications that improve packing in the hydrophobic core, increase beta sheet forming propensity, improve helix capping and dipole interactions, or remove unfavorable electrostatic interactions (increasing the stability of a protein may improve solubility by decreasing the population of partially folded or misfolded states that are prone to aggregation), and 4) modify one or more residues that can affect the isoelectric point of the protein (that is, aspartic acid, glutamic acid, histidine, lysine, arginine, tyrosine, and cysteine residues).
  • Protein solubility is typically at a minimum when the isoelectric point of the protein is equal to the pH of the surrounding solution. Modifications that perturb the isoelectric point of the protein away from the pH of a relevant environment, such as serum, may therefore serve to improve solubility. Furthermore, modifications that decrease the isoelectric point of a protein may improve injection site absorption (Holash et. al. (2002) Proc. Nat. Acad. Sci. USA 99: 11393-11398).
  • BMP variants with improved receptor binding affinity or specificity.
  • diversity is incorporated at one or more receptor interface positions.
  • modifications at positions distal to the receptor binding interface may also alter binding affinity or specificity.
  • modifications are made to positions in BMP that contact one or more non-conserved receptor positions. For example, Arg 48, Gln 53, and Glu 60 in BMP-7 contacts position 76 in the type II receptor; this position is Glu in ActRIIb, Lys in ActRII, and Thr in BMPRII.
  • BMP-7 Some BMPs, such as BMP-2, bind more tightly to type I receptors while other BMPs, such as BMP-7, have higher affinity for type II receptors.
  • a BMP is modified such that its lower affinity receptor binding site is made more similar to a BMP for which that site is the higher affinity site.
  • the type I receptor interface of BMP-7 may be modified to be more similar to BMP-2, or the type II receptor interface of BMP-2 may be altered to be more BMP-7-like.
  • modifications are made to stabilize the bound conformation of BMP versus the free conformation.
  • BMP-7 binds first to the type II receptor and then to the type I receptor, and binding to the type II receptor may increase binding affinity for the type I receptor. Binding to the type II receptor causes a conformational change in BMP, producing what may be a higher affinity state. Accordingly, mutations may be introduced to stabilize the bound state.
  • BMPs are engineered to reduce or eliminate binding affinity for one or more BMP inhibitors while retaining affinity for one or more of the BMP receptors. Rational alteration of inhibitor specificity may be used to control the site of BMP action, as many of the inhibitors are expressed in specific tissues or organs. Similar approaches may be used to alter specificity for co-receptors such as DRAGON, extracellular matrix components such as heparin and heparin sulfate, and serum components such as alpha2-macroglobulin.
  • co-receptors such as DRAGON, extracellular matrix components such as heparin and heparin sulfate, and serum components such as alpha2-macroglobulin.
  • a number of methods can be used to identify modifications (that is, insertion, deletion, or substitution mutations) that will yield BMP variants with improved properties. These methods include, but are not limited to, sequence profiling (Bowie and Eisenberg (1991) Science 253: 164-170), rotamer library selections (Dahiyat and Mayo (1996) Protein Sci 5: 895-903; Dahiyat and Mayo, Science (1997) 278: 82-87; Desjarlais and Handel (1995) Prot. Sci. (1995) 4: 2006-2018; Harbury et. al. (1995) Proc. Nat. Acad. Sci.
  • one or more sequence alignments of BMPs and related proteins is analyzed to identify residues that are likely to be compatible with each position.
  • the PFAM or BLAST alignment algorithm is used to generate alignments of the BMP subfamily, the TGF- ⁇ family, or the cysteine knot cytokine superfamily.
  • suitable substitutions may be defined as those residues that are observed at the same position in homologous sequences.
  • Especially preferred substitutions are those substitutions that are frequently observed in homologous sequences.
  • ACE Analogous Contact Environment
  • the structure of a human BMP is obtained by x-ray crystallography or NMR. Structures of BMPs include BMP-2 (PDB code 3BMP, Scheufler et. al. (1999) J. Mol. Biol. 287: 103), BMP-2 mutant L51P (PDB code 1 REU, Keller et. al. (2004) Nat. Struct. Mol. Biol. 11: 481) and wild type human BMP-7 (PDB code 1 LXI Griffith et. al. (1996) Proc. Nat. Acad. Sci. USA 93: 878-883).
  • BMP-2 PDB code 3BMP, Scheufler et. al. (1999) J. Mol. Biol. 287: 103
  • BMP-2 mutant L51P (PDB code 1 REU, Keller et. al. (2004) Nat. Struct. Mol. Biol. 11: 481)
  • wild type human BMP-7 (PDB code 1 LXI Griffith et. al. (1996) Proc. Nat
  • the crystal structure of another cysteine knot cytokine protein such as TGF- ⁇ 2 (PDB code 1TFG, Schlunegger and Grutter (1992) Nature 358: 430), or NMR structures of cysteine knot cytokine proteins such as TFG- ⁇ 1 (PDB codes 1KLA, 1KLC, and 1KLD; Hinck et. al. (1996) Biochem. 35: 5817)
  • the crystal structure is a co-crystal structure comprising a BMP and a BMP receptor. High-resolution structures are available for BMP-7 in complex with the receptor ActRIIa (PDB code 1LX5, Greenwald et. al. (2003) Mol.
  • the crystal structure is a co-crystal structure comprising BMP and a BMP inhibitor.
  • a high resolution structure is available for BMP-7 bound to the soluble inhibitor noggin (PDB code 1M4U, Groppe et. al.
  • Structures of additional BMPs alone and bound to one or more receptors or inhibitors may be built using NMR or x-ray crystal structures including but not limited to those described above in conjunction with homology modeling, structural alignment, and protein-protein docking methods known in the art.
  • the furin cleavage sites of BMPs may be determined by scanning for the consensus furin cleavage site, R-X-X-K/R (SEQ ID NO:84), in the residues located N-terminally relative to the aligned regions of the BMP mature domains.
  • the sequence of BMP-7 in the region of the cleavage site is (from P8 to P1 before the cleavage site and from P1′ to P4′ after the cleavage site, with “
  • the most favored furin cleavage site comprises R at P4, R at P1, and K or R at P2. It is also favorable to have at least one basic residue in residues P5-P8.
  • Some BMPs have multiple cleavage sites. For example, BMP-4 has two cleavage sites, and sequential cleavage is thought to provide a mechanism for regulation of activation and signaling range (Degnin et. al. (2004) Mol. Biol. Cell 15: 5012-5020).
  • BMP-7 has an N-linked glycosylation site at Asn 80.
  • the mature domain of BMP-7 does not include any O-linked glycosylation sites.
  • one or more serine or threonine residues would be susceptible to glycosylation in alternate expression hosts, including but not limited to yeast and Baculovirus expression systems. The presence and location of such O-linked glycosylation sites may be determined experimentally, for example using mass spectrometry.
  • exposed hydrophobic residues in BMP-7 include but are not limited to Tyr 44, Trp 52, Trp 55, Ile 57, Phe 73, Tyr 78, Ile 86, Leu 90, Phe 93, Ile 94, Leu 115, Tyr 116, Tyr 117, Val 123, Leu 125, and Tyr 128.
  • BMP-7 also contains three hydrophobic residues in the disordered N-terminal region (that is, residues 1-35). While these residues are not observed in the crystal structures of BMP-7, it is highly likely that they are significantly exposed to solvent. In a preferred embodiment, these additional hydrophobic residues, Leu 21, Met 23, and Val 26, are also considered solvent exposed hydrophobic residues.
  • residues that mediate intermolecular interactions between BMPs and their receptors are replaced with structurally and functionally compatible residues that confer improved receptor binding affinity or specificity.
  • Preferred residues at the BMP/type I receptor interface include, but are not limited to, residues Lys 39, Phe 47, Asp 49, Leu 50, Gly 51, Pro 74, Leu 75, Asn 76, Ser 77, Tyr 78, Asn 80, Asn 83, Ile 86, Leu 90, Phe 93, Ile 94, Pro 96, Tyr 116, Lys 126, Tyr 128, Arg 129, Asn 130, and Met 131.
  • Preferred residues at the BMP/type II receptor interface include, but are not limited to, residues Tyr 44, Arg 48, Gln 53, Ile 57, Ala 58, Pro 59, Glu 60, Gly 61, Tyr 62, Ala 63, Gln 108, Asn 110, Ala 111, Ile 112, Ser 113, Val 114, Leu 115, Phe 117, Asn 122, Val 123, Leu 125, Lys 127, and Arg 134.
  • residues that mediate intermolecular interactions between BMPs and their inhibitors are replaced with structurally and functionally compatible residues that confer reduced inhibitor binding affinity or increased inhibitor binding specificity.
  • Preferred residues at the noggin/BMP-7 interface include, but are not limited to, Phe 73, Pro 74, Leu 75, Asn 76, Ser 77, Asn 83, Ile 86, Val 87, and Leu 90.
  • Proteins may be destabilized by the presence of unfavorable electrostatic interactions or stabilized by the presence of favorable electrostatic interactions. Accordingly, a protein may be stabilized by removing unfavorable electrostatic interactions or by incorporating favorable electrostatic interactions. Modifying regions of high electrostatic potential may also modulate interactions with serum and extracellular matrix components, which may affect pharmacokinetics properties. In a preferred embodiment, the electrostatic potential that is present at each residue position is determined, for example by using Debye-Huckel calculations.
  • Residues in BMP-7 that are located in regions of electrostatic potential greater than 0.25 or less than ⁇ 0.25 include, but are not limited to, Lys 40, Ser 46, Arg 48, Tyr 62, Ala 64, Tyr 65, Tyr 66, Cys 67, Glu 68, Gly 69, Glu 70, Cys 71, Ala 72, Tyr 78, Asn 80, Ala 81, Thr 82, Asn 83, His 84, Ala 85, Val 87, Gln 88, Thr 89, Ile 94, Pro 100, Cys 104, Ala 105, Pro 106, Thr 107, Gin 108, Leu 109, Asn 110, Ala 111, Ile 112, Ser 113, Asn 122, Ile 124, Asn 130, Met 131, Val 132, Val 133, Arg 134, Ala 135, Cys 136, Gly 137, and His 139.
  • furin cleavage sequences of several BMPs differ somewhat from the consensus furin cleavage sequence.
  • preferred modifications to improve proteolytic processing include, but are not limited to, (P8) E ⁇ Q or K; (P6) H ⁇ K or R; (P5) L ⁇ K; and (P2) I ⁇ K or R.
  • residues comprising a N- or O-linked glycosylation site are replaced with structurally and functionally compatible residues that do not comprise a glycosylation site.
  • N-linked glycosylation sites are specified by the sequence N-X-(S/T)-X (SEQ ID NO:86), where X may be any residue other than proline.
  • an N-linked glycosylation site may be eliminated by 1) replacing the N with any other residue, 2) replacing either X with proline, or 3) replacing the S or T with any residue other than T, S, or C.
  • Preferred modifications that remove the N-linked glycosylation site include, but are not limited to, replacing Asn 80 with Asp, Gln, Ser, or Thr; replacing Thr 82 with Val, and replacing Asn 83 with Pro.
  • solvent exposed hydrophobic residues are replaced with structurally and functionally compatible polar residues.
  • Alanine and glycine may also serve as suitable replacements, constituting a reduction in hydrophobicity.
  • mutations that increase polar character, such as Phe to Tyr, and mutations that reduce hydrophobicity, such as Ile to Val may be appropriate.
  • preferred suitable polar residues are defined as those polar residues: 1) whose energy in the optimal rotameric configuration, as determined using PDA® technology, is more favorable than the energy of the exposed hydrophobic residue at that position and 2) whose energy in the optimal rotameric configuration is among the most favorable of the set of energies of all polar residues at that position.
  • the polar residues that are included in the library at each variable position are deemed suitable by both PDA® technology calculations and by sequence alignment data.
  • one or more of the polar residues that are included in the library are deemed suitable by either PDA® technology calculations or sequence alignment data.
  • Especially preferred modifications to BMP-7 include, but are not limited to, the following substitutions: L21D, L21G, L21K, L21N, L21R, L21S, M23D, M23G, M23K, M23N, M23R, M23S, V26D, V26E, V26G, V26K, V26N, V26S, Y44A, Y44D, Y44E, Y44G, Y44H, Y44K, Y44N, Y44P, Y44Q, Y44R, Y44S, W52A, W52E, W52K, W52Q, W55A, W55E, W55H, W55K, W55N, W55Q, I57A, I57D, I57E, I57H, I57K, I57L, I57T, I57V, E60R, F73A, F73D, F73E, F73H, F73Q, F73R, F73S, Y
  • Most especially preferred modifications are those modifications that confer improved properties, such as improved expression yield or activity.
  • Most especially preferred modifications to exposed hydrophobic residues in BMP-7 include, but are not limited to, L21G, L21R, M23G, M23N, M23R, M23S, V26G, V26N, Y65N, Y78H, Y78R, I86A, F93D, F93E, F93G, F93H, F93S, F93T, 194R, Y116H, F117H, F117Y, and Y128D.
  • Suitable residues for interface residues are meant all amino acid residues that are compatible with the structure of a BMP and that retain appreciable binding affinity for at least one of the BMP receptors.
  • competitive inhibitor variants may be generated by identifying alternate residues that are compatible with the structure of a BMP but that substantially eliminate binding affinity for at least one of the BMP receptors.
  • Suitable residues may confer binding specificity by maintaining or increasing affinity for one or two receptors or inhibitors while substantially reducing binding affinity for the other receptors, inhibitors, or additional binding partners. In other cases, modifications are selected to confer other desired properties, for example improved expression yield, while maintaining binding affinities that are substantially similar to the wild type protein.
  • the interface positions will be substantially exposed to solvent.
  • Suitable substitutions include the polar residues, alanine, and glycine. However, for interface positions that are substantially buried in the dimer structure, hydrophobic replacements are preferred. Suitable polar residues may also include the subset of polar residues that are observed in analogous positions in homologous proteins, especially other BMPs. In an especially preferred embodiment, suitable polar residues include the subset of polar residues with low or favorable energies as determined using PDA® technology calculations or SPA calculations (described above).
  • polar BMP-7 interface residues include, but are not limited to, K39D, K39E, K39G, K39N, K39R, K39S, K39T, R48D, R48E, R48H, R48K, R48N, R48Q, Q53A, Q53D, Q53E, Q53G, Q53H, Q53K, Q53R, Q53S, Q53T, E60H, E60K, E60N, E60P, E60Q, E60R, E60S, E60T, N76A, N76D, N76S, N76T, S77A, S77D, S77E, S77H, S77K, S77N, S77P, S77Q, S77T, K126D, K126E, K126G, K126Q, K126R, K127A, K127D, K127E, K127H, K127N, K127P, K127Q, K127S, K127T, R129D, R129D, R129
  • Most especially preferred modifications are those modifications that confer improved properties, such as improved expression yield, improved activity, or enhanced receptor binding specificity.
  • Most especially preferred modifications to residues in regions of high electrostatic potential in BMP-7 include, but are not limited to, K39A, K39S, R48H, R48N, R48Q, Q53A, Q53K, Q53D, Q53G, Q53S, Q53T, E60R, K126R, K127E, R129D, R129N, R134E, and R134S.
  • Additional especially preferred modifications are those modifications that reduce binding to either type I or type II receptors, thereby potentially acting as a competitive inhibitor of BMP.
  • Additional especially preferred modifications to receptor interface residues in BMP-7 include, but are not limited to, Y44T, W52E, and 157Q.
  • Preferred modifications are those modifications that alter binding affinity or specificity to a BMP inhibitor.
  • Preferred modifications that reduce binding to noggin include, but are not limited to, W55I, W55L, W55K, W55R, I57M, I57Y, I57E, I57H, I57K, I57Q, I57R, A58I, A58L, A58M, A58Y, A58V, A58E, A58H, A58K, A58Q, A58R, P59Y, N76E, N76Q, N76R, S77E, S77Q, N83F, N83W, N83Y, N83H, N83K, N83R, I86L, I86M, I86F, I86Y, I86R, V87H, S113I, S113L, S113M, S113F, S113Y, S113E, S113H, S113K, S113Q, S113R, L115M, L115K, L115R, V123M, V123
  • Preferred modifications that increase binding to noggin include, but are not limited to, R48M, P59M, E601, E60L, E60M, E60V, P74M, N76I, N76V, N76A, S77T, D119I, D119L, K126W, and K127M.
  • Regions of high electrostatic potential may be modified in order to increase protein stability or to alter receptor binding affinity and specificity.
  • residues that are located in a region of high electrostatic potential are replaced by structurally and functionally compatible residues that are predicted to interact favorably with the local electrostatic field.
  • suitable polar residues include the subset of electrostatically favorable residues that are observed in analogous positions in homologous proteins, especially other BMPs.
  • suitable polar residues include the subset of polar residues with low or favorable energies as determined using PDA® technology calculations or SPA calculations (described above).
  • Especially preferred modifications to BMP-7 residues located in regions of high electrostatic potential include, but are not limited to, Q88E, N110D, N110E, N110H, A111D, A111S, N130D, A135D, A135E, and A135S. Most especially preferred modifications are those modifications that confer improved properties, such as improved expression yield, improved activity, or enhanced receptor binding specificity. Most especially preferred modifications to receptor interface residues in BMP-7 include, but are not limited to, N110D, A135E, and A135S.
  • suitable polar residues include the subset of polar residues that are observed in analogous positions in homologous proteins, especially other BMPs.
  • suitable polar residues include the subset of polar residues with low or favorable energies as determined using PDA® technology calculations or SPA calculations (described above).
  • Additional especially preferred modifications to BMP-7 surface residues include but are not limited to Q36E, Q36N, Q36R, E42D, E42Q, E42R, E42T, D49E, D49S, D54K, D54N, D54R, D54S, E70A, E70Q, N95D, N95K, N95Q, N95R, E97D, E97K, E97R, T98A, T98E, T98K, T98R, Q108D, Q108K, Q108S, D119E, D119N, D119S, D119T, S120D, S120E, S120N, S120R, S121D, S121E, S121K, S121N, S121T, N122E, N122Q, and N122R.
  • residue T98 may be deleted.
  • Most especially preferred modifications are those modifications that confer improved properties, such as improved expression yield, improved activity, or enhanced receptor binding specificity.
  • Most especially preferred modifications to additional residues in BMP-7 include, but
  • variants comprising two or more mutations, including but not limited to those disclosed above, are made. Such variants may exhibit greater improvements in expression yield, solubility, or receptor specificity than point mutants. Such variants may also exhibit improvements in more than one protein property.
  • Especially preferred variants comprising two mutations include but are not limited to L21G/F93H, L21R/F93H, M23N/Y65N, M23R/Y65N, K39A/Y65N, K39A/F93H, K39S/Y78H, K39S/F93H, K39S/N110D, K39S/S120D, K39S/N130D, K39S/R134E, K39S/A135E, R48N/F93H, Q53D/Y65N, Q53G/Y65N, Q53G/Y78H, Q53S/Y65N, Q53T/Y65N, 157L/Y65N, Y65N/Y78H, Y65N/Y78R, Y65N/S120D, Y65N/A135E, Y65N/A135S, A72D/F93H, Y78H/F93H, Y78H/A105V, Y78H
  • Especially preferred variants comprising three mutations include but are not limited to L21 G/K39S/S120D, M23R/K39S/S120D, K39S/Y65N/S120D, K39S/A72D/S120D, K39S/Y78H/S120D, K39S/Q108D/S120D, Y65N/Y78H/F93H, Y65N/Y78H/R134E, A72D/Y78H/F93H, Y78H/F93H/Q108D, Y78H/F93H/F117H, Y78H/F93H/S120D, and Y78H/F93H/R134E.
  • a second trend is that the substitution of exposed hydrophobic amino acids with more polar or less hydrophobic alternatives generally leads to enhanced expression yield or activity, exemplified by variants such as Y78H, 186A, Y128D, and multiple substitutions of F93.
  • I124 another exposed hydrophobic residue, suggests the additional expression- or activity-enhancing variants I124A, I124D, I124E, I124K, I124N, I124Q, I124R, I124S, I124T, and I124V.
  • variant BMPs may be modified by adding an epitope tag (e.g. a poly-histidine (poly-His), c-myc, or FLAG-tag) or a fusion partner (e.g.
  • BMPs are naturally expressed as pro-proteins comprising a long pro-domain, one or more cleavage sites, and a mature domain. This pro-protein is then processed by the cellular machinery to yield a dimeric mature BMP molecule.
  • the variants of the invention are produced in a similar manner.
  • the pro-domain is believed to aid in the correct folding and processing of BMPs.
  • the pro-domain may noncovalently bind the mature domain and may act as a chaperone, as well as an inhibitor (eg. Thies et. al. (2001) Growth Factors 18: 251-259).
  • the variants of the invention are produced and/or administered therapeutically in this form.
  • BMPs may be produced in other forms, including, but not limited to, mature domain produced directly or refolded from inclusion bodies, or full-length intact pro-protein. The variants of the invention are expected to find use in these and other forms.
  • nucleic acids encoding BMP variants are prepared by total gene synthesis, or by site-directed mutagenesis of a nucleic acid encoding wild type or variant BMP.
  • Methods including template-directed ligation, recursive PCR, cassette mutagenesis, site-directed mutagenesis or other techniques that are well known in the art may be utilized (see for example Strizhov et. al. PNAS 93:15012-15017 (1996), Prodromou and Perl, Prot. Eng. 5: 827-829 (1992), Jayaraman and Puccini, Biotechniques 12: 392-398 (1992), and Chalmers et. at. Biotechniques 30: 249-252 (2001)).
  • BMP variants include yeast, bacteria, archaebacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are fungi such as Saccharomyces cerevisiae and Pichia pastoris and mammalian cell lines including 293 (eg. 293-T and 293-EBNA), BRK, CHO (eg. CHOK1 and DG44), COS, Jurkat, NIH3T3, etc. (see the ATCC cell line catalog). BMP variants can also be produced in more complex organisms, including but not limited to plants (such as corn, tobacco, and algae) and animals (such as chickens, goats, cows); see for example Dove, Nature Biotechnol. 20: 777-779 (2002). In one embodiment, the cells may be additionally genetically engineered, that is, contain exogenous nucleic acid other than the expression vector comprising the variant BMP nucleic acid.
  • the variant BMP of the invention are labeled with at least one element, isotope or chemical compound.
  • labels fall into three classes: a) isotopic labels, which may be radioactive or heavy isotopes; b) immune labels, which may be antibodies or antigens; and c) colored or fluorescent dyes.
  • the labels may be incorporated into the compound at any position. Labels include but are not limited to biotin, tag (e.g. FLAG, Myc) and fluorescent labels (e.g. fluorescein).
  • Such derivatization may improve the solubility, absorption, transport across the blood brain barrier, serum half-life, and the like.
  • Modifications of variant BMP polypeptides may alternatively eliminate or attenuate any possible undesirable side effect of the protein. Moieties capable of mediating such effects are disclosed, for example, in Remington's Pharmaceutical Sciences, 16th ed., Mack Publishing Co., Easton, Pa. (1980).
  • variant BMP comprises linking the variant BMP polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (“PEG”), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Pat. No. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.
  • PEG polyethylene glycol
  • a variety of coupling chemistries may be used to achieve PEG attachment, as is well known in the art.
  • Examples include but are not limited to, the technologies of Shearwater and Enzon, which allow modification at cysteine residues and primary amines, including but not limited to histidine groups, lysine groups and the N-terminus (see, Kinstler et al, Advanced Drug Deliveries Reviews, 54, 477-485 (2002) and M J Roberts et al, Advanced Drug Delivery Reviews, 54, 459-476 (2002)). Both labile and non-labile PEG linkages may be used.
  • An additional form of covalent modification includes coupling of the variant BMP polypeptide with one or more molecules of a polymer comprised of a lipophililic and a hydrophilic moiety. Such composition may enhance resistance to hydrolytic or enzymatic degradation of the BMP.
  • Polymers utilized may incorporate, for example, fatty acids for the lipophilic moiety and linear polyalkylene glycols for the hydrophilic moiety.
  • the polymers may additionally incorporate acceptable sugar moieties as well as spacers used for BMP attachment.
  • Polymer compositions and methods for covalent conjugation are described, for example, in U.S. Pat. Nos. 5,681,811; 5,359,030.
  • Another type of modification is chemical or enzymatic coupling of glycosides to the variant BMP.
  • Such methods are described in the art, e.g., in WO 87/05330 published 11 Sep. 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).
  • removal of carbohydrate moieties present on the variant BMP polypeptide may be accomplished chemically or enzymatically.
  • Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981).
  • Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo-and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).
  • a primary object of the current invention is the identification of variant BMPs with increased expression yield. Accordingly, the yield, using one or more set of expression conditions, of the variant and wild type BMPs is determined.
  • expression yields are determined using ELISA.
  • ELISAs are performed using at least two monoclonal antibodies that recognize distinct epitopes. It is also possible to derive ELISA correction factors for selected variants by purifying said variants and determining their concentration through orthogonal methods, such as UV absorption or BCA assay.
  • the BMPs may be engineered to contain a tag, such as a FLAG tag or His tag, and anti-tag antibodies may be used in the ELISA.
  • expression yields are determined using Western blotting. As with ELISA, a limitation is that some mutations may confer increased or decreased antibody binding affinity.
  • the variant BMPs are assayed for solubility using methods including but not limited to those described below.
  • the variant and wild type proteins are compared directly in the same assay system and under the same conditions in order to evaluate the solubility of each variant.
  • the solubility of the BMP variants may be determined under a number of solution conditions. A variety of excipients, including solubilizing and stabilizing agents, may be tested for their ability to promote the highest soluble BMP concentration. In addition, different salt concentrations and varying pH may be tested.
  • solubility is assayed under pharmaceutically acceptable conditions.
  • DLS Differential light scattering
  • DLS determines diffusion coefficients based on signal correlation from fluctuation of laser light scattered from Brownian motion of particles in solution (Heimenz, Chapter 10 in Polymer Chemistry, Marcel Dekker, Inc., NY, 1984, pp. 659-701).
  • Commercially available instruments provide graphical or table readouts of particle population(s) by size(s) after transforming the diffusion coefficient(s) measured by deconvolution/autocorrelation of laser light scattering data using the Stokes-Einstein equation. The size is therefore the hydrodynamic radius.
  • the distribution of particle sizes within a population(s) is the dispersity, and this factor provides data on the uniformity of the particle population(s).
  • DLS dispersity and the appearance of aggregates over time may be monitored to test for solubility.
  • Aggregated protein may be easily resolved by DLS, and readily detected at low levels due to the physical property of aggregates: they scatter more laser light per unit due to the greater target surface area.
  • the sample may be directly introduced into the cuvette (i.e. it is not necessary to perform a chromatographic step first).
  • a relative ratio of monodisperse to aggregate particle population may be determined.
  • this ratio may be weighted by mass or by light scattering intensity.
  • analytical ultracentrifugation is used to determine the oligomerization state of the variant BMPs.
  • AUC can be performed in two different ‘modes’, either velocity or equilibrium. Equilibrium AUC is the most preferred method for determining protein molecular weight and oligomeric state measurement.
  • a further preferred embodiment is to use size-exclusion chromatography (SEC) to determine the oligomerization state of the BMP variants.
  • SEC size-exclusion chromatography
  • sample may be introduced to an isocratic mobile phase and separated on a gel permeation matrix designed to exclude protein on the basis of size.
  • the samples will be “sieved” such that the aggregated protein will elute first with the shortest retention time, and will be easily separated from the remainder. This can identify aggregates and allow a relative quantification by peak integration using the peak analysis software provided with the instrument.
  • protein concentration is monitored as a function of time.
  • aggregates will form over time in the protein solution, and eventually precipitate entirely. This may be performed following centrifugation and sampling of the solution phase, in which case insolubility can be measured as a drop in solution protein concentration over time will be observed following centrifugation.
  • the oligomerization state is determined by monitoring relative mobility on native gel electrophoresis.
  • the amount of protein that is expressed solubly is determined. While factors other than the solubility of the native protein can impact levels of soluble expression, improvements in soluble expression may correlate with improvements in solubility. Any of a number of methods may be used; for example, following expression, SDS-polyacrylamide gel electrophoresis and/or western blots can be done on the soluble fraction of crude cell lysates or the expression media.
  • the protein of interest is fused to a fluorescent protein such as GFP, and the cells monitored for fluorescence (Waldo et. al. Nat. Biotechnol. 17: 691 (1999)).
  • the protein of interest is fused to the antibiotic resistance enzyme chloramphenicol transferase. If the protein expresses solubly, the enzyme will be functional, thereby allowing growth on media with increased concentration of the antibiotic chloramphenicol (Maxwell et. al. Protein Sci. 8: 1908 (1999)).
  • the protein of interest is expressed as a fusion with the alpha domain of the enzyme beta-galactosidase.
  • the alpha domain will complement the omega domain to yield a functional enzyme. This may be detected as blue rather than white colony formation when the cells are plated on media containing the indicator X-gal (Wigley et. al. Nat. Biotechnol. 19: 131 (2001)).
  • the activity of the wild-type and variant proteins are analyzed using in vitro receptor binding assays, cell-based activity assays, or in vivo activity assays.
  • the affinity of the variant BMPs for one or more BMP receptors is determined.
  • affinities for ALK-2, ALK-3, ALK-6, ActRII, ActRIIb, and BMPRII are determined.
  • Suitable binding assays include, but are not limited to, ELISA, fluorescence anisotropy and intensity, scintilation proximity assays (SPA) Biacore (Pearce et al., Biochemistry 38:81-89 (1999)), DELFIA assays, and AlphaScreenTM (commercially available from PerkinElmer; Bosse R., Illy C., and Chelsky D (2002)).
  • Biacore or surface plasmon resonance assays are used to determine the affinity of one or more BMP variants for one or more BMP receptors.
  • Biacore experiments may be performed, for example, by binding BMP receptor-Fc fusion proteins to a protein A derivitized chip or an NTA chip and testing each BMP variant as an analyte. It is also possible to bind an anti-BMP antibody to the chip, or to bind the BMP variant to the chip and test soluble receptor or Fc-receptor fusion proteins as analytes.
  • AlphaScreenTM assays (Bosse R., Illy C., and Chelsky D (2002). Principles of AlphaScreenTM PerkinElmer Literaure Aplication Note Ref# s4069. http://lifesciences.perkinelmer.com/Notes/S4069-0802.pdf) are used to characterize receptor and inhibitor binding.
  • AlphaScreenTM is a bead-based non-radioactive luminescent proximity assay where the donor beads are excited by a laser at 680 nm to release singlet oxygen. The singlet oxygen diffuses and reacts with the thioxene derivative on the surface of acceptor beads leading to fluorescence emission at ⁇ 600 nm.
  • AlphaScreenTM assays are performed using 1) BMP modified by the addition of a suitable tag or label; 2) donor beads capable of binding the tag or label used to modify the BMP; 3) a BMP receptor or inhibitor modified by the addition of a suitable tag or label; 4) acceptor beads capable of binding the tag or label used to modify the BMP receptor, and 5) varying amounts of an unlabeled variant BMP-7 molecule, which acts as a competitor. It is also possible to coat the donor or acceptor beads with antibodies that specifically recognize the native BMP or BMP receptor, or to bind the receptor to the donor beads and the ligand to the acceptor beads.
  • AlphaScreenTM assays are performed using 1) a type I BMP receptor modified by the addition of a suitable tag or label; 2) donor beads capable of binding the tag or label used to modify the type I BMP receptor; 3) a type II BMP receptor modified by the addition of a suitable tag or label; 4) acceptor beads capable of binding the tag or label used to modify the type II BMP receptor; 5) BMP, and 6) varying amounts of an unlabeled variant BMP-7 molecule, which acts as a competitor. It is also possible to bind the type I BMP receptor to the acceptor beads and the type II BMP receptor to the donor beads.
  • fluorescence assays are used. Either BMP-7 or a BMP-7 receptor or inhibitor may be labeled with a fluorescent dye (for examples of suitable dyes, see the Molecular Probes catalog). As is known in the art, the fluorescence intensity or anisotropy of a labeled molecule may change upon binding to another molecule. Fluorescence assays may be performed using 1) fluorescently labeled BMP-7, 2) a BMP receptor or inhibitor, and 3) varying amounts of an unlabeled variant BMP-7 protein, which acts as a competitor.
  • SPA scintillation proximity assays
  • BMP receptor-Fc fusions may be bound to protein A coated SPA beads or flash-plate and treated with S35-labeled BMP; the binding event results in production of light.
  • BMPs promote the growth and differentiation of a number of types of cells.
  • BMP activity may be monitored, for example, by measuring BMP-induced differentiation of MC3T3-E1 (an osteoblast-like cell derived from murine calvaria), C3H10T1/2 (a mouse mesenchymal stem cell line derived from embryonic connective tissue), ATDC5 (a mouse embryonal carcinoma cell), L-6 (a rat myoblast cell line) or C2C12 (a mouse myoblastic cell line) cells.
  • Differentiation may be monitored using, for example, luminescence reporters for alkaline phosphatase or colorimetric reagents such as Alcian Blue or PNPP (Asahina et. al. (1996) Exp. Cell Res.
  • the rat limb bud cartilage differentiation assay may also be used to monitor activity in primary cells.
  • reporter gene or kinase assays may be used.
  • BMPs activate the JAK-STAT signal transduction pathway. Accordingly, a BMP responsive cell line containing a STAT-responsive reporter such as GFP or luciferase may be used (Kusanagi et. al. (2000) Mol. Biol. Cell. 11: 555-565).
  • BMP activity in kidney cells is determined using cell-based assays; see for example Wang and Hirschberg (2004) J. Biol. Chem. 279: 23200-23206.
  • BMP activity in an animal is measured as bone induction following subcutaneous injection.
  • the activity of one or more BMP variants is determined in an animal model of a BMP-responsive disease or condition.
  • Animal models of renal disease include, but are not limited to, the rat nephrotoxic serum nephritis model (Zeisberg et. al. 2003)), the rat chronic cyclosporine A-induced nephropathy model (Li et. al. (2004) Am. J. Physiol. Renal Physiol. 286: F46-57), the mouse unilateral uretreral obstruction model (Schanstra et. al. (2003) Thromb. Haemost.
  • liver disease include, but are not limited to, rat bile duct ligation/scission model (Park et. al. (2000) Pharmacol.
  • Animal models of neurological disease include, but are not limited to, animal models for Parkinson's disease such as the 6-hydroxydopamine (6-OHDA) hemilesioned rat model and MPTP-induced Parkinson's disease, animal models of ALS such as rats or mice expressing mutant SOD1 (Shibata et. al. (2002) Neuropathology 22: 337-349), and animal models of stroke induced by intracortical microinjection of endothelin or quinolinic acid (Gilmour et. al. (2004) Behav. Brain Res. 150: 171-183) or cerebral artery occlusion (Merchenthaler et. al. (2003) Ann. NY Acad. Sci. 1007: 89-100).
  • Parkinson's disease such as the 6-hydroxydopamine (6-OHDA) hemilesioned rat model and MPTP-induced Parkinson's disease
  • animal models of ALS such as rats or mice expressing mutant SOD1 (Shibata et. al. (2002) Neuropathology 22
  • the BMP variants of the invention may be administered to a patient to treat a BMP related disorder.
  • the BMP variants may be administered in a variety of ways, including, but not limited to orally, parenterally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonarally, vaginally, rectally, intranasally or intraocularly.
  • the variant BMP may be directly applied as a solution or spray.
  • compositions of the present invention comprise a BMP variant in a form suitable for administration to a patient.
  • the pharmaceutical compositions are in a sterile, water-soluble form and may include pharmaceutically acceptable acid addition salts or pharmaceutically acceptable base addition salts.
  • the pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers such as NaOAc; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol.
  • carrier proteins such as serum albumin
  • buffers such as NaOAc
  • fillers such as microcrystalline cellulose, lactose, corn and other starches
  • binding agents such as microcrystalline cellulose, lactose, corn and other starches
  • sweeteners and other flavoring agents coloring agents
  • polyethylene glycol polyethylene glycol
  • a variant BMP may be administered as a pro-protein comprising a BMP pro-domain and a BMP mature domain.
  • BMPs may also be administered as BMP-impregnated matrix material (for example Geiger et. al. Adv. Drug Deliv. Rev. (2003) 55: 1613-1629; Hu et. al. J. Biomed. Mater. Res. (2003) 67A: 591-598; Peel et. al. J. Craniofac Surg. (2003) 14: 284-291); such a method of administration is especially preferred for promoting bone healing and growth.
  • implants for bone repair may be coated with BMPs to promote bone healing and improve bone strength (Schmidmaier et. al. Bone (2002) 30: 816-822).
  • the variant BMPs are added in a micellular formulation (U.S. Pat. No. 5,833,948), liposomes (Matsuo et. al. J. Biomed. Mater. Res. (2003) 66A: 747-754), biodegradable polymers (Saito and Takaoka, Biomaterials (2003) 24: 2287-2293; Saito et. al. Bone (2003) 32: 381-386; Weber et. al. Int. J. Oral Maxillofac. Surg.
  • Combinations of pharmaceutical compositions may be administered. Moreover, the compositions may be administered in combination with other therapeutics.
  • Nucleic acid encoding the variant BMPs may also be used in gene therapy.
  • genes are introduced into cells in order to achieve in vivo synthesis of a therapeutically effective genetic product, for example for replacement of a defective gene.
  • Gene therapy includes both conventional gene therapy where a lasting effect is achieved by a single treatment, and the administration of gene therapeutic agents, which involves the one time or repeated administration of a therapeutically effective DNA or mRNA. Any of a variety of techniques known in the art may be used to introduce nucleic acids to the relevant cells.
  • the oligonucleotides may be modified to enhance their uptake, e.g. by substituting their negatively charged phosphodiester groups by uncharged groups. For review of gene marking and gene therapy protocols see Anderson et al., Science 256:808-813 (1992).
  • Hexameric complexes comprising a BMP-7 dimer or a BMP-2 dimer bound to two ALK-3 receptors and two ActRIIa receptors was constructed using the structure of BMP-7 bound to ActRIIa (PDB code 1LX5) and the structure of BMP-2 bound to ALK-3 (PDB code 1ES7).
  • PDB code 1LX5 the structure of BMP-7 bound to ActRIIa
  • PDB code 1ES7 the structure of BMP-7 bound to ActRIIa
  • BMP-4 was modeled using the BMP-2 structure while BMP-5, BMP-6, and BMP-8 were modeled using the BMP-7 structure.
  • the BMP sequences were aligned as shown in FIG. 3 (SEQ ID NOS:7-12).
  • PDA® technology calculations were used to model the BMP-4, BMP-5, BMP-6, and BMP-8 structures.
  • BMP-7 dimer (“dimer”) and BMP-7 dimer bound to ALK-3 and ActRIIa “hexamer”) were analyzed to identify solvent-exposed hydrophobic residues.
  • the absolute and fractional solvent-exposed hydrophobic surface area of each residue was calculated using the method of Lee and Richards (J. Mol. Biol. 55: 379-400 (1971)) using an add-on radius of 1.4 ⁇ (Angstroms).
  • Each residue was also classified as core, boundary, or surface (see Dahiyat and Mayo Science 278: 82-87 (1997)).
  • Solvent exposed hydrophobic residues in BMP-7 were defined to be hydrophobic residues with at least 50 ⁇ 2 (square Angstroms) exposed hydrophobic surface area in the BMP-7 dimer (PDB code 1LX5, chain A, plus symmetry-related BMP-7 molecule). Exposed hydrophobic surface area was also measured in the context of the BMP-7/ALK-2/ActRIIa hexamer and RESCLASS was run to categorize each position as core, boundary, or surface. TABLE 1 Exposed hydrophobic residues in BMP-7.
  • BMP-7 and ALK-3, BMP-7 and ActRIIa, and BMP-7 and noggin were identified by examining the structure of the hexameric structure described in Example 1 and the co-crystal structure of BMP-7 and noggin (PDB code 1M4U). Next, distance measurements were used to identify residues that may participate in intermolecular interactions. Residues in BMP-7 that are within 5 ⁇ (Angstroms) of the ALK-3, ActRIIa, or noggin interfaces (as measured by CA-CA distances) are shown below, along with the receptor or inhibitor positions that are contacted. Next, the receptor sequence alignments used for homology modeling were analyzed for polymorphisms.
  • receptor polymorphisms were used to design receptor-specific variants, described below. If the receptor positions are polymorphic, it is noted in Table 2; “na” indicates that the receptor positions were not sufficiently well-aligned to unambiguously identify the polymorphisms. However, receptor-specific BMP variants may be identified that contact such unaligned regions of the receptors.
  • the electrostatic potential at each position in BMP-7 was determined using the Dybye-Huckel equation in the context of the BMP-7 dimer. Positions with electrostatic potential greater than 0.5 or less than ⁇ 0.5 are listed in the table below; modifications at these positions may confer increased stability or receptor binding specificity.
  • Electrostatic number name potential 46 SER ⁇ 0.72 67 CYS 0.73 68 GLU 0.50 69 GLY 0.58 70 GLU 0.55 71 CYS 0.50 72 ALA 0.62 82 THR 0.57 105 ALA 0.54 106 PRO 0.67 107 THR 0.65 108 GLN 0.68 109 LEU 0.79 110 ASN 1.00 111 ALA 1.51 113 SER 0.68 122 ASN ⁇ 0.64 133 VAL 0.68 135 ALA 0.53 136 CYS 0.62
  • ACE Analogous contact environment
  • Modifications to BMP-7 have substantially similar effects on other BMPs if the energy difference between the modification in the BMP-7 template and another BMP template are less than 1 kcal/mol, or if both energies are higher than 50 kcal/mol.
  • BMP-7 modifications have substantially similar effects in BMP-2: Q36E, A37K, K39D, E42R, E42T, R48N, R48Q, Q53D, Q53S, W55A, W55E, W55N, W55Q, E60K, E60Q, E60R, E60S, E60T, A63E, A63Q, Y65D, Y65N, E70Q, S77Q, S77T, Q88E, L90E, L90N, L90Q, F93A, F93D, F93R, F93S, I94E, I94K, I94Q, I94T, N95K, E97D, N110E, A111D, L115E, L115K, Y116D, Y116E, Y116K, Y116T, S120D, S120N, S121D, S121E, S121N, V123A, V123D, V123R, V123T, L125A, L125E, L125
  • BMP-7 modifications have substantially similar effects in BMP-4: Q36R, A37K, K39D, K39E, E42Q, E42R, E42T, R48N, R48Q, Q53D, Q53S, W55A, W55E, W55N, W55Q, 157V, E60K, E60Q, E60R, E60S, E60T, A63E, A63Q, E70A, E70Q, A72D, A72E, A72R, S77Q, S77T, Q88E, L90E, L90N, L90Q, F93A, F93D, F93R, F93S, I94E, I94K, I94Q, I94T, E97D, N110E, A111D, L115E, L115K, Y116D, Y116E, Y116K, Y116T, F117A, S120D, S120N, S121D, S121E, S121N, V123A, V123D,
  • BMP-7 modifications have substantially similar effects in BMP-5: Q36E, Q36N, Q36R, A37D, A37K, A37R, K39E, K39S, E42D, E42Q, E42R, E42T, Y44A, Y44E, Y44H, Y44K, Y44Q, Y44R, R48E, R48K, R48N, R48Q, D49E, D49S, W52A, W52E, W52K, W52Q, Q53A, Q53D, Q53E, Q53H, Q53R, Q53S, D54S, W55A, W55E, W55H, W55K, W55N, W55Q, W55R, I57V, I57A, I57D, I57E, I57H, I57K, I57T, E60K, E60S, A63S, Y65D, Y65E, Y65N, E70A, E70Q, A72D
  • BMP-7 modifications have substantially similar effects in BMP-8: Q36E, Q36N, Q36R, A37R, K39T, E42D, E42Q, E42R, E42T, Y44A, Y44H, R48Q, D49E, D49S, W52A, W52E, Q53H, D54K, D54R, D54S, W55A, W55E, W55H, W55K, W55N, W55Q, W55R, 157V, 157A, 157D, 157E, 157H, 157T, E60K, E60Q, E60S, A63S, Y65D, Y65N, E70A, E70Q, A72D, A72H, A72K, A72N, A72R, A72S, F73D, F73E, F73Q, F73R, F73S, N76D, S77A, S77D, S77K, S77Q, Y78D, Y78
  • ACE calculations were also performed to assess the similarity of the structural environment at each variable position in BMP-7 vs. BMP-2, BMP-4, BMP-5, BMP-6, and BMP-8. At positions with an ACE similarity score of 0.4 or higher in the table below, mutations will have similar effects in BMP-7 vs. the other BMP. ACE similarity scores between 0.6 and 0.8 indicate that the effects of mutations are highly likely to have similar effects, and ACE similarity scores greater than 0.8 indicate that the effects of mutations should be substantially identical.
  • BMP-7 variants at the following positions are transferable to BMP-2: 36, 55, 60, 83, 115, 119, 125, 126, and 128.
  • BMP-7 variants at the following positions are transferable to BMP-3: 57, 116, 117, 119, 121, 123, and 125.
  • BMP-7 variants at the following positions are transferable to BMP-3b: 116 and 119.
  • BMP-7 variants at the following positions are transferable to BMP-4: 55, 60, 115, 125, 126, and 128.
  • BMP-7 variants at the following positions are transferable to BMP-5: 36, 37, 39, 42, 44, 48, 49, 52, 53, 54, 55, 57, 60, 65, 72, 73, 76, 77, 78, 82, 83, 86, 88, 93, 105, 110, 111, 115, 116, 117, 119, 120, 121, 122, 123, 125, 126, 127, 128, 129, 130, and 139.
  • BMP-7 variants at the following positions are transferable to BMP-6: 36, 39, 44, 48, 49, 52, 53, 54, 55, 57, 60, 65, 72, 73, 76, 77, 78, 80, 82, 83, 86, 88, 93, 97, 98, 105, 108, 110, 111, 115, 116, 117, 119, 120, 121, 122, 123, 125, 126, 127, 128, 129, 130, and 139.
  • BMP-7 variants at the following positions are transferable to BMP-9: 36, 42, 44, 49, 52, 53, 55, 57, 60, 63, 75, 78, 82, 83, 93, 105, 108, 115, 117, 119, 121, 122, 123, 125, 127, 129, 130, and 139.
  • BMP-7 variants at the following positions are transferable to BMP-9: 52, 125, and 126.
  • BMP-7 variants at the following positions are transferable to BMP-10: 60, 119, and 125.
  • BMP-7 variants at the following positions are transferable to BMP-15: 49, 52, 125, and 128.
  • BMP-7 variants at the following positions are transferable to GDF-1: 36, 57, 60, 115, 116, 117, 119, 121, 123, and 125.
  • BMP-7 variants at the following positions are transferable to GDF-3: 36, 52, 60, 93, 115, 117, 119, 125, and 126.
  • BMP-7 variants at the following positions are transferable to GDF-5: 52, 53, 55, 93, 116, 117, 119, 125, and 128.
  • BMP-7 variants at the following positions are transferable to GDF-8: 57, 97, and 123.
  • BMP-7 variants at the following positions are transferable to GDF-9: 125.
  • BMP-7 variants at the following positions are transferable to TGF- ⁇ 1: 60 and 97.
  • BMP-7 variants at the following positions are transferable to TGF- ⁇ 2: 60, 93 and 97.
  • BMP-7 variants at the following positions are transferable to TGF- ⁇ 3: 60 and 97.
  • a number of constructs for the expression of wild type human BMP-7 were made and tested: (1) native BMP-7 Image clone in pSport6 vector (obtained from ATCC), (2) FLAG-tagged BMP-7, with G4S linker and FLAG tag located just after the RXXR (SEQ ID NO:87) cleavage site in pCMVTnT vector (Promega), (3) FLAG-tagged BMP-7 with a perfect Kozak sequence (MAV rather than MHV) in pCMVTnT vector, (4) FLAG-tagged BMP-7 using native BMP-2 Kozak sequence, signal sequence, and pro-domain in pCMVTnT vector, (5) FLAG-tagged BMP-7 using native MIC-1 Kozak sequence, signal sequence, and pro-domain in pCMVTnT vector, and (6) native BMP-7 Image clone in pSport6 vector (obtained from ATCC) with 6 ⁇ His tag at the N-terminus of the pro-domain.
  • Such variants include the following: L21E, L21G, L21N, L21R, M23G, M23N, M23R, V26E, V26G, V26N, K39A, K39G, K39N, Y44D, Y44G, Y44N, Y44P, Y44S, Y44T, R48D, R48H, W52P, W52T, Q53G, Q53K, Q53T, W55P, W55T, 157L, 157P, 157Q, E60H, E60N, E60P, F73G, F73K, F73N, F73T, N76Y, S77E, S77H, S77N, S77P, Y78P, Y78R, 186P, L90G, L90H, L90P, F93G, F93H, F93P, L115A, L115Q, Y116A, Y116Q, F117S, F117Y, V123G, I
  • each construct had a spacer, T7 promoter, globin UTR, and optimized ribosomal binding site preceeding the gene.
  • Luciferase was used as a positive control.
  • a coupled transcription/translation off the PCR product was used (TnT, Promega). Protein expression comparable to luciferase was obtained for all of the BMP-7 constructs other than (11) above.
  • the following small-scale expression protocol was used for initial library screening. 293T cells were plated into 6-well dishes (1-5 ⁇ 10 5 cells/mL in 4 mL DMEM 10% FBS). The next day, the cells were transfected using 5 ug DNA/well. As an internal control for transformation efficiency, several mini-preps of the native Image clone were used. After three days, the conditioned media was harvested and screened. Expression yields were determined using ELISA (all variants, not corrected for changes in antibody binding affinity, using R&D Systems ELISA Duoset Cat#DY354) and Western blotting (selected variants).
  • Preferred modifications include those modifications that increase the expression yield in 293T cells by at least 2-fold, including but not limited to L21N, K39A, K39S, Q53D, Q53T, I57L, E60Q, A63E, A63Q, A63R, A63S, Y65D, Y65N, A72D, A72E, A72H, A72K, A72S, F73H, N76A, N76D, N76S, N76T, Y78D, Y78N, Y78T, I86A, I86D, I86E, I86K, I86Q, F93H, E97D, T98K, N110D, A111S, Y116H, F117H, F117Y, S120D, R129D, N130D, R134E, R134L, R134S, A135E, A135S, and H139R.
  • Especially preferred modifications include those modifications that increase the expression yield in 293T cells by at least 5-fold, including but not limited to A63Q, A63S, Y65D, Y65N, A72D, F73H, Y78N, Y78T, I86A, and R134L. Furthermore, a silent mutation at Y116 from codon TCA to codon TAT was observed to increase the expression yield in 293T cells by 2.6-fold.
  • Expression yields of selected Library 1 variants were determined for 293T, CHO, and BRK21 cells, as shown below. Expression of the wild type Image clone does vary between expression hosts. However, the relative expression yields for the different variants tend to be improved across hosts, indicating that a variant that improves expression yield in one host tends to improve expression yield in other hosts. TABLE 13 Expression yields of selected Library 1 variants in different expression hosts Variant Variant Variant Variant Yield vs.
  • Relative expression yield was also tested as a function of DNA dose (5.0, 2.5, and 1.0 ug were tested) and was found to be dose-independent.
  • the affinity of human and variant BMP-7 for several BMP receptors was measured using an ELISA-like assay, described below.
  • 96-well plates were coated with a capture antibody (R&D Systems BMP-7 ELISA Duoset DY354, part # 840971) by diluting the antibody to 2 ⁇ g/mL in PBS, applying 50 ⁇ L/well, and incubating overnight or over the weekend at 4° C. in a humidified chamber. Excess liquid was removed from each plate. The plates were blocked by adding 175 ⁇ L blocking solution (1% BSA and 5% sucrose in PBS) to each well and incubating 1-2 hours at room temperature in a humidified chamber.
  • 175 ⁇ L blocking solution 1% BSA and 5% sucrose in PBS
  • the plates were then washed using an automated plate washer.
  • 50 ⁇ L of BMP-7 containing solution for example, diluted conditioned media obtained from the BMP-7 expression protocol above, or purified recombinant human BMP-7 of a known concentration
  • 50 ⁇ L of 5 ⁇ g/mL BMP receptor-Fc fusion in PBS was added to each well and incubated 1.5 hours at room temperature in a humidified chamber.
  • the plates were then washed using an automated plate washer.
  • the table below shows the receptor binding affinity of a selection of BMP-7 variants relative to the wild type protein (normalized to 1.0). Note that the assays were performed using a fixed volume of conditioned media rather than a specific concentration of protein, so differences in expression levels as well as differences in receptor binding affinity may affect the results. Data is shown only for variants with expression yields greater than 10.0 ng/mL. TABLE 14 Receptor binding affinity of BMP-7 Library 1 variants. ELISA Conc.
  • dissociation constants K D below
  • K D dissociation constants
  • the vast majority of the variants have receptor binding affinities that are similar to wild type BMP-7.
  • the following variants appear to have altered specificity for the type II receptors: M23N, Q53G, Q53H, and I86D.
  • Q53H and I86D bind to ActRIIa with similar affinity to wild type, but bind BMPRII with approximately 10-fold reduced affinity relative to wild type.
  • M23N and Q53G bind to ActRIIa with approximately 10-fold increased affinity relative to wild type, but bind BMPRII with similar affinity to wild type.
  • C2C12 cells are a mouse myoblastic cell line that differentiates in response to BMPs such as BMP-7.
  • C2C12 cells were trypsinized and diluted to approximately 60,000 cells/mL in C2C12 media (DMEM, 4 mM L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10% FBS, and antibiotics). 50 ⁇ L (3000 cells) were dispensed into each well of a 96-well plate and incubated overnight at 37° C.
  • BMP-7 containing solution for example, diluted conditioned media obtained from the BMP-7 expression protocol above, or purified recombinant human BMP-7 of a known concentration
  • BMP-7 containing solution for example, diluted conditioned media obtained from the BMP-7 expression protocol above, or purified recombinant human BMP-7 of a known concentration
  • CSPD SapphireII luminescent alkaline phosphatase substrate 100-150 ⁇ L CSPD SapphireII luminescent alkaline phosphatase substrate (Applied Biosystems #T2210) was added to each well and incubated at room temperature in the dark. Luminescence readings were obtained for each well using the TopCount plate reader. Luminescence of the BMP-7 variants were compared to the luminescence of known quantities of recombinant human BMP-7 in order to determine the relative biological activity of the variants.
  • the table below shows the bioactivity of a selection of BMP-7 variants relative to the wild type protein (normalized to 1.0). Note that the assays were performed using a fixed volume of conditioned media rather than a specific concentration of protein, so differences in expression levels as well as differences in receptor binding affinity may affect the results. Data is shown only for variants with expression yields greater than 10.0 ng/mL. TABLE 17 Bioactivity of BMP-7 Library 1 variants var# wt res # var ELISA Conc.
  • the point mutations from selected Library 1 variants were combined to yield a library of double mutants, referred to as Library 2.
  • Methods for making and screening the Library 2 variants are as for the Library 1 variants described above.
  • C2C12 bioassay data was determined at a single point by diluting conditioned media 1:66; due to the low expression yield of the Image clone, its bioassay signal is at background at this dilution. TABLE 18 Expression yield and bioassay data, BMP-7 Library 2 variants.
  • a number of the Library 2 variants have significantly increased expression yield, in both 293T and CHO cells, relative to the wild type Image clone.
  • Preferred variants show at least a 10-fold increase in at least one expression host; examples of such variants include but are not limited to L21G/F93H, K39A/F93H, K39S/N110D, K39S/S120D, K39S/N130D, K39S/R134E, Q53D/Y65N, Y65N/Y78H, Y65N/Y78R, Y65N/S120D, Y65N/A135S, A72D/F93H, Y78H/F93H, Y78H/Q108D, Y78H/Y116H, Y78H/F117Y, Y78H/S120D, Y78H/R134E, Y78H/R134S, Y78H/A135E, Y78H/A135S
  • variants show at least a 10-fold increase in expression yield in both 293T and CHO cells; examples of such variants include but are not limited to K39A/F93H, Y65N/S120D, A72D/F93H, Y78H/S120D, Y78H/R134E, Y78H/A135E, F93H/F117Y, F93H/S120D, F93H/R134S, and F93H/H139R.
  • triples have expression yields that are at least 50-fold higher than wild type, and at least 2-fold higher than the best doubles. Furthermore, the majority of the above triples have significantly increased bioactivity relative to wild type and the best doubles. Triple variants with especially high bioactivity include, but are not limited to, K39S/F93S/S120D, K39S/S120D/R134E, Y65N/Y78H/R134E, and A72D/Y78H/R134E. TABLE 20 Expression yield in CHO-K1 cells and bioactivity data for selected triple variants with high expression yield in CHO-K1 cells Fold Fold ELISA Increase Increase Western Conc.
  • triple mutants were generated to determine the impact of different substitutions on receptor and inhibitor binding specificity. These variants included the Y65N and S120D substitutions, which confer increased expression yield and do not significantly affect receptor or inhibitor binding, and one additional substitution that may alter binding specificity. Triples comprising Y65N/S120D, and one of the following substitutions were made: M23R, R48H, R48N, R48Q, Q53G, Q53H, Q53K, Q53T, E60R, F73S, F73T, Y78D, Y78S, Y78T, 186D, K126R, Y128D, Y128H, and Y128Q.
  • Y65N/S120D was partially purified using conventional chromatography. Heparin-sulphate sepharose (17-0407-01) was equilibrated in PBS. Conditioned media containing the Y65N/S120D variant was diluted 1:1 with 40 mM phosphate pH 6.5 filtered through a 0.45 micron filter, loaded onto the column, washed with 2-3 column volumes of PBS, and eluted in a single isocratic step with PBS/1M NaCl. The heparin bound fractions were dialyzed into 20 mM phosphate, 50 mM NaCl pH 7.0, loaded onto a SP-sepharose column, and eluted with a linear gradient (0-100% PBS/1M NaCl).
  • a second purification protocol was used for larger scale purification of variants 457 (K39S/F93S), 471 (K39S/N130D), 492 (Y65N/Y78H), 504 (Y65N/S120D), 526 (K39S/S120D/R134E), and 565 (Y65N/F93T/R129D).
  • Conditioned media was diluted 1:1 at neutral pH to lower the salt concentration to ⁇ 75 mM and loaded onto a SP-sepharose column. The column was then washed in 75 mM salt and then 300 mM salt, and BMP-7 was eluted with 1M salt.
  • BMP-7 variant Y65N/S120D partially purified as described above, was labeled with the dye AlexaFluor 568 (Molecular Probes).
  • Small-scale (25 uL) reactions were performed using 15 uM BMP-7 and dye concentrations ranging from 0.3 uM to 1000 uM. Reactions using 333 uM and 10 uM dye then were performed using 750 uL protein. The reaction was quenched with Tris pH 8.0 and cleaned up using a PD-10 desalt column; the second fraction was used in the experiments described below.
  • BMP-7 was also labeled with C6-FXS, a FITC-derived fluorophore with a 6-carbon spacer between the fluor and the NHS group. Labeling conditions with various ratios of protein to dye were tested, in 20 mM PO4, 500 mM NaCl, pH 7 solution. After establishing labeling conditions, 500 ug Y65N/S120D was labeled. Excess dye was removed by centrifugation and a PD-10 desalt column.
  • the flourescently labeled BMP-7 was added to serial dilutions of receptor/Fc fusions of the BMP-7 receptors ActRIa, BMPRIa, BMPRIb, ActRIIa, ActRIIb, and BMPRII (R&D Systems). Experiments were also performed in which the fluorescently labeled BMP-7 was added to serial dilutions of noggin/Fc or gremlin (R&D Systems). The labeled BMP-7 and receptor or inhibitor was allowed to incubate, and the fluorescence polarization and intensity was measured using a TopCount plate reader. Significant changes in intensity or anisotropy were observed for all of the receptors and inhibitors tested, for at least one of the labeled BMP-7 molecules.
  • Binding affinity of different BMP variants to these receptors and inhibitors may be determined by performing competition experiments. To perform these experiments, labeled BMP-7 and receptor or inhibitor are combined in amounts that yield an appreciable change in anisotropy or intensity relative to free labeled BMP-7. Then, varying amounts of a second, unlabeled BMP-7 molecule are added and the change in anisotropy or polarization is measured. The EC50 is then given by the concentration of competitor when half of the labeled BMP-7 is bound and half is free.
  • the Y65N/S120D variant of BMP-7 was also biotinylated for use in AlphaScreen assays using NHS-biotin. Bioactivity of the biotinylated protein was confirmed.
  • AlphaScreen assays were performed to determine the binding affinity of selected BMP-7 variants for Fc fusions of the receptors BMPRIa, BMPRIb, ActRIIa, and BMPRII and the inhibitor noggin (R&D Systems).
  • AlphaScreen assays were also performed to determine the affinity of selected variants for an anti-BMP-7 monoclonal antibody (R&D Systems mAb 3541). In all cases, 12-point binding curves were obtained in triplicate.
  • Each data point corresponds to the luminescence produced from a solution comprising 10 uL of serially diluted BMP-7 variant, 10 uL receptor, inhibitor, or antibody, 10 uL biotinylated BMP-7, 10 uL AlphaScreenTM acceptor beads, and 10 uL AlphaScreenTM donor beads. Prism was used to calculate EC50 values for selected experiments. TABLE 21 EC50 of wild type human BMP-7 (R&D Systems) and BMP-7 variants 504, 526, and 565 for the BMP receptors BMPRIb, ActRIIa, and BMPRII and the BMP inhibitor noggin, as determined using AlphaScreen TM assays. std.
  • binding affinities that are similar to wild type. Potentially significant differences include, but are not limited to, decreased noggin affinity of v526 and increased noggin affinity of v565.
  • Glycosylation removal variants are mutant BMP-7 proteins, built in either the native or F93H/R134S background that contain mutations in the consensus glycosylation site, these variants are predicted to be aglycosylated.
  • the following table summaries specific variant BMP-7 proteins created to have the listed properties: TABLE 23 Variant Property K39S_S120D_Q108D_F93S High activity and yield K39S_S120D_R129D_F93S High activity and yield K39S_S120D_Y65N_F93S High activity and yield K39S_S120D_A72D_F93S High activity and yield Y78H_R134E_Y65N_F93S High activity and yield Y78H_R134E_A72D_F93S High activity and yield K39S_S120D_Q108D_Q108D High activity and yield K39S_S120D_R129D_Q108D High activity and yield K39S_S120D_Y78H_Q108D High activity

Abstract

The invention relates to variants of BMP-2 with improved properties and methods for their use.

Description

  • This application claims benefit under 35 U.S.C. §119(e) to U.S. Ser. No. 60/558,189 filed on Mar. 31, 2004, entitled “Cysteine Knot Cytokine Variants with Improved Properties”; U.S. Ser. No. 60/570,520 filed on May 11, 2004 entitled “Cysteine Knot Cytokine Variants with Improved Properties”; U.S. Ser. No. 60/578,432 filed on Jun. 9, 2004 entitled “Cysteine Knot Cytokine Variants with Improved Properties”; and U.S. Ser. No. 60/587,464, filed on Jul. 13, 2004 entitled “Cysteine Knot Cytokine Variants with Improved Properties”, all of which are expressly incorporated by reference in their entirety.
    • FIELD OF THE INVENTION
  • The invention relates to variants of bone morphogenetic proteins and other cysteine knot growth factors with improved properties, and to methods of making and using compositions utilizing these variants.
    • BACKGROUND OF THE INVENTION
  • Bone morphogenetic proteins (BMPs) are a well-known family of growth factors that contribute to developmental processes such as pattern formation and tissue specification as well as promoting wound healing and repair processes in adult tissues. BMPs were initially isolated by their ability to induce bone and cartilage formation and are now known to regulate cell proliferation, migration, differentiation, and apoptosis in a number of tissues and organs.
  • BMPs include a number of related human proteins, such as BMP-2, BMP-3 (osteogenin), BMP-3b (GDF-10), BMP-4 (BMP-2b), BMP-5, BMP-6, BMP-7 (osteogenic protein-1 or OP-1), BMP-8 (OP-2), BMP-8B (OP-3), BMP-9 (GDF-2), BMP-10, BMP-11 (GDF-11), BMP-12 (GDF-7), BMP-13 (GDF-6, CDMP-2), BMP-15 (GDF-9), BMP-16, GDF-1, GDF-3, GDF-5 (CDMP-1), and GDF-8 (myostatin). BMPs may be grouped into subfamilies. For example, BMP-2 and BMP-4 are closely related, as are BMP-5, BMP-6, BMP-7, BMP-8, and BMP-8B. BMP-13, BMP-14, and BMP-12 also constitute a subfamily. BMPs are also present in other animal species. Furthermore, there is some allelic variation in BMP sequences among different members of the human population.
  • BMPs are a subset of the transforming growth factor-β (TGF-β) family, which also includes TGFs (TGF-β1, TGF-β2, and TGF-β3), activins (activin A) and inhibins, macrophage inhibitory cytokine-1 (MIC-1), Mullerian inhibiting substance, anti-Mullerian hormone, and glial cell line derived neurotrophic factor (GDNF). The TGF-β family is in turn a subset of the cysteine knot cytokine superfamily. Additional members of the cysteine knot cytokine superfamily include, but are not limited to, platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), placenta growth factor (PIGF), noggin, neurotrophins (BDNF, NT3, NT4, and βNGF), gonadotropin, follitropin, lutropin, interleukin-17, and coagulogen.
  • BMPs have demonstrated utility in the treatment of a variety of conditions and diseases. BMP-2 and BMP-7 have been used to promote bone formation, bone fracture healing, and spinal fusion. BMP-4 (Rundle et. al. (2003) Bone 32: 591-601), BMP-5 (Arosarena and Collins (2003) Arch. Otolaryngol. Head Neck Surg. 129: 1125-1130), BMP-6 (Helm (2003) Gene Ther. 10: 1735-1743), and BMP-9 (Li et. al. (2003) J. Gene Med. 5: 748-756), have also been demonstrated to promote bone healing in animal models. Animal studies indicate that BMP-7 may be used to treat renal fibrosis and renal failure (Wang et. al. (2001) J. Am. Soc. Nephrol. 12: 2392-2399; Wang and Hirshberg (2003) Am. J. Physiol. Renal Physiol. 284: 1006-1013; Zeisberg et. al. (2003) Nat. Med. 9: 964-968; and Zeisberg et. al. (2003) Am. J. Physiol. Renal Physiol. 285: F1060-F1067), ischemic stroke (Chang et. al. (2003) Stroke 34: 558-564 and Harvey et. al. Pharmacol. Ther. (2005) 105: 113-125) and inflammatory bowel diseases (Maric et. al. (2003) J. Cell Physiol. 196: 258-264).
  • Structurally, BMPs are dimeric cysteine knot proteins. Each BMP monomer comprises multiple intramolecular disulfide bonds. An additional intermolecular disulfide bond mediates dimerization in most BMPs. BMPs may form homodimers; furthermore some BMPs may form heterodimers. BMPs are expressed as pro-proteins comprising a long pro-domain, one or more cleavage sites, and a mature domain. The pro-domain is believed to aid in the correct folding and processing of BMPs. Furthermore, in some but not all BMPs, the pro-domain may noncovalently bind the mature domain and may act as an inhibitor (eg. Thies et. al. (2001) Growth Factors 18: 251-259).
  • BMP signal transduction is initiated when a BMP dimer binds two type I and two type 11 serine/threonine kinase receptors. Type I receptors include but are not limited to ALK-1, ALK-2 (also called ActRIa or ActRI), ALK-3 (also called BMPRIa), and ALK-6 (also called BMPRIb) and type II receptors include but are not limited to ActRIIa (also called ActRII), ActRIIb, and BMPRII. Following BMP binding, the type II receptors phosphorylate the type I receptors, the type I receptors phosphorylate members of the Smad family of transcription factors, and the Smads translocate to the nucleus and activate the expression of a number of genes.
  • BMPs also interact with inhibitors, soluble receptors, and decoy receptors, including BAMBI (BMP and activin membrane bound inhibitor), BMPER (BMP-binding endothelial cell precursor-derived regulator), Cerberus, cordin, cordin-like, Dan, Dante, follistatin, follistatin-related protein (FSRP), ectodin, gremlin, noggin, protein related to Dan and cerberus (PRDC), sclerostin, sclerostin-like, and uterine sensitization-associated gene-1 (USAG-1). Furthermore, BMPs may interact with co-receptors, for example BMP-2 and BMP-4 bind the co-receptor DRAGON (Samad et. al. (2005) J. Biol. Chem.), and extracellular matrix components such as heparin sulfate and heparin (Irie et. al. (2003) Biochem. Biophys. Res. Commun. 308: 858-865)
  • For further background on the BMP family, see Balemans and Hul (2002) Dev. Biol. 250: 231-250; Bubnoff and Cho (2001) Dev. Biol. 239: 1-14; Celeste et. al. (1990) Proc. Nat. Acad. Sci. USA 87: 9843-9847; and Cheng et. al. (2003) J. Bone Joint Surgery 85A: 1544-1552
  • A number of unfavorable properties of naturally occurring BMPs limit the development and use of BMP therapeutics. BMP expression yields are typically poor and suitable expression hosts are limited, hindering development and production. BMPs often possess multiple biological effects, including unwanted side effects. Many BMPs are poorly soluble, reducing storage stability and bioavailability. Finally, BMPs may induce unwanted immune responses.
  • Earlier studies have identified BMP variants with a number of interesting properties. BMP variants with improved yield in the context of E. coli expression and subsequent refolding from inclusion bodies have been disclosed (U.S. Pat. No. 5,399,677; U.S. Pat. No. 5,804,416; and U.S. Pat. No. 6,677,432). Consensus BMP variants with BMP-like activity have also been described (U.S. Pat. No. 5,011,691; U.S. Pat. No. 6,395,883; U.S. Pat. No. 6,531,445). A BMP-2 point mutant, L51P, has been described that does not bind type I receptors but binds type II receptors normally (Keller et. al. (2004) Nat. Struct. Mol. Biol. 11: 481-488). Deletion mutants of BMP-4 that act as competitive inhibitors of BMP signaling have been disclosed (Weber et. al. (2003) J. Bone Miner. Res. 18: 2142-2151). Mutagenesis experiments have also been performed on BMP-2 to identify residues important for receptor binding; some of these variants were found to act as antagonists (Kirsch et. al. (2000) EMBO J. 19: 3314-3324 and Nickel et. al. (2001) J. Bone Joint Surg. Am. 83-A: S7-S14). In addition, methods for identifying analogs of morphogenetic proteins have been claimed (U.S. Pat. No. 6,273,598). Furthermore, several point mutants of ActA with reduced ALK-4 binding have been identified: S60P, 163P, M91 E, 1105E, and M108A (Harrison et. al. (2004) J. Biol. Chem. 279: 28036-28044).
    • SUMMARY OF THE INVENTION
  • The present invention is related to variants of human bone morphogenetic proteins and other cysteine knot cytokine proteins with improved properties, including increased expression yield, expression in the absence of a pro-domain, increased solubility, increased specific activity, altered receptor, co-receptor, and inhibitor specificity, and decreased immunogenicity.
  • In one aspect, the invention provides variant BMP-7 protein comprising the sequence:
    Fx(1-20)-Vb(21)-Fx(22-38)-Vb(39)-Fx(40-64)-Vb(65)-Fx(66-71)-Vb(72)-Fx(73-77)-Vb(78)-Fx(79-92)-Vb(93)-Fx(94-119)-Vb(120)-Fx(121-134)-Vb(135)
  • wherein
      • Fx1(1-20) corresponds to amino acid residues 1-20 of human BMP-7 (SEQ ID NO:5);
      • Vb(21) is selected from the group consisting of L and G;
      • Fx(22-38) corresponds to amino acid residues 22-38 of human BMP-7 (SEQ ID NO:5);
      • Vb(39) is selected from the group consisting of K, A and S;
      • Fx(40-64) corresponds to amino acid residues 40-64 of human BMP-7 (SEQ ID NO:5);
      • Vb(65) is selected from the group consisting of Y and N;
      • Fx(66-71) corresponds to amino acid residues 66-71 of human BMP-7 (SEQ ID NO:5);
      • Vb(72) is selected from the group consisting of A and D;
      • Fx(73-77) corresponds to amino acid residues 73-77 of human BMP-7 (SEQ ID NO:5);
      • Vb(78) is selected from the group consisting of Y and H;
      • Fx(79-92) corresponds to amino acid residues 79-92 of human BMP-7 (SEQ ID NO:5);
      • Vb(93) is selected from the group consisting of F, H, S and T;
      • Fx(94-119) corresponds to amino acid residues 94-119 of human BMP-7 (SEQ ID NO:5);
      • Vb(120) is selected from the group consisting of S and D;
      • Fx(121-134) corresponds to amino acid residues 121-134 of human BMP-7 (SEQ ID NO:5);
      • Vb(135) is selected from the group consisting of A and E;
      • wherein the variant comprises an amino acid substitution as compared to human BMP-7 (SEQ ID NO:5).
  • In a further aspect, the invention provides variant BMP-7 proteins comprising a substitution as compared to human BMP-7 (SEQ ID NO:5) selected from the group consisting of: L21G, K39A, K39S, Y65N, A72D, Y78H, F93H, F93S, F93T, SI 20D and A135E. In both cases, particular variants with single substitutions include, L21G, K39A, K39S, Y65N, A72D, Y78H, F93H, F93S, F93T, S120D and A135E. Particular sets of substitutions include, K39S-F93S; K39S-S120D; K39S-S120D-Y65N; K39S-S120D-A72D; K39S-S120D-Y78H; K39S-S120D-F93H; K39S-S120D-F93S; Y65N-L21G; Y65N-L21R; Y65N-K39S; Y65N-Y78H; Y65N-S120D; Y78H-A72D; Y78H-F93H-Y65N; Y78H-F93H-A72D; Y78H-F93H-S120D; Y78H-S120D and F93H-K39S.
  • In an additional aspect, the invention provides variant BMP-7 proteins having altered receptor binding affinity compared to wild-type BMP-7 (SEQ ID NO:5), the variant BMP-7 protein comprising one or more substitutions selected from the group consisting of: M23N, Q53G, Q53H and I86D.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows sequence alignments of the mature domains of human BMP and GDF proteins (Residues 14-114 of SEQ ID NO:1, residues 16-116 of SEQ ID NO:2, residues 37-138 of SEQ ID NO:3, residues 38-139 of SEQ ID NO:4, residues 38-139 of SEQ ID NO:5, residues 38-139 of SEQ ID NO:6 and SEQ ID NOS:71-83). The consensus BMP sequence and the MIC-1 sequence are shown for reference. The N-terminal most residues of the mature domain, which are significantly less well aligned, are not shown.
  • FIG. 2 shows the hexameric structure comprising BMP-7 dimer bound to two type I receptors and two type II receptors. The structure was generated by superimposing BMP-2 (white) bound to ALK-3 (gray, upper right and lower left) and BMP-7 (black) bound to ActRIIa (gray, upper left and lower right).
  • FIG. 3 shows alignments of human type I BMP receptors and human type II BMP receptors used for homology modeling (SEQ ID NOS:7-12).
  • FIG. 4 shows 12-point binding curves for wild-type BMP-7 (Image clone) binding to ActRIIa, BMPRII, BMPRIa, and BMPRIb.
  • FIG. 5 shows 12-point binding curves for (A) BMPRIa (ALK-3), (B) BMPRIb (ALK-6), (C) ActRIIa, and (D) BMPRII. The thick black lines are wild type BMP-7 (Image clone). The thin gray lines correspond to variants.
  • FIG. 6 shows dose-response C2C12 biassay data for selected Library 1 variants. Highlighted variants in (A) include: F93Q (black hollow circles), F93S (gray filled diamonds), N110D (gray filled squares), S120D (black hollow squares), A135E (black hollow triangles), A135S (black filled circles) and wild type (thick black line, no markers). Additional variants are shown in (A) and (B)
  • FIG. 7 shows 12-point binding curves for (A) BMPRIa (ALK-3), (B) BMPRIb (ALK-6), (C) ActRIIa, and (D) BMPRII. Two replicates of wild type (Image clone) are shown (thick black line, filled black circles). Variants are shown in thin gray lines, no markers.
  • FIG. 8 shows a summary of 12-point receptor binding curves for wild type human BMP-7 (Image clone) and variants.
  • FIG. 9 shows dose-response C2C12 biassay data for selected Library 2 variants.
  • FIG. 10 shows dose-response C2C12 biassay data for selected Library 3 variants, Library 1 variants (thick gray lines, no markers), and wild type (thick black line, no markers).
  • FIG. 11 shows (A) ELISA quantitation of the expression yield of the best single, double, and triple variants in 293T cells (black bars) and CHO cells (white bars) and (B) that enhanced expression yield of the best-expressing single, double, and triple mutant variants results in increased C2C12 bioactivity from serially diluted conditioned media.
  • FIG. 12 shows appropriate correction factors when using a commercial ELISA (R&D Systems) to determine the concentration of selected BMP-7 variants.
  • FIG. 13 shows purification of selected BMP-7 variants.
  • FIG. 14 shows fluorescence images of SDS-PAGE gels showing (A) Alexa 568 labeling of BMP-7 variant Y65N/S120D as a function of dye concentration; and (B) scale-up of Alexa-568 labeled Y65N/S120D BMP-7.
  • FIG. 15 shows fluorescence anisotropy as a function of receptor concentration.
  • FIG. 16 shows that binding of Alexa568-labeled Y65N/S120D BMP-7 to the receptor ActRIIa can be competed with unlabeled BMP-7.
  • FIG. 17 shows competitive binding of (A) recombinant human BMP-7 (R&D Systems), (B) BMP-7 variant 565 (Y65N/F93T/R129D), (C) BMP-7 variant 526 (K39S/S120D/R134E), and (D) BMP-7 variant 504 (Y65N/S120D) to the BMP receptors and inhibitors BMPRIb (open circles), ActRIIa (closed diamonds), BMPRII (closed triangles), and Noggin (stars) determined using AlphaScreen.
  • FIG. 18 shows a bar graph indicating the EC50 of binding for four BMP-7 variants to three receptors and one inhibitor.
    • DETAILED DESCRIPTION OF THE INVENTION
  • By “BMP responsive disorders” and grammatical equivalents herein is meant diseases, disorders, and conditions that may benefit from treatment with one or more BMPs. Examples of BMP responsive disorders include, but are not limited to, cartilage, bone, and tooth disorders or conditions including but not limited to bone fractures, bone degeneration, osteoporosis, spinal fusion, spinal degenerative disc disease, osteotomy, orthopedic and reconstructive surgery, and periodontal disease; repair of tendons and ligaments; renal disease including but not limited to chronic or acute renal failure, renal injury due to reperfusion, drug-induced renal toxicity, renal fibrosis, renal osteodystrophy, and vascular complications resulting from kidney disease; liver disease including but not limited to cirrhosis and hepatic fibrosis; lung disease including but not limited to asthma, emphysema, and pulmonary fibrosis; wound healing; cancers including but not limited to prostate cancer; inflammatory bowel disease; conditions that would benefit from a neuroprotective agent including but not limited to stroke, Parkinson's disease, traumatic brain injury, and amyotrophic lateral sclerosis; and skin and hair disorders. By “exposed residues” and grammatical equivalents herein are meant those residues whose side chains have at least 50 Å2 (square Angstroms) of solvent accessible surface area in the context of a specified protein structure, preferably an x-ray crystal structure. As will be appreciated by those skilled in the art, other values such as 75 Å2 (square Angstroms) or fractional values such as 50% could be used instead. Furthermore, alternative methods such as contact models, among others, may be used to identify exposed residues. By “expression yield” and grammatical equivalents herein is meant the amount of protein, preferably in mg/L or PCD (picograms per cell per day) that is produced or secreted under a given expression protocol (that is, a specific expression host, transfection method, media, time, etc.). By “improved expression yield” and grammatical equivalents herein is meant an increase in expression yield, relative to a wild type or parent protein, under a given set of expression conditions. In a preferred embodiment, at least a 50% improvement is achieved, with improvements of at least 100%, 5-fold, 10-fold, or more being especially preferred. In another preferred embodiment, the expression yield is improved to yields of at least 1 μg/ml, with at least 10 μg/ml or 100 μg/ml being especially preferred. By “hydrophobic residues” and grammatical equivalents are meant valine, isoleucine, leucine, methionine, phenylalanine, tyrosine, and tryptophan. By “interface residues” and grammatical equivalents herein are meant those residues located within 8 Å (Angstroms) of a protein-protein contact. Distances of less than 5 Å (Angstroms) are especially preferred. Distances may be measured in the context of any structure, with high-resolution crystal structures being especially preferred. By “library” as used herein is meant a collection of protein sequences that are likely to take on a particular fold or have particular protein properties. The library preferably comprises a set of sequences resulting from computation, which may include energy calculations or statistical or knowledge based approaches. Libraries that range in size from about 5 to about 1013 sequences are preferred. Libraries are generally generated experimentally and analyzed for the presence of members possessing desired protein properties. By “mature domain” herein is meant, in the context of BMP-7, a domain substantially comprising residues 1-137 of BMP-7. In wild type BMP-7, the mature domain is cleaved from the pro-domain by furin or a furin-like proprotein convertase. By “modification” and grammatical equivalents is meant one or more insertions, deletions, or substitutions to a protein or nucleic acid sequence. By “naturally occurring” or “wild type” or “wt” and grammatical equivalents thereof herein is meant an amino acid sequence or a nucleotide sequence that is found in nature, including allelic variations. In a preferred embodiment, the wild type sequence is the most prevalent human sequence. However, the wild type BMP nucleic acids and proteins may be a less prevalent human allele or BMP nucleic acids and proteins from any number of organisms, including but not limited to rodents (rats, mice, hamsters, guinea pigs, etc.), primates, and farm animals (including sheep, goats, pigs, cows, horses, etc). By “nucleic acid” and grammatical equivalents herein is meant DNA, RNA, or molecules which contain both deoxy- and ribonucleotides. Nucleic acids include genomic DNA, cDNA and oligonucleotides including sense and anti-sense nucleic acids. Nucleic acids may also contain modifications, such as modifications in the ribose-phosphate backbone that confer increased stability and half-life. By “polar residues” and grammatical equivalents herein are meant aspartic acid, asparagine, glutamic acid, glutamine, lysine, arginine, histidine, serine, and threonine. By “pro-domain” herein is meant, in the context of a BMP or other TGF-β family member, the N-terminal domain that is removed following cleavage by furin or a furin-like proprotein convertase. The presence of the pro-domain may promote proper folding and processing. By “protein” herein is meant a molecule comprising at least two covalently attached amino acids, which includes proteins, polypeptides, oligopeptides and peptides. The protein may be made up of naturally occurring amino acids and peptide bonds, or synthetic peptidomimetic structures such as peptoids (see Simon et al. (1992) Proc. Natl. Acad. Sci. USA 89: 9367-9371). For example, homo-phenylalanine, citrulline, and noreleucine are considered amino acids for the purposes of the invention, and both D- and L-amino acids may be utilized. By “protein properties” herein are meant physical, chemical, and biological properties including but not limited to physical properties (including molecular weight, hydrodynamic properties such as radius of gyration, net charge, isoelectric point, and spectral properties such as extinction coefficient), structural properties (including secondary, tertiary, and quaternary structural elements) stability (including thermal stability, stability as a function of pH or solution conditions, storage stability, and resistance or susceptibility to ubiquitination, proteolytic degradation, or chemical modifications such as methionine oxidation, asparagine and glutamine deamidation, sidechain racemerization or epimerization, and hydrolysis of peptide bonds), solubility (including susceptibility to aggregation under various conditions, oligomerization state, and crystallizability), kinetic and dynamic properties (including flexibility, rigidity, folding rate, folding mechanism, allostery, and the ability to undergo conformational changes and correlated motions), binding affinity and specificity (to one or more molecules including proteins, nucleic acids, polysaccharides, lipids, and small molecules, and including affinities and association and dissociation rates), enzymatic activity (including substrate specificity; association, reaction, and dissociation rates; reaction mechanism; and pH profile), ammenability to synthetic modification (including PEGylation and attachment to other molecules or surfaces), expression properties (such as yield in one or more expression hosts, soluble versus inclusion body expression, subcellular localization, ability to be secreted, and ability to be displayed on the surface of a cell), processing and posttranslational modifications (including proteolytic processing, N- or C-linked glycosylation, lipidation, sulfation, and phosphorylation), pharmacokinetic and pharmacodynamic properties (including bioavailability following subcutaneous, intramuscular, oral, or pulmonary delivery; serum half-life, distribution, and mechanism and rate of elimination) and ability to induce altered phenotype or changed physiology (including immunogenicity, toxicity, ability to signal or inhibit signaling, ability to stimulate or inhibit cell proliferation, differentiation, or migration, ability to induce apoptosis, and ability to treat disease). By “solubility” and grammatical equivalents herein is meant the maximum possible concentration of protein, in the desired or physiologically appropriate oligomerization state, in a solution of specified condition (i.e. pH, temperature, concentration of any buffer components, salts, detergents, osmolytes, etc.). Unless otherwise noted, dimeric BMPs are the desired species. By “soluble expression” and grammatical equivalents herein is meant that the protein is able to be produced at least partially in soluble form rather than in inclusion bodies when expressed in a prokaryotic host. It is preferred that at least 1 μg soluble protein is produced per 100 mL culture, with at least 10 μg or 100 μg being especially preferred. By “improved solubility” and grammatical equivalents herein is meant an increase in the maximum possible concentration of protein, in the desired or physiologically appropriate oligomerization state, in solution. For example, if the naturally occurring protein can be concentrated to 1 mM and the variant can be concentrated to 5 mM under the same solution conditions, the variant can be said to have improved solubility. In a preferred embodiment, solubility is increased by at least a factor of 2, with increases of at least 5-fold or 10-fold being especially preferred. As will be appreciated by those skilled in the art, solubility is a function of solution conditions. For the purposes of this invention, solubility should be assessed under solution conditions that are pharmaceutically acceptable. Specifically, pH should be between 6.0 and 8.0, salt concentration should be between 50 and 250 mM. Additional buffer components such as excipients may also be included; although it is preferred that albumin is not required. By “variant BMP nucleic acids” and grammatical equivalents herein is meant nucleic acids that encode variant BMPs. Due to the degeneracy of the genetic code, an extremely large number of nucleic acids may be made, all of which encode the variant BMPs of the present invention, by simply modifying the sequence of one or more codons in a way that does not change the amino acid sequence of the variant BMP. By “variant BMPs” or “non-naturally occurring BMPs” and grammatical equivalents thereof herein is meant non-naturally occurring BMPs which differ from a wild type or parent BMP by at least one (1) amino acid insertion, deletion, or substitution. It should be noted that unless otherwise stated, all positional numbering of variant BMPs and variant BMP nucleic acids is based on these sequences. BMP variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the BMP sequence. BMP variants must retain at least 50% of wild type BMP activity in one or more cell types, as determined using an appropriate assay described below. Variants that retain at least 75% or 90% of wild type activity are more preferred, and variants that are more active than wild type are especially preferred. Alternatively, in some embodiments BMP variants may be engineered to have different activities than a wild type BMP. For example, competitive inhibitors may be designed. A variant BMP may contain insertions, deletions, and/or substitutions at the N-terminus, C-terminus, or internally. In a preferred embodiment, variant BMPs have at least 1 residue that differs from the most similar human BMP sequence, with at least 2, 3, 4, or 5 different residues being more preferred. Variant BMPs may contain further modifications, for instance mutations that alter additional protein properties such as stability or immunogenicity or which enable or prevent posttranslational modifications such as PEGylation or glycosylation. Variant BMPs may be subjected to co- or post-translational modifications, including but not limited to synthetic derivatization of one or more side chains or termini, glycosylation, PEGylation, circular permutation, cyclization, fusion to proteins or protein domains, and addition of peptide tags or labels.
  • Naturally occurring BMPs regulate cell proliferation, migration, differentiation, and apoptosis in a number of tissues and organs; as a result BMPs may serve many therapeutic uses. However, naturally occurring BMPs are difficult to produce in large amounts, are sparingly soluble, exhibit pleiotropic activities, and may induce unwanted immune responses.
  • Here, are disclosed novel variants of human BMPs. These BMP variants comprise one or more modifications that were selected to improve biophysical properties and clinical performance.
  • Strategies for Improving Expression Yield
  • Reported expression yields for BMPs are typically very low. Reported yields range from 2-6 ng/mL for transiently transfected COS-1 cells in roller bottle culture to 100-200 ng/mL in DHFR-amplified stably transfected CHO cells, see U.S. Pat. No. 6,048,964 to John C. Lee, et al. To facilitate the development and therapeutic use of BMPs, it would be desirable to increase the expression yield to at least 10 μg/ml, with at least 100 μg/ml being more preferred and at least 1000 μg/ml being especially preferred.
  • A number of nucleic acid properties and protein properties may influence expression yields; furthermore the expression host and expression protocol contribute to yields. Any of these parameters may be optimized to improve expression yields. Also, expression yield may be improved by the incorporation of one or mutations that confer improved stability and/or solubility, as discussed further below. Furthermore, interactions between the pro-domain and the mature domain may influence folding efficiency, and so the pro-domain may also be targeted for modification.
  • In a preferred embodiment, nucleic acid properties are optimized to improve expression yields using one or more of the following strategies: 1) replace imperfect Kozak sequence, 2) reduce 5′ GC content and secondary structure of the RNA, 3) optimize codon usage, 4) use an alternate leader sequence, 5) include a chimeric intron, or 6) add an optimized poly-A tail to the C-terminus of the message. In another preferred embodiment, protein properties are optimized to improve expression yields using one or more of the following strategies: 1) optimize the signal sequence, 2) optimize the proteolytic processing site, 3) replace one or more cysteine residues in order to minimize formation of improper disulfide bonds, 4) improve the rate or efficiency of protein folding, or 5) increase protein stability, especially proteolytic stability. In an alternate preferred embodiment, alternate pro-domain sequences are used. For example, the pro-domain from BMP-2 may be used to aid in the expression of BMP-4 (Wozney et. al. (1988) Science 242: 1528-1534). Pro-domains that may be used include but are not limited to the pro-domains from any BMP sequence and the MIC-1 pro-domain. The pro-domain may be expressed in cis or in trans.
  • In an additional preferred embodiment, transfection or expression conditions are optimized to increase expression yields. For example, since furin and other pro-protein convertase enzymes require calcium, the addition of calcium to the media during expression may increase the yield of properly processed protein. As another example, proteosome inhibitors may be added to minimize proteosomal degradation. Fetal calf serum or heparin may also be used. In a further preferred embodiment, the expression host is selected to optimize expression yields. Folding and processing of BMPs is relatively complex and may be assisted by appropriate chaperones. These chaperones may not be expressed equally in all mammalian cell lines. BMP-7 is naturally produced in the kidney and several well-established expression lines are derived from the kidney; in a preferred embodiment BMP-7 is expressed in a kidney cell line including but not limited to 293T, 239-EBNA, COS, and BHK. In another preferred embodiment, the cleavage site in BMP-7 is optimized to promote more efficient proteolytic processing by furin and related subtilisin-like proprotein convertase enzymes. Substrate preferences for furin have been well-characterized (Henrich et. al. (2003) Nat. Struct. Biol. 10: 520-526; Holyoak et. al. (2004) Biochem. 43: 2412-2421; and Duckert et. al. (2004) PEDS 17: 107-112), and cleavage sites in BMP and TGF-β proteins have been analyzed (Constam and Robertson (1999) JBC 144: 139-149). In an alternate preferred embodiment, BMP-7 is expressed in a cell line that is co-transfected with one or more chaperone or processing proteins, including but not limited to furin.
  • Strategies for Enabling the Use of Alternate Expression Hosts
  • BMPs are typically expressed in mammalian cells. In order to enable the use of alternate expression systems, including but not limited to yeast expression systems, it would be desirable to 1) eliminate the N-linked glycosylation site, 2) eliminate potential O-linked glycosylation sites, 3) enable expression in the absence of the pro-domain, and 4) enable processing by an alternate protease present in the desired expression host. In a preferred embodiment, one or more N- or O-linked glycosylation sites is removed. Removal of glycosylation sites from variant BMP polypeptides may be accomplished, for example, by the elimination of one or more serine or threonine residues to the native sequence or variant BMP polypeptide (for O-linked glycosylation sites) or by the modification of a canonical N-linked glycosylation site, N-X-Y-X, where X is any amino acid except for proline and Y is threonine, serine or cysteine. In another preferred embodiment, pro-domain dependence is reduced or eliminated by 1) introducing mutations that stabilize the folded state of the BMP; 2) reducing the exposed hydrophobic surface area of BMP; 3) stabilizing one or more intermediates along the folding pathway of BMP; or 4) replacing one or more pairs of cysteine residues forming a disulfide bond. In an additional preferred embodiment, the furin cleavage site is modified to allow recognition by an alternate protease that is present in the desired expression host. For example, the furin cleavage site may be changed to a kexin cleavage site to facilitate yeast expression. Kexin cleavage sites have been well characterized; see for example Holyoak et. al. (2004) Biochem. 43: 2412-2421.
  • In an alternate preferred embodiment, the BMPs are expressed using in vitro translation. A number of factors may be added to the reaction to improve the yield of total protein and of correctly folded protein, including but not limited to 1) pro-domains from any TGF-β family member, including but not limited to BMP-2, BMP-4, BMP-7, and MIC-1; 2) accessory factors and chaperones including but not limited to cysteine isomerases, proline isomerases, BiP, heat shock proteins, furin, and other proprotein convertases; 3) redox agents including but not limited to glutathione; 4) monovalent and divalent cations including but not limited to sodium, potassium, calcium, zinc, and magnesium; and 5) microsomes.
  • Strategies for Improving Solubility
  • A variety of strategies may be utilized to design BMP variants with improved solubility and expression yield. In a preferred embodiment, one or more of the following strategies are used: 1) reduce hydrophobicity by substituting one or more solvent-exposed hydrophobic residues with suitable polar residues, 2) increase polar character by substituting one or more neutral polar residues with charged polar residues, 3) increase protein stability, for example by one or more modifications that improve packing in the hydrophobic core, increase beta sheet forming propensity, improve helix capping and dipole interactions, or remove unfavorable electrostatic interactions (increasing the stability of a protein may improve solubility by decreasing the population of partially folded or misfolded states that are prone to aggregation), and 4) modify one or more residues that can affect the isoelectric point of the protein (that is, aspartic acid, glutamic acid, histidine, lysine, arginine, tyrosine, and cysteine residues). Protein solubility is typically at a minimum when the isoelectric point of the protein is equal to the pH of the surrounding solution. Modifications that perturb the isoelectric point of the protein away from the pH of a relevant environment, such as serum, may therefore serve to improve solubility. Furthermore, modifications that decrease the isoelectric point of a protein may improve injection site absorption (Holash et. al. (2002) Proc. Nat. Acad. Sci. USA 99: 11393-11398).
  • Strategies for Altering Receptor Binding Affinity or Specificity
  • Several strategies may be used to design BMP variants with improved receptor binding affinity or specificity. In a preferred embodiment, diversity is incorporated at one or more receptor interface positions. However, as is known in the art, modifications at positions distal to the receptor binding interface may also alter binding affinity or specificity. In an especially preferred embodiment, modifications are made to positions in BMP that contact one or more non-conserved receptor positions. For example, Arg 48, Gln 53, and Glu 60 in BMP-7 contacts position 76 in the type II receptor; this position is Glu in ActRIIb, Lys in ActRII, and Thr in BMPRII. Some BMPs, such as BMP-2, bind more tightly to type I receptors while other BMPs, such as BMP-7, have higher affinity for type II receptors. In an additional preferred embodiment, a BMP is modified such that its lower affinity receptor binding site is made more similar to a BMP for which that site is the higher affinity site. For example, the type I receptor interface of BMP-7 may be modified to be more similar to BMP-2, or the type II receptor interface of BMP-2 may be altered to be more BMP-7-like. In an alternate embodiment, modifications are made to stabilize the bound conformation of BMP versus the free conformation. For example, BMP-7 binds first to the type II receptor and then to the type I receptor, and binding to the type II receptor may increase binding affinity for the type I receptor. Binding to the type II receptor causes a conformational change in BMP, producing what may be a higher affinity state. Accordingly, mutations may be introduced to stabilize the bound state.
  • Strategies for Evading BMP Inhibitors
  • A number of soluble and membrane bound proteins function as endogenous inhibitors of BMP action. In a preferred embodiment, BMPs are engineered to reduce or eliminate binding affinity for one or more BMP inhibitors while retaining affinity for one or more of the BMP receptors. Rational alteration of inhibitor specificity may be used to control the site of BMP action, as many of the inhibitors are expressed in specific tissues or organs. Similar approaches may be used to alter specificity for co-receptors such as DRAGON, extracellular matrix components such as heparin and heparin sulfate, and serum components such as alpha2-macroglobulin.
  • Protein Design and Engineering Methods
  • A number of methods can be used to identify modifications (that is, insertion, deletion, or substitution mutations) that will yield BMP variants with improved properties. These methods include, but are not limited to, sequence profiling (Bowie and Eisenberg (1991) Science 253: 164-170), rotamer library selections (Dahiyat and Mayo (1996) Protein Sci 5: 895-903; Dahiyat and Mayo, Science (1997) 278: 82-87; Desjarlais and Handel (1995) Prot. Sci. (1995) 4: 2006-2018; Harbury et. al. (1995) Proc. Nat. Acad. Sci. USA 92: 8408-8412; Kono et al., Proteins (1994) 19: 244-255; Hellinga and Richards (1994) Proc. Nat. Acad. Sci. USA 91: 5803-5807); and residue pair potentials (Jones (1994) Prot. Sci. 3: 567-574).
  • In a preferred embodiment, one or more sequence alignments of BMPs and related proteins is analyzed to identify residues that are likely to be compatible with each position. In a preferred embodiment, the PFAM or BLAST alignment algorithm is used to generate alignments of the BMP subfamily, the TGF-β family, or the cysteine knot cytokine superfamily. For each variable position, suitable substitutions may be defined as those residues that are observed at the same position in homologous sequences. Especially preferred substitutions are those substitutions that are frequently observed in homologous sequences. In an additional preferred embodiment, an Analogous Contact Environment (ACE) algorithm, U.S. patent application Ser. No. 11/00,647, filed Dec. 8, 2004, is used in conjunction with the sequence alignment information to identify alternate suitable residues that are located in structurally similar environments in other BMPs or homologs. In an especially preferred embodiment, rational design of improved BMP variants is achieved by using Protein Design Automation® (PDA®) technology; see U.S. Pat. Nos. 6,188,965; 6,269,312; 6,403,312; 6,708,120; WO98/47089 and U.S. Ser. Nos. 09/058,459, 09/127,926, 60/104,612, 60/158,700, 09/419,351, 60/181,630, 60/186,904, 09/419,351, 09/782,004 and 09/927,790, 60/347,772, and 10/218,102; and PCT/US01/218,102 and U.S. Ser. No. 10/218,102, U.S. Ser. No. 60/345,805; U.S. Ser. No. 60/373,453 and U.S. Ser. No. 60/374,035, or using the sequence prediction algorithm (SPA) (Raha et al. (2000) Protein Sci., 9: 1106-1119; U.S. Ser. No. 09/877,695, filed Jun. 8, 2001 and 10/071,859, filed Feb. 6, 2002).
  • Structural Analysis of BMPS
  • Obtaining Structures of BMPS
  • PDA® technology calculations require a template protein structure. In one embodiment, the structure of a human BMP is obtained by x-ray crystallography or NMR. Structures of BMPs include BMP-2 (PDB code 3BMP, Scheufler et. al. (1999) J. Mol. Biol. 287: 103), BMP-2 mutant L51P (PDB code 1 REU, Keller et. al. (2004) Nat. Struct. Mol. Biol. 11: 481) and wild type human BMP-7 (PDB code 1 LXI Griffith et. al. (1996) Proc. Nat. Acad. Sci. USA 93: 878-883). It is also possible to use the crystal structure of another cysteine knot cytokine protein, such as TGF-β2 (PDB code 1TFG, Schlunegger and Grutter (1992) Nature 358: 430), or NMR structures of cysteine knot cytokine proteins such as TFG-β1 (PDB codes 1KLA, 1KLC, and 1KLD; Hinck et. al. (1996) Biochem. 35: 5817) In an especially preferred embodiment, the crystal structure is a co-crystal structure comprising a BMP and a BMP receptor. High-resolution structures are available for BMP-7 in complex with the receptor ActRIIa (PDB code 1LX5, Greenwald et. al. (2003) Mol. Cell 11: 605-617), activin A bound to ActRIIb (PDB codes 1NYS and 1NYU, Thompson et. al. (2003) EMBO J. 22: 1555-1566), and BMP-2 bound to ALK-3 (PDB code 1ES7, Kirsch et. al. (2000) Nat. Struct. Biol. 7: 492; and PDB code 1REW, Keller et. al. (2004) Nat. Struct. Mol. Biol. 11: 481). In another preferred embodiment, the crystal structure is a co-crystal structure comprising BMP and a BMP inhibitor. A high resolution structure is available for BMP-7 bound to the soluble inhibitor noggin (PDB code 1M4U, Groppe et. al. (2002) Nature 420: 636). Structures of additional BMPs alone and bound to one or more receptors or inhibitors may be built using NMR or x-ray crystal structures including but not limited to those described above in conjunction with homology modeling, structural alignment, and protein-protein docking methods known in the art.
  • Identifying Furin Cleavage Sites
  • The furin cleavage sites of BMPs may be determined by scanning for the consensus furin cleavage site, R-X-X-K/R (SEQ ID NO:84), in the residues located N-terminally relative to the aligned regions of the BMP mature domains. The sequence of BMP-7 in the region of the cleavage site is (from P8 to P1 before the cleavage site and from P1′ to P4′ after the cleavage site, with “|” indicating the cleaved bond) is EVHLRSIR|STGG (SEQ ID NO:85), wherein the residues “STGG” comprise residues 1 through 4 of the BMP-7 mature domain (SEQ ID NO:5). The most favored furin cleavage site comprises R at P4, R at P1, and K or R at P2. It is also favorable to have at least one basic residue in residues P5-P8. Some BMPs have multiple cleavage sites. For example, BMP-4 has two cleavage sites, and sequential cleavage is thought to provide a mechanism for regulation of activation and signaling range (Degnin et. al. (2004) Mol. Biol. Cell 15: 5012-5020).
  • Identifying Glycosylation Sites
  • BMP-7 has an N-linked glycosylation site at Asn 80. When expressed in mammalian cells, the mature domain of BMP-7 does not include any O-linked glycosylation sites. However, it is possible that one or more serine or threonine residues would be susceptible to glycosylation in alternate expression hosts, including but not limited to yeast and Baculovirus expression systems. The presence and location of such O-linked glycosylation sites may be determined experimentally, for example using mass spectrometry.
  • Identifying Solvent-Exposed Hydrophobic Residues
  • As used herein, exposed hydrophobic residues in BMP-7 include but are not limited to Tyr 44, Trp 52, Trp 55, Ile 57, Phe 73, Tyr 78, Ile 86, Leu 90, Phe 93, Ile 94, Leu 115, Tyr 116, Tyr 117, Val 123, Leu 125, and Tyr 128. BMP-7 also contains three hydrophobic residues in the disordered N-terminal region (that is, residues 1-35). While these residues are not observed in the crystal structures of BMP-7, it is highly likely that they are significantly exposed to solvent. In a preferred embodiment, these additional hydrophobic residues, Leu 21, Met 23, and Val 26, are also considered solvent exposed hydrophobic residues.
  • Identifying Residues at the Receptor Binding Sites
  • In a preferred embodiment, residues that mediate intermolecular interactions between BMPs and their receptors are replaced with structurally and functionally compatible residues that confer improved receptor binding affinity or specificity. Preferred residues at the BMP/type I receptor interface include, but are not limited to, residues Lys 39, Phe 47, Asp 49, Leu 50, Gly 51, Pro 74, Leu 75, Asn 76, Ser 77, Tyr 78, Asn 80, Asn 83, Ile 86, Leu 90, Phe 93, Ile 94, Pro 96, Tyr 116, Lys 126, Tyr 128, Arg 129, Asn 130, and Met 131. Preferred residues at the BMP/type II receptor interface include, but are not limited to, residues Tyr 44, Arg 48, Gln 53, Ile 57, Ala 58, Pro 59, Glu 60, Gly 61, Tyr 62, Ala 63, Gln 108, Asn 110, Ala 111, Ile 112, Ser 113, Val 114, Leu 115, Phe 117, Asn 122, Val 123, Leu 125, Lys 127, and Arg 134.
  • Identifying Residues at Inhibitor Binding Sites
  • In a preferred embodiment, residues that mediate intermolecular interactions between BMPs and their inhibitors are replaced with structurally and functionally compatible residues that confer reduced inhibitor binding affinity or increased inhibitor binding specificity. Preferred residues at the noggin/BMP-7 interface include, but are not limited to, Phe 73, Pro 74, Leu 75, Asn 76, Ser 77, Asn 83, Ile 86, Val 87, and Leu 90.
  • Identifying Residues in Regions of High Electrostatic Potential
  • Proteins may be destabilized by the presence of unfavorable electrostatic interactions or stabilized by the presence of favorable electrostatic interactions. Accordingly, a protein may be stabilized by removing unfavorable electrostatic interactions or by incorporating favorable electrostatic interactions. Modifying regions of high electrostatic potential may also modulate interactions with serum and extracellular matrix components, which may affect pharmacokinetics properties. In a preferred embodiment, the electrostatic potential that is present at each residue position is determined, for example by using Debye-Huckel calculations. Residues in BMP-7 that are located in regions of electrostatic potential greater than 0.25 or less than −0.25 include, but are not limited to, Lys 40, Ser 46, Arg 48, Tyr 62, Ala 64, Tyr 65, Tyr 66, Cys 67, Glu 68, Gly 69, Glu 70, Cys 71, Ala 72, Tyr 78, Asn 80, Ala 81, Thr 82, Asn 83, His 84, Ala 85, Val 87, Gln 88, Thr 89, Ile 94, Pro 100, Cys 104, Ala 105, Pro 106, Thr 107, Gin 108, Leu 109, Asn 110, Ala 111, Ile 112, Ser 113, Asn 122, Ile 124, Asn 130, Met 131, Val 132, Val 133, Arg 134, Ala 135, Cys 136, Gly 137, and His 139.
  • Design of Optimized BMP Variants
  • Identifying Suitable Modifications of the Furin Cleavage Site
  • The furin cleavage sequences of several BMPs differ somewhat from the consensus furin cleavage sequence. In BMP-7, preferred modifications to improve proteolytic processing include, but are not limited to, (P8) E→Q or K; (P6) H→K or R; (P5) L→K; and (P2) I→K or R.
  • Identifying Suitable Replacements for Glycosylation Sites
  • In a preferred embodiment, residues comprising a N- or O-linked glycosylation site are replaced with structurally and functionally compatible residues that do not comprise a glycosylation site. As is known in the art, N-linked glycosylation sites are specified by the sequence N-X-(S/T)-X (SEQ ID NO:86), where X may be any residue other than proline. Accordingly, an N-linked glycosylation site may be eliminated by 1) replacing the N with any other residue, 2) replacing either X with proline, or 3) replacing the S or T with any residue other than T, S, or C. Preferred modifications that remove the N-linked glycosylation site include, but are not limited to, replacing Asn 80 with Asp, Gln, Ser, or Thr; replacing Thr 82 with Val, and replacing Asn 83 with Pro.
  • Identifying Suitable Polar Residues for Each Exposed Hydrophobic Position
  • In a preferred embodiment, solvent exposed hydrophobic residues are replaced with structurally and functionally compatible polar residues. Alanine and glycine may also serve as suitable replacements, constituting a reduction in hydrophobicity. Furthermore, mutations that increase polar character, such as Phe to Tyr, and mutations that reduce hydrophobicity, such as Ile to Val, may be appropriate. In a preferred embodiment, preferred suitable polar residues are defined as those polar residues: 1) whose energy in the optimal rotameric configuration, as determined using PDA® technology, is more favorable than the energy of the exposed hydrophobic residue at that position and 2) whose energy in the optimal rotameric configuration is among the most favorable of the set of energies of all polar residues at that position. In a preferred embodiment, the polar residues that are included in the library at each variable position are deemed suitable by both PDA® technology calculations and by sequence alignment data. Alternatively, one or more of the polar residues that are included in the library are deemed suitable by either PDA® technology calculations or sequence alignment data.
  • Especially preferred modifications to BMP-7 include, but are not limited to, the following substitutions: L21D, L21G, L21K, L21N, L21R, L21S, M23D, M23G, M23K, M23N, M23R, M23S, V26D, V26E, V26G, V26K, V26N, V26S, Y44A, Y44D, Y44E, Y44G, Y44H, Y44K, Y44N, Y44P, Y44Q, Y44R, Y44S, W52A, W52E, W52K, W52Q, W55A, W55E, W55H, W55K, W55N, W55Q, I57A, I57D, I57E, I57H, I57K, I57L, I57T, I57V, E60R, F73A, F73D, F73E, F73H, F73Q, F73R, F73S, Y78D, Y78G, Y78H, Y78N, Y78R, Y78S, Y78T, I86A, I86D, I86E, I86K, I86Q, I86T, L90E, L90K, L90N, L90Q, L90R, L90S, L90T, F93A, F93D, F93E, F93G, F93H, F93Q, F93R, F93S, F93T, I94A, I94E, I94H, I94K, I94Q, I94R, I94T, L115E, L1115K, L115T, Y116A, Y116D, Y116E, Y116H, Y116K, Y116S, Y116T, F117A, F117D, F117E, F117H, F117K, F117Q, F117R, F117Y, V123A, V123D, V123N, V123R, V123T, L125A, L125E, L125K, L125Q, Y128D, Y128E, Y128H, Y128K, and Y128Q. Most especially preferred modifications are those modifications that confer improved properties, such as improved expression yield or activity. Most especially preferred modifications to exposed hydrophobic residues in BMP-7 include, but are not limited to, L21G, L21R, M23G, M23N, M23R, M23S, V26G, V26N, Y65N, Y78H, Y78R, I86A, F93D, F93E, F93G, F93H, F93S, F93T, 194R, Y116H, F117H, F117Y, and Y128D.
  • Identifying Suitable Residues for Each Interface Position
  • Suitable residues for interface residues as used herein are meant all amino acid residues that are compatible with the structure of a BMP and that retain appreciable binding affinity for at least one of the BMP receptors. Alternatively, competitive inhibitor variants may be generated by identifying alternate residues that are compatible with the structure of a BMP but that substantially eliminate binding affinity for at least one of the BMP receptors. Suitable residues may confer binding specificity by maintaining or increasing affinity for one or two receptors or inhibitors while substantially reducing binding affinity for the other receptors, inhibitors, or additional binding partners. In other cases, modifications are selected to confer other desired properties, for example improved expression yield, while maintaining binding affinities that are substantially similar to the wild type protein. Typically, the interface positions will be substantially exposed to solvent. In such cases, preferred substitutions include the polar residues, alanine, and glycine. However, for interface positions that are substantially buried in the dimer structure, hydrophobic replacements are preferred. Suitable polar residues may also include the subset of polar residues that are observed in analogous positions in homologous proteins, especially other BMPs. In an especially preferred embodiment, suitable polar residues include the subset of polar residues with low or favorable energies as determined using PDA® technology calculations or SPA calculations (described above).
  • Especially preferred modifications to polar BMP-7 interface residues include, but are not limited to, K39D, K39E, K39G, K39N, K39R, K39S, K39T, R48D, R48E, R48H, R48K, R48N, R48Q, Q53A, Q53D, Q53E, Q53G, Q53H, Q53K, Q53R, Q53S, Q53T, E60H, E60K, E60N, E60P, E60Q, E60R, E60S, E60T, N76A, N76D, N76S, N76T, S77A, S77D, S77E, S77H, S77K, S77N, S77P, S77Q, S77T, K126D, K126E, K126G, K126Q, K126R, K127A, K127D, K127E, K127H, K127N, K127P, K127Q, K127S, K127T, R129D, R129E, R129K, R129N, R129S, R134D, R134E, R134K, R134Q, and R134S. Most especially preferred modifications are those modifications that confer improved properties, such as improved expression yield, improved activity, or enhanced receptor binding specificity. Most especially preferred modifications to residues in regions of high electrostatic potential in BMP-7 include, but are not limited to, K39A, K39S, R48H, R48N, R48Q, Q53A, Q53K, Q53D, Q53G, Q53S, Q53T, E60R, K126R, K127E, R129D, R129N, R134E, and R134S. Additional especially preferred modifications are those modifications that reduce binding to either type I or type II receptors, thereby potentially acting as a competitive inhibitor of BMP. Additional especially preferred modifications to receptor interface residues in BMP-7 include, but are not limited to, Y44T, W52E, and 157Q.
  • Further preferred modifications are those modifications that alter binding affinity or specificity to a BMP inhibitor. Preferred modifications that reduce binding to noggin include, but are not limited to, W55I, W55L, W55K, W55R, I57M, I57Y, I57E, I57H, I57K, I57Q, I57R, A58I, A58L, A58M, A58Y, A58V, A58E, A58H, A58K, A58Q, A58R, P59Y, N76E, N76Q, N76R, S77E, S77Q, N83F, N83W, N83Y, N83H, N83K, N83R, I86L, I86M, I86F, I86Y, I86R, V87H, S113I, S113L, S113M, S113F, S113Y, S113E, S113H, S113K, S113Q, S113R, L115M, L115K, L115R, V123M, V123Y, V123H, K1271, K127V, K127H, Y1281, and Y128R. Preferred modifications that increase binding to noggin include, but are not limited to, R48M, P59M, E601, E60L, E60M, E60V, P74M, N76I, N76V, N76A, S77T, D119I, D119L, K126W, and K127M.
  • Identifying Suitable Residues for Regions of High Electrostatic Potential
  • Regions of high electrostatic potential may be modified in order to increase protein stability or to alter receptor binding affinity and specificity. In a preferred embodiment, residues that are located in a region of high electrostatic potential are replaced by structurally and functionally compatible residues that are predicted to interact favorably with the local electrostatic field. In a preferred embodiment, suitable polar residues include the subset of electrostatically favorable residues that are observed in analogous positions in homologous proteins, especially other BMPs. In an especially preferred embodiment, suitable polar residues include the subset of polar residues with low or favorable energies as determined using PDA® technology calculations or SPA calculations (described above).
  • Especially preferred modifications to BMP-7 residues located in regions of high electrostatic potential include, but are not limited to, Q88E, N110D, N110E, N110H, A111D, A111S, N130D, A135D, A135E, and A135S. Most especially preferred modifications are those modifications that confer improved properties, such as improved expression yield, improved activity, or enhanced receptor binding specificity. Most especially preferred modifications to receptor interface residues in BMP-7 include, but are not limited to, N110D, A135E, and A135S.
  • Identifying Suitable Residues for Additional Surface Positions
  • Additional residues on the surface of a BMP may be modified in order to improve stability, solubility, or expression yield. In a preferred embodiment, suitable polar residues include the subset of polar residues that are observed in analogous positions in homologous proteins, especially other BMPs. In an especially preferred embodiment, suitable polar residues include the subset of polar residues with low or favorable energies as determined using PDA® technology calculations or SPA calculations (described above).
  • Additional especially preferred modifications to BMP-7 surface residues include but are not limited to Q36E, Q36N, Q36R, E42D, E42Q, E42R, E42T, D49E, D49S, D54K, D54N, D54R, D54S, E70A, E70Q, N95D, N95K, N95Q, N95R, E97D, E97K, E97R, T98A, T98E, T98K, T98R, Q108D, Q108K, Q108S, D119E, D119N, D119S, D119T, S120D, S120E, S120N, S120R, S121D, S121E, S121K, S121N, S121T, N122E, N122Q, and N122R. Furthermore, residue T98 may be deleted. Most especially preferred modifications are those modifications that confer improved properties, such as improved expression yield, improved activity, or enhanced receptor binding specificity. Most especially preferred modifications to additional residues in BMP-7 include, but are not limited to, S120D.
  • Identifying Suitable Combinations of Mutations
  • In a preferred embodiment, variants comprising two or more mutations, including but not limited to those disclosed above, are made. Such variants may exhibit greater improvements in expression yield, solubility, or receptor specificity than point mutants. Such variants may also exhibit improvements in more than one protein property.
  • Especially preferred variants comprising two mutations include but are not limited to L21G/F93H, L21R/F93H, M23N/Y65N, M23R/Y65N, K39A/Y65N, K39A/F93H, K39S/Y78H, K39S/F93H, K39S/N110D, K39S/S120D, K39S/N130D, K39S/R134E, K39S/A135E, R48N/F93H, Q53D/Y65N, Q53G/Y65N, Q53G/Y78H, Q53S/Y65N, Q53T/Y65N, 157L/Y65N, Y65N/Y78H, Y65N/Y78R, Y65N/S120D, Y65N/A135E, Y65N/A135S, A72D/F93H, Y78H/F93H, Y78H/A105V, Y78H/Q108D, Y78H/Y116H, Y78H/F117Y, Y78H/S120D, Y78H/N130D, Y78H/R134E, Y78H/R134S, Y78H/A135E, Y78H/A135S, Y78H/H139R, Y78R/F93H, F93H/F117Y, F93H/S120D, F93H/R134S, and F93H/H139R. Especially preferred variants comprising three mutations include but are not limited to L21 G/K39S/S120D, M23R/K39S/S120D, K39S/Y65N/S120D, K39S/A72D/S120D, K39S/Y78H/S120D, K39S/Q108D/S120D, Y65N/Y78H/F93H, Y65N/Y78H/R134E, A72D/Y78H/F93H, Y78H/F93H/Q108D, Y78H/F93H/F117H, Y78H/F93H/S120D, and Y78H/F93H/R134E. Especially preferred variants comprising four modifications include but are not limited to K39S/F93S/Q108D/S120D, K39S/F93S/S120D/R129D, K39S/Y65N/F93S/S120D, K39S/Y78H/F93S/S120D, K39S/F93S/S120D/R134E, K39S/A72D/F92S/S120D, Y65N/Y78H/F93S/R134E, A72D/Y78H/F93S/R134E, M23R/Y65N/F93S/R129D, Y65N/F93S/Q108D/R129D, K39S/F93T/Q108D/S120D, K39S/F93T/S120D/R129D, K39S/Y65N/F93T/S120D, K39S/Y78H/F93T/S120D, K39S/F93T/S120D/R134E, K39S/A72D/F93T/S120D, Y65N/Y78H/F93T/R134E, A72D/Y78H/F93T/R134E, M23R/Y65N/F93T/R129D, and Y65N/F93T/Q108D/R129D.
  • Additional Modifications
  • Additional modifications that might favorably impact expression yield and/or activity can be deduced by observing significant trends in the data obtained. Once such trend is the observation that introduction of a negatively charged amino (E or D) within the Finger 2 region of BMP7 (positions 105-139) leads in most cases to enhanced expression or activity, exemplified by the expression and activity of variants such as Q108D, N110D, N110E, S120D, K127E, Y128D, R129D, N130D, and A135E. Analysis of additional positions within this region indicates that BMP7 substitutions T107D, T107E, S113D, S113E will most likely also possess superior expression and/or activity. A second trend is that the substitution of exposed hydrophobic amino acids with more polar or less hydrophobic alternatives generally leads to enhanced expression yield or activity, exemplified by variants such as Y78H, 186A, Y128D, and multiple substitutions of F93. Application of this trend to I124, another exposed hydrophobic residue, suggests the additional expression- or activity-enhancing variants I124A, I124D, I124E, I124K, I124N, I124Q, I124R, I124S, I124T, and I124V.
  • Additional insertions, deletions, and substitutions may be incorporated into the variant BMPs of the invention in order to confer other desired properties. In a preferred embodiment, the BMP variant comprises insertions, deletions, or substitutions that reduce immunogenicity, as described in “Antibodies And Fc Fusion Proteins With Altered Immunogenicity,” U.S. Ser. No. 60/643,313, filed Jan. 12, 2005. In an alternate preferred embodiment, the BMP variant is further modified to increase stability. As discussed above, modifications that improve stability can also improve solubility, for example by decreasing the concentration of partially unfolded, aggregation-prone species. For example, modifications can be introduced to the protein core that improve packing or remove polar or charged groups that are not forming favorable hydrogen bond or electrostatic interactions. It is also possible to introduce modifications that introduce stabilizing electrostatic interactions or remove destabilizing interactions. Additional stabilizing modifications also may be used. In another preferred embodiment, one or more cysteine, lysine, histidine, or other reactive amino acids are added to or eliminated from variant BMPs in order to incorporate or remove sites that are susceptible to covalent modification. For example, see “Rational Chemical Modification,” U.S. patent application Ser. No. 10/956,352, filed Sep. 30, 2004. As is known in the art, variant BMPs may be modified by adding an epitope tag (e.g. a poly-histidine (poly-His), c-myc, or FLAG-tag) or a fusion partner (e.g. an immunoglobulin, the Fc region of an immunoglobulin, albumin, other BMPs, other cytokine proteins, the extracellular domain of a BMP receptor protein, etc). For further details see the descriptions of tags and fusion partners in “Optimized Fc Variants,” U.S. Patent Application No. 60/627,774, filed Nov. 12, 2004.
  • BMP Forms
  • BMPs are naturally expressed as pro-proteins comprising a long pro-domain, one or more cleavage sites, and a mature domain. This pro-protein is then processed by the cellular machinery to yield a dimeric mature BMP molecule. In a preferred embodiment, the variants of the invention are produced in a similar manner. The pro-domain is believed to aid in the correct folding and processing of BMPs. Furthermore, in some but not all BMPs, the pro-domain may noncovalently bind the mature domain and may act as a chaperone, as well as an inhibitor (eg. Thies et. al. (2001) Growth Factors 18: 251-259). In additional preferred embodiments, the variants of the invention are produced and/or administered therapeutically in this form. In alternative embodiments, BMPs may be produced in other forms, including, but not limited to, mature domain produced directly or refolded from inclusion bodies, or full-length intact pro-protein. The variants of the invention are expected to find use in these and other forms.
  • Generating The Variants
  • Variant BMP nucleic acids and proteins of the invention may be produced using a number of methods known in the art, as elaborated upon below.
  • Preparing Nucleic Acids Encoding the BMP Variants
  • In a preferred embodiment, nucleic acids encoding BMP variants are prepared by total gene synthesis, or by site-directed mutagenesis of a nucleic acid encoding wild type or variant BMP. Methods including template-directed ligation, recursive PCR, cassette mutagenesis, site-directed mutagenesis or other techniques that are well known in the art may be utilized (see for example Strizhov et. al. PNAS 93:15012-15017 (1996), Prodromou and Perl, Prot. Eng. 5: 827-829 (1992), Jayaraman and Puccini, Biotechniques 12: 392-398 (1992), and Chalmers et. at. Biotechniques 30: 249-252 (2001)).
  • Expression Vectors
  • In a preferred embodiment, an expression vector that comprises the components described below and a gene encoding a variant BMP is prepared. Numerous types of appropriate expression vectors and suitable regulatory sequences for a variety of host cells are known in the art. The expression vectors may contain transcriptional and translational regulatory sequences including but not limited to promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, transcription terminator signals, polyadenylation signals, and enhancer or activator sequences. In a preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences. In addition, the expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, for example in mammalian or insect cells for expression and in a prokaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences, which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art. In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used. The expression vectors may be either self-replicating extrachromosomal vectors or vectors which integrate into a host genome.
  • The expression vector may include a secretory leader sequence or signal peptide sequence that provides for secretion of the variant BMP from the host cell. Suitable secretory leader sequences that lead to the secretion of a protein are known in the art. The signal sequence typically encodes a signal peptide comprised of hydrophobic amino acids, which direct the secretion of the protein from the cell. The protein is either secreted into the growth media or, for prokaryotes, into the periplasmic space, located between the inner and outer membrane of the cell. For expression in bacteria, bacterial secretory leader sequences, operably linked to a variant BMP encoding nucleic acid, are usually preferred.
  • Transfection/Transformation
  • The variant BMP nucleic acids are introduced into the cells either alone or in combination with an expression vector in a manner suitable for subsequent expression of the nucleic acid. The method of introduction is largely dictated by the targeted cell type. Exemplary methods include CaPO4 precipitation, liposome fusion (eg. using the reagent Lipofectin® or FuGene), electroporation, viral infection (eg. as outlined in PCT/US97/01019), dextran-mediated transfection, polybrene mediated transfection, protoplast fusion, direct microinjection, etc. The variant BMP nucleic acids may stably integrate into the genome of the host cell or may exist either transiently or stably in the cytoplasm.
  • Hosts for the Expression of BMP Variants
  • Appropriate host cells for the expression of BMP variants include yeast, bacteria, archaebacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are fungi such as Saccharomyces cerevisiae and Pichia pastoris and mammalian cell lines including 293 (eg. 293-T and 293-EBNA), BRK, CHO (eg. CHOK1 and DG44), COS, Jurkat, NIH3T3, etc. (see the ATCC cell line catalog). BMP variants can also be produced in more complex organisms, including but not limited to plants (such as corn, tobacco, and algae) and animals (such as chickens, goats, cows); see for example Dove, Nature Biotechnol. 20: 777-779 (2002). In one embodiment, the cells may be additionally genetically engineered, that is, contain exogenous nucleic acid other than the expression vector comprising the variant BMP nucleic acid.
  • Expression Methods
  • The variant BMPs of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a variant BMP, under the appropriate conditions to induce or cause expression of the variant BMP. Either transient or stable transfection methods may be used. The conditions appropriate for variant BMP expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation.
  • Purification
  • In a preferred embodiment, the BMP variants are purified or isolated after expression. Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing. For example, a BMP variant may be purified using a standard anti-recombinant protein antibody column. Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful. For general guidance in suitable purification techniques, see Scopes, R., Protein Purification, Springer-Verlag, NY, 3d ed. (1994). The degree of purification necessary will vary depending on the desired use, and in some instances no purification will be necessary.
  • Posttranslational Modification and Derivatization
  • Once made, the variant BMP may be covalently modified. Covalent and non-covalent modifications of the protein are thus included within the scope of the present invention. Such modifications may be introduced into a variant BMP polypeptide by reacting targeted amino acid residues of the polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues. Optimal sites for modification can be chosen using a variety of criteria, including but not limited to, visual inspection, structural analysis, sequence analysis and molecular simulation. Sites for modification may be located in the pro-domain or the mature domain.
  • In one embodiment, the variant BMP of the invention are labeled with at least one element, isotope or chemical compound. In general, labels fall into three classes: a) isotopic labels, which may be radioactive or heavy isotopes; b) immune labels, which may be antibodies or antigens; and c) colored or fluorescent dyes. The labels may be incorporated into the compound at any position. Labels include but are not limited to biotin, tag (e.g. FLAG, Myc) and fluorescent labels (e.g. fluorescein). Derivatization with bifunctional agents is useful, for instance, for cross linking a variant BMP to a water-insoluble support matrix or surface for use in the method for purifying anti-variant BMP antibodies or screening assays, as is more fully described below. Commonly used cross linking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azidosalicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3′-dithiobis(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimidate. Other modifications include deamidation of glutaminyl and asparaginyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the amino groups of lysine, arginine, and histidine side chains (T. E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group. Such derivatization may improve the solubility, absorption, transport across the blood brain barrier, serum half-life, and the like. Modifications of variant BMP polypeptides may alternatively eliminate or attenuate any possible undesirable side effect of the protein. Moieties capable of mediating such effects are disclosed, for example, in Remington's Pharmaceutical Sciences, 16th ed., Mack Publishing Co., Easton, Pa. (1980).
  • Another type of covalent modification of variant BMP comprises linking the variant BMP polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol (“PEG”), polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Pat. No. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337. A variety of coupling chemistries may be used to achieve PEG attachment, as is well known in the art. Examples, include but are not limited to, the technologies of Shearwater and Enzon, which allow modification at cysteine residues and primary amines, including but not limited to histidine groups, lysine groups and the N-terminus (see, Kinstler et al, Advanced Drug Deliveries Reviews, 54, 477-485 (2002) and M J Roberts et al, Advanced Drug Delivery Reviews, 54, 459-476 (2002)). Both labile and non-labile PEG linkages may be used. An additional form of covalent modification includes coupling of the variant BMP polypeptide with one or more molecules of a polymer comprised of a lipophililic and a hydrophilic moiety. Such composition may enhance resistance to hydrolytic or enzymatic degradation of the BMP. Polymers utilized may incorporate, for example, fatty acids for the lipophilic moiety and linear polyalkylene glycols for the hydrophilic moiety. The polymers may additionally incorporate acceptable sugar moieties as well as spacers used for BMP attachment. Polymer compositions and methods for covalent conjugation are described, for example, in U.S. Pat. Nos. 5,681,811; 5,359,030.
  • Another type of modification is chemical or enzymatic coupling of glycosides to the variant BMP. Such methods are described in the art, e.g., in WO 87/05330 published 11 Sep. 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981). Alternatively, removal of carbohydrate moieties present on the variant BMP polypeptide may be accomplished chemically or enzymatically. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo-and exo-glycosidases as described by Thotakura et al., Meth. Enzymol., 138:350 (1987).
  • Assaying the Expression Yield of the Variants
  • A primary object of the current invention is the identification of variant BMPs with increased expression yield. Accordingly, the yield, using one or more set of expression conditions, of the variant and wild type BMPs is determined. In one embodiment, expression yields are determined using ELISA. One limitation of this technique is that some variants may confer increased or decreased antibody binding affinity. Accordingly, in a preferred embodiment ELISAs are performed using at least two monoclonal antibodies that recognize distinct epitopes. It is also possible to derive ELISA correction factors for selected variants by purifying said variants and determining their concentration through orthogonal methods, such as UV absorption or BCA assay. Alternatively, the BMPs may be engineered to contain a tag, such as a FLAG tag or His tag, and anti-tag antibodies may be used in the ELISA. In another embodiment, expression yields are determined using Western blotting. As with ELISA, a limitation is that some mutations may confer increased or decreased antibody binding affinity.
  • Assaying the Solubility of the Variants
  • In a preferred embodiment, the variant BMPs are assayed for solubility using methods including but not limited to those described below. In all preferred embodiments, the variant and wild type proteins are compared directly in the same assay system and under the same conditions in order to evaluate the solubility of each variant. The solubility of the BMP variants may be determined under a number of solution conditions. A variety of excipients, including solubilizing and stabilizing agents, may be tested for their ability to promote the highest soluble BMP concentration. In addition, different salt concentrations and varying pH may be tested. In a preferred embodiment, solubility is assayed under pharmaceutically acceptable conditions.
  • Differential light scattering (DLS) may be used to determine oligomerization state. DLS determines diffusion coefficients based on signal correlation from fluctuation of laser light scattered from Brownian motion of particles in solution (Heimenz, Chapter 10 in Polymer Chemistry, Marcel Dekker, Inc., NY, 1984, pp. 659-701). Commercially available instruments provide graphical or table readouts of particle population(s) by size(s) after transforming the diffusion coefficient(s) measured by deconvolution/autocorrelation of laser light scattering data using the Stokes-Einstein equation. The size is therefore the hydrodynamic radius. The distribution of particle sizes within a population(s) is the dispersity, and this factor provides data on the uniformity of the particle population(s). Both dispersity and the appearance of aggregates over time may be monitored to test for solubility. Aggregated protein may be easily resolved by DLS, and readily detected at low levels due to the physical property of aggregates: they scatter more laser light per unit due to the greater target surface area. The sample may be directly introduced into the cuvette (i.e. it is not necessary to perform a chromatographic step first). A relative ratio of monodisperse to aggregate particle population may be determined. Optionally, this ratio may be weighted by mass or by light scattering intensity. Thus, DLS is a preferred technique to monitor formation of aggregates, and holds the advantage in that it is a non-intrusive technique.
  • In another preferred embodiment analytical ultracentrifugation (AUC) is used to determine the oligomerization state of the variant BMPs. AUC can be performed in two different ‘modes’, either velocity or equilibrium. Equilibrium AUC is the most preferred method for determining protein molecular weight and oligomeric state measurement.
  • A further preferred embodiment is to use size-exclusion chromatography (SEC) to determine the oligomerization state of the BMP variants. Utilizing high performance liquid chromatography, sample may be introduced to an isocratic mobile phase and separated on a gel permeation matrix designed to exclude protein on the basis of size. Thus, the samples will be “sieved” such that the aggregated protein will elute first with the shortest retention time, and will be easily separated from the remainder. This can identify aggregates and allow a relative quantification by peak integration using the peak analysis software provided with the instrument.
  • In an alternate embodiment, protein concentration is monitored as a function of time. In the case of poor solubility, aggregates will form over time in the protein solution, and eventually precipitate entirely. This may be performed following centrifugation and sampling of the solution phase, in which case insolubility can be measured as a drop in solution protein concentration over time will be observed following centrifugation.
  • In an alternate embodiment, the oligomerization state is determined by monitoring relative mobility on native gel electrophoresis.
  • In another embodiment, the amount of protein that is expressed solubly is determined. While factors other than the solubility of the native protein can impact levels of soluble expression, improvements in soluble expression may correlate with improvements in solubility. Any of a number of methods may be used; for example, following expression, SDS-polyacrylamide gel electrophoresis and/or western blots can be done on the soluble fraction of crude cell lysates or the expression media.
  • Furthermore, any of a number of high throughput screens for soluble expression may be used. In one embodiment, the protein of interest is fused to a fluorescent protein such as GFP, and the cells monitored for fluorescence (Waldo et. al. Nat. Biotechnol. 17: 691 (1999)). In an alternate embodiment, the protein of interest is fused to the antibiotic resistance enzyme chloramphenicol transferase. If the protein expresses solubly, the enzyme will be functional, thereby allowing growth on media with increased concentration of the antibiotic chloramphenicol (Maxwell et. al. Protein Sci. 8: 1908 (1999)). In another embodiment, the protein of interest is expressed as a fusion with the alpha domain of the enzyme beta-galactosidase. If the protein expresses in soluble form, the alpha domain will complement the omega domain to yield a functional enzyme. This may be detected as blue rather than white colony formation when the cells are plated on media containing the indicator X-gal (Wigley et. al. Nat. Biotechnol. 19: 131 (2001)).
  • Assaying the Activity of the Variants
  • In a preferred embodiment, the activity of the wild-type and variant proteins are analyzed using in vitro receptor binding assays, cell-based activity assays, or in vivo activity assays.
  • Receptor Binding Assays
  • In a preferred embodiment, the affinity of the variant BMPs for one or more BMP receptors is determined. In an especially preferred embodiment, affinities for ALK-2, ALK-3, ALK-6, ActRII, ActRIIb, and BMPRII are determined. Suitable binding assays include, but are not limited to, ELISA, fluorescence anisotropy and intensity, scintilation proximity assays (SPA) Biacore (Pearce et al., Biochemistry 38:81-89 (1999)), DELFIA assays, and AlphaScreen™ (commercially available from PerkinElmer; Bosse R., Illy C., and Chelsky D (2002)).
  • In a preferred embodiment, Biacore or surface plasmon resonance assays (see for example McDonnell (2001) Curr. Opin. Chem. Biol. 5:572-577) are used to determine the affinity of one or more BMP variants for one or more BMP receptors. Biacore experiments may be performed, for example, by binding BMP receptor-Fc fusion proteins to a protein A derivitized chip or an NTA chip and testing each BMP variant as an analyte. It is also possible to bind an anti-BMP antibody to the chip, or to bind the BMP variant to the chip and test soluble receptor or Fc-receptor fusion proteins as analytes. Biacore experiments have been used previously to characterize binding of TGF-β isoforms to their receptors (De Crescenzo et. al. (2001) J. Biol. Chem. 276: 29632-29643, De Crescenzo et. al. (2003) J. Mol. Biol. 328: 1173-1183).
  • In an alternate preferred embodiment, a plate-based Direct Binding Assay is used to determine the affinity of one or more BMP variants for one or more BMP receptors. This method is a modified sandwich ELISA in which BMP is captured using an anti-BMP monoclonal antibody and then detected using a BMP receptor/Fc fusion protein.
  • In another preferred embodiment, AlphaScreen™ assays (Bosse R., Illy C., and Chelsky D (2002). Principles of AlphaScreen™ PerkinElmer Literaure Aplication Note Ref# s4069. http://lifesciences.perkinelmer.com/Notes/S4069-0802.pdf) are used to characterize receptor and inhibitor binding. AlphaScreen™ is a bead-based non-radioactive luminescent proximity assay where the donor beads are excited by a laser at 680 nm to release singlet oxygen. The singlet oxygen diffuses and reacts with the thioxene derivative on the surface of acceptor beads leading to fluorescence emission at ˜600 nm. The fluorescence emission occurs only when the donor and acceptor beads are brought into close proximity by molecular interactions occurring when each is linked to ligand and receptor (or ligand and inhibitor) respectively. This interaction may be competed away by adding an appropriate amount of unlabeled BMP variant that binds the relevant receptor or inhibitor.
  • In one embodiment, AlphaScreen™ assays are performed using 1) BMP modified by the addition of a suitable tag or label; 2) donor beads capable of binding the tag or label used to modify the BMP; 3) a BMP receptor or inhibitor modified by the addition of a suitable tag or label; 4) acceptor beads capable of binding the tag or label used to modify the BMP receptor, and 5) varying amounts of an unlabeled variant BMP-7 molecule, which acts as a competitor. It is also possible to coat the donor or acceptor beads with antibodies that specifically recognize the native BMP or BMP receptor, or to bind the receptor to the donor beads and the ligand to the acceptor beads. In an alternate embodiment, AlphaScreen™ assays are performed using 1) a type I BMP receptor modified by the addition of a suitable tag or label; 2) donor beads capable of binding the tag or label used to modify the type I BMP receptor; 3) a type II BMP receptor modified by the addition of a suitable tag or label; 4) acceptor beads capable of binding the tag or label used to modify the type II BMP receptor; 5) BMP, and 6) varying amounts of an unlabeled variant BMP-7 molecule, which acts as a competitor. It is also possible to bind the type I BMP receptor to the acceptor beads and the type II BMP receptor to the donor beads.
  • In another embodiment, fluorescence assays are used. Either BMP-7 or a BMP-7 receptor or inhibitor may be labeled with a fluorescent dye (for examples of suitable dyes, see the Molecular Probes catalog). As is known in the art, the fluorescence intensity or anisotropy of a labeled molecule may change upon binding to another molecule. Fluorescence assays may be performed using 1) fluorescently labeled BMP-7, 2) a BMP receptor or inhibitor, and 3) varying amounts of an unlabeled variant BMP-7 protein, which acts as a competitor.
  • In an additional embodiment, scintillation proximity assays (SPA) are used to determine receptor binding affinity. For example, BMP receptor-Fc fusions may be bound to protein A coated SPA beads or flash-plate and treated with S35-labeled BMP; the binding event results in production of light.
  • Cell-Based Activity Assays
  • BMPs promote the growth and differentiation of a number of types of cells. BMP activity may be monitored, for example, by measuring BMP-induced differentiation of MC3T3-E1 (an osteoblast-like cell derived from murine calvaria), C3H10T1/2 (a mouse mesenchymal stem cell line derived from embryonic connective tissue), ATDC5 (a mouse embryonal carcinoma cell), L-6 (a rat myoblast cell line) or C2C12 (a mouse myoblastic cell line) cells. Differentiation may be monitored using, for example, luminescence reporters for alkaline phosphatase or colorimetric reagents such as Alcian Blue or PNPP (Asahina et. al. (1996) Exp. Cell Res. 222: 38-47; Inada et. al. (1996) Biochem. Biophys. Res. Commun. 222: 317-322; Jortikka et. al. (1998) Life Sci. 62: 2359-2368; Cheng et. al. (2003) J. Bone Joint Surgery 95A: 1544-1552). The rat limb bud cartilage differentiation assay may also be used to monitor activity in primary cells. In an alternate embodiment, reporter gene or kinase assays may be used. BMPs activate the JAK-STAT signal transduction pathway. Accordingly, a BMP responsive cell line containing a STAT-responsive reporter such as GFP or luciferase may be used (Kusanagi et. al. (2000) Mol. Biol. Cell. 11: 555-565). In a preferred embodiment, BMP activity in kidney cells is determined using cell-based assays; see for example Wang and Hirschberg (2004) J. Biol. Chem. 279: 23200-23206.
  • Animal Models of BMP Activity
  • In the simplest embodiment, BMP activity in an animal is measured as bone induction following subcutaneous injection. In a preferred embodiment, the activity of one or more BMP variants is determined in an animal model of a BMP-responsive disease or condition. Animal models of renal disease include, but are not limited to, the rat nephrotoxic serum nephritis model (Zeisberg et. al. 2003)), the rat chronic cyclosporine A-induced nephropathy model (Li et. al. (2004) Am. J. Physiol. Renal Physiol. 286: F46-57), the mouse unilateral uretreral obstruction model (Schanstra et. al. (2003) Thromb. Haemost. 89: 735-740), streptozotocin-induced diabetic nephropathy (Taneda et. al. (2003) J. Am. Soc. Nephrol. 14: 968-980), the anti-thy 1.1 mAb and Habu snake venom induced glomerulonephritis models (Dimmler et. al. (2003) Diagn. Mol. Pathol. 12: 108-117), and the rat 5/6 remnant kidney model (Romero et. al. (1999) Kidney Int. 55: 945-955). Animal models of liver disease include, but are not limited to, rat bile duct ligation/scission model (Park et. al. (2000) Pharmacol. Toxicol. 87: 261-268), CCl4 plus ethanol-induced liver damage (Hall et. al. (1991) Hepatology 12: 815-819), dimethylnitrosamine-induced liver cirrhosis (Kondou et. al. (2003) J. Hepatol. 39: 742-748), and thioacetamide-induced liver damage (Muller et. al. (1988) Exp. Pathol. 34: 229-236). Animal models of lung disease include, but are not limited to, ovalbumin-induced airway fibrosis (Kenyon et. al. (2003) Toxicol. Appl. Pharmacol. 186: 90-100), bleomycin-induced lung fibrosis (Izbicki et. al. (2002) Int. J. Exp. Pathol. 83: 111-119), monocrotaline-induced pulmonary fibrosis (Hayashi et. al. (1995) Toxicol. Pathol. 23: 63-71), and selective irradiation (Pauluhn et. al. (2001) Toxicology 161: 153-163). Animal models of neurological disease include, but are not limited to, animal models for Parkinson's disease such as the 6-hydroxydopamine (6-OHDA) hemilesioned rat model and MPTP-induced Parkinson's disease, animal models of ALS such as rats or mice expressing mutant SOD1 (Shibata et. al. (2002) Neuropathology 22: 337-349), and animal models of stroke induced by intracortical microinjection of endothelin or quinolinic acid (Gilmour et. al. (2004) Behav. Brain Res. 150: 171-183) or cerebral artery occlusion (Merchenthaler et. al. (2003) Ann. NY Acad. Sci. 1007: 89-100).
  • Administration and Treatment Using BMP Variants
  • Once made, the BMP variants of the invention may be administered to a patient to treat a BMP related disorder. The BMP variants may be administered in a variety of ways, including, but not limited to orally, parenterally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonarally, vaginally, rectally, intranasally or intraocularly. In some instances, the variant BMP may be directly applied as a solution or spray.
  • The pharmaceutical compositions of the present invention comprise a BMP variant in a form suitable for administration to a patient. In the preferred embodiment, the pharmaceutical compositions are in a sterile, water-soluble form and may include pharmaceutically acceptable acid addition salts or pharmaceutically acceptable base addition salts. The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers such as NaOAc; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol. Additives that are “generally recognized as safe” (GRAS) are well known in the art, and are used in a variety of formulations.
  • Any of a number of drug delivery devices or sustained release formulations may be used. For example, a variant BMP may be administered as a pro-protein comprising a BMP pro-domain and a BMP mature domain. BMPs may also be administered as BMP-impregnated matrix material (for example Geiger et. al. Adv. Drug Deliv. Rev. (2003) 55: 1613-1629; Hu et. al. J. Biomed. Mater. Res. (2003) 67A: 591-598; Peel et. al. J. Craniofac Surg. (2003) 14: 284-291); such a method of administration is especially preferred for promoting bone healing and growth. Furthermore, implants for bone repair may be coated with BMPs to promote bone healing and improve bone strength (Schmidmaier et. al. Bone (2002) 30: 816-822). In a further embodiment, the variant BMPs are added in a micellular formulation (U.S. Pat. No. 5,833,948), liposomes (Matsuo et. al. J. Biomed. Mater. Res. (2003) 66A: 747-754), biodegradable polymers (Saito and Takaoka, Biomaterials (2003) 24: 2287-2293; Saito et. al. Bone (2003) 32: 381-386; Weber et. al. Int. J. Oral Maxillofac. Surg. (2002) 31: 60-65; Saito et. al. J. Bone Joint Surg. Am. (2001) 83-A: S92-S98), hydrogels (Yamamoto et. al. Biomaterials (2003) 24: 4375-4383), or the like.
  • Combinations of pharmaceutical compositions may be administered. Moreover, the compositions may be administered in combination with other therapeutics.
  • Nucleic acid encoding the variant BMPs may also be used in gene therapy. In gene therapy applications, genes are introduced into cells in order to achieve in vivo synthesis of a therapeutically effective genetic product, for example for replacement of a defective gene. “Gene therapy” includes both conventional gene therapy where a lasting effect is achieved by a single treatment, and the administration of gene therapeutic agents, which involves the one time or repeated administration of a therapeutically effective DNA or mRNA. Any of a variety of techniques known in the art may be used to introduce nucleic acids to the relevant cells. The oligonucleotides may be modified to enhance their uptake, e.g. by substituting their negatively charged phosphodiester groups by uncharged groups. For review of gene marking and gene therapy protocols see Anderson et al., Science 256:808-813 (1992).
    • EXAMPLES Example 1 Structural Modeling
  • Hexameric complexes comprising a BMP-7 dimer or a BMP-2 dimer bound to two ALK-3 receptors and two ActRIIa receptors was constructed using the structure of BMP-7 bound to ActRIIa (PDB code 1LX5) and the structure of BMP-2 bound to ALK-3 (PDB code 1ES7). Using InsightII (Accelrys), the BMP structures were superimposed as follows: BMP-2 residues 22-32 superimposed with BMP-7 residues 47-56, BMP-2 residues 49-71 superimposed with BMP-7 residues 73-95, and BMP-2 residues 101-106 superimposed with BMP-7 residues 126-131. This yielded a backbone atom RMSD of 0.77 Å. The superposition was repeated so that chain A in the BMP-7 structure was superimposed onto chains A and C of the BMP-2 structure. The sequence alignment between BMP-2 and BMP-7 is shown in FIG. 3 and the structure of the hexameric complex is shown in FIG. 2.
  • Homology modeling was used to generate structures of additional BMP receptors bound to BMP-2 and BMP-7. As shown in FIG. 5, the sequences of ALK-2 and ALK-6 were aligned with ALK-3, and the sequences of ActRIIb and BMPRII were aligned with ActRIIa. The Modeler tool in InsightII (Accelrys) was used to generate the homology models. Disulfide pairs were manually constrained as follows (using the crystallographic numbering from 1LX5 and 1ES7): Alk3: 238-259, 240-244, 253-277, 287-301, 302-307; ActRIIa: 11-41, 31-59, 66-85, 72-84, and 86-91. Three models were generated for each molecule; the model with the best energy and —InPDF score was selected for subsequent PDA® technology calculations. Homology modeling was also used to generate structures of BMP-4, BMP-5, BMP-6, and BMP-8. BMP-4 was modeled using the BMP-2 structure while BMP-5, BMP-6, and BMP-8 were modeled using the BMP-7 structure. The BMP sequences were aligned as shown in FIG. 3 (SEQ ID NOS:7-12). PDA® technology calculations were used to model the BMP-4, BMP-5, BMP-6, and BMP-8 structures.
    • Example 2 Identification of Exposed Hydrophobic Residues in BMPs
  • Structures of BMP-7 dimer (“dimer”) and BMP-7 dimer bound to ALK-3 and ActRIIa “hexamer”) were analyzed to identify solvent-exposed hydrophobic residues. The absolute and fractional solvent-exposed hydrophobic surface area of each residue was calculated using the method of Lee and Richards (J. Mol. Biol. 55: 379-400 (1971)) using an add-on radius of 1.4 Å (Angstroms). Each residue was also classified as core, boundary, or surface (see Dahiyat and Mayo Science 278: 82-87 (1997)).
  • Solvent exposed hydrophobic residues in BMP-7 were defined to be hydrophobic residues with at least 50 Å2 (square Angstroms) exposed hydrophobic surface area in the BMP-7 dimer (PDB code 1LX5, chain A, plus symmetry-related BMP-7 molecule). Exposed hydrophobic surface area was also measured in the context of the BMP-7/ALK-2/ActRIIa hexamer and RESCLASS was run to categorize each position as core, boundary, or surface.
    TABLE 1
    Exposed hydrophobic residues in BMP-7.
    hexamer dimer hexamer
    # wt dimer RC RC expH expH
    44 TYR surface surface 85.5 95.5
    52 TRP boundary core 82.9 5.9
    55 TRP boundary boundary 168.4 125.5
    57 ILE boundary core 70.3 29.8
    73 PHE surface core 70.5 64.6
    78 TYR surface core 107.9 71.2
    86 ILE surface core 60.7 4.3
    90 LEU boundary core 51.7 10.6
    93 PHE boundary core 113.1 10.9
    94 ILE boundary core 79.0 37.3
    115 LEU surface core 56.9 0.0
    116 TYR boundary core 51.5 51.6
    117 PHE surface boundary 97.5 25.4
    123 VAL surface core 86.0 14.4
    125 LEU surface core 88.4 60.9
    128 TYR boundary core 64.9 17.4
    • Example 3 Identification of Receptor and Inhibitor Interface Residues in BMP-7
  • Potential sites of interactions between BMP-7 and ALK-3, BMP-7 and ActRIIa, and BMP-7 and noggin were identified by examining the structure of the hexameric structure described in Example 1 and the co-crystal structure of BMP-7 and noggin (PDB code 1M4U). Next, distance measurements were used to identify residues that may participate in intermolecular interactions. Residues in BMP-7 that are within 5 Å (Angstroms) of the ALK-3, ActRIIa, or noggin interfaces (as measured by CA-CA distances) are shown below, along with the receptor or inhibitor positions that are contacted. Next, the receptor sequence alignments used for homology modeling were analyzed for polymorphisms. Information about receptor polymorphisms was used to design receptor-specific variants, described below. If the receptor positions are polymorphic, it is noted in Table 2; “na” indicates that the receptor positions were not sufficiently well-aligned to unambiguously identify the polymorphisms. However, receptor-specific BMP variants may be identified that contact such unaligned regions of the receptors.
    TABLE 2
    BMP-7 receptor and inhibitor contacts
    Contacts: A, B = ALK-3;
    # Wt D, F = ActRIIa; and N = noggin receptor polymorphisms
    39 LYS ASP A 246 246 (ALK6 = E, ALK3 = D, ALK2 na)
    44 TYR ASN D 65, ILE D 64, 65(ActRIIa, ActRIIb N, BMPRII na),
    ASP D 63 64(ActRIIb = F, ActRIIa = I, BMPRII na),
    63(ActRIIa, ActRIIb D, BMPRII na)
    47 PHE PHE B 285 285(ALK6, ALK3 = F, ALK2 = M)
    48 ARG LYS D 76, GLN N 208, 76(ActRIIb = E, ActRIIa = K, BMPRII = T)
    ARG N 209, ARG N 210
    49 ASP LYS B 292 na
    50 LEU SER B 290, PHE B 285 290(ALK6 = T, ALK3 = S, ALK2 = P),
    285(ALK6, ALK3 = F, ALK2 = M)
    51 GLY PRO B 291, SER B 290, 291 P conserved, 290(ALK6 = T,
    LYS B 292 ALK3 = S, ALK2 = P), 292 na
    52 TRP PHE B 285, LYS B 288, 285(ALK6, ALK3 = F, ALK2 = M),
    SER B 290, PRO B 291, 288(ALK6 = R, ALK3, ALK2 = K),
    ILE N 33, ARG N 34, 290(ALK6 = T, ALK3 = S, ALK2 = P), 291
    PRO N 35 P conserved
    53 GLN LYS D 76, ARG N 206 76 (ActRIIb = E, ActRIIa = K, BMPRII = T)
    54 ASP LYS B 288, GLU D 80, 288(ALK6 = R, ALK3, ALK2 = K),
    ARG N 206, GLN N 208 80(ActRIIb = Q, ActRIIa = E, BMPRII
    na)
    55 TRP LYS B 288, ARG N 34, 288(ALK6 = R, ALK3, ALK2 = K)
    PRO N 35
    56 ILE PHE B 285 285(ALK6, ALK3 = F, ALK2 = M)
    57 ILE PHE D 83, VAL D 81, 83 F conserved, 81(ActRIIa, ActRIIb
    THR D 44, ARG N 204, V, BMPRII na), 44(ActRIIb = S,
    ARG N 206, ILE N 218 ActRIIa = T, BMPRII = L)
    58 ALA PHE D 83, TRP D 60, 60 W conserved, 83 F conserved
    LEU N 46, GLU N 48,
    ARG N 204
    59 PRO ASP D 63, ASN D 65, 63(ActRIIa, ActRIIb D, BMPRII na),
    TRP D 60, PHE D 83, 65(ActRIIa, ActRIIb N, BMPRII na),
    LEU N 46, ILE N 47 60 W conserved, 83 F conserved
    60 GLU LYS D 76, ASN D 65, 76(ActRIIb = E, ActRIIa = K, BMPRII = T),
    GLU D 74, PHE N 54 65(ActRIIa, ActRIIb N, BMPRII na),
    74(ActRIIb = A, ActRIIa = E, BMPRII = V)
    61 GLY ASN D 65 65(ActRIIa, ActRIIb N, BMPRII na)
    62 TYR ASP D 63, ASN D 65, 63(ActRIIa, ActRIIb D, BMPRII na),
    ILE D 64 65(ActRIIa, ActRIIb N, BMPRII na),
    64(ActRIIb = F, ActRIIa = I, BMPRII na)
    63 ALA ILE D 64 64(ActRIIb = F, ActRIIa = I, BMPRII na)
    73 PHE ARG A 297, GLU A 264, 297(ALK6, ALK3 = R, ALK2 = Q)
    ILE N 33 264(ALK6, ALK3 = E, ALK2 = S)
    74 PRO HIS A 243, ILE A 262, 243(ALK3, ALK6 H, ALK2 na),
    ILE A 299, PHE A 260, 262(ALK6 = M, ALK3 = I, ALK2 = S),
    GLU A 264, GLN A 286, 299(ALK6, ALK3 = I ALK2 = V), 260 F
    MET A 278, LEU N 31, conserved, 264(ALK6, ALK3 = E,
    ILE N 33 ALK2 = S), 286(ALK6, ALK3 = Q
    ALK2 = T), 278(ALK6 = L, ALK3 = M,
    ALK2 = F)
    75 LEU GLN A 286, TYR N 30, 286(ALK6, ALK3 = Q ALK2 = T)
    LEU N 31, HIS N 32, ILE
    N 33
    76 ASN HIS A 243, PHE A 260, 243(ALK3, ALK6 H, ALK2 na), 260 F
    GLY A 276, MET A 278, conserved, 276 G conserved,
    PRO A 245, CYS A 277, 278(ALK6 = L, ALK3 = M, ALK2 = F),
    TYR N 30, LEU N 31, 245(ALK3, ALK6 P, ALK2 na), 277 C
    HIS N 32 conserved
    77 SER CYS A 277, CYS A 253, 277 C conserved, 253 C conserved,
    THR A 255, PHE A 260, 255(ALK3, ALK6 T, ALK2 na), 260 F
    LYS A 279, GLY A 276, conserved, 279(ALK6 = G, ALK3 = K,
    MET A 278, PRO A 245, ALK2 na), 276 G conserved,
    MET N 27, HIS N 29, 278(ALK6 = L, ALK3 = M, ALK2 = F),
    TYR N 30, HIS N 32 245(ALK3, ALK6 P, ALK2 na)
    78 TYR ASP A 246, PRO A 245, 246(ALK6 = E, ALK3 = D, ALK2 na),
    ASP A 247 245(ALK3, ALK6 P, ALK2 na),
    247(ALK3, ALK6 D, ALK2 na)
    80 ASN LYS A 279 279(ALK6 = G, ALK3 = K, ALK2 na)
    83 ASN GLU A 281, GLY A 282, 281(ALK3, ALK6, 282 ALK2 na),
    PHE A 285, ARG N 34, 282(ALK3, ALK6 G, ALK2 na),
    PRO N 35, ALA N 36 285(ALK6, ALK3 = F ALK2 = M)
    86 ILE GLN A 286, GLY A 282, 286(ALK6, ALK3 = Q ALK2 = T),
    PHE A 285, HIS N 32, 282(ALK3, ALK6 G, ALK2 na),
    ILE N 33, ARG N 34, 285(ALK6, ALK3 = F ALK2 = M)
    PRO N 35
    87 VAL PRO N 35
    90 LEU ASP A 289, SER A 290, 289(ALK6, ALK3 = D ALK2 = T),
    PHE A 285, ARG A 297, 290(ALK6 = T ALK3 = S ALK2 = P),
    GLN A 286, ILE N 33 285(ALK6, ALK3 = F ALK2 = M),
    297(ALK6, ALK3 = R ALK2 = Q),
    296(ALK3, ALK6 R, ALK2 na)
    93 PHE ALA A 293, ARG A 297, 293(na), 295(na), 294(na),
    ASP A 289, LEU A 295, 297(ALK6, ALK3 = R ALK2 = Q),
    SER A 290, GLN A 294, 289(ALK6, ALK3 = D ALK2 = T),
    GLU A 264 290(ALK6 = T ALK3 = S ALK2 = P),
    264(ALK6, ALK3 = E ALK2 = S)
    94 ILE SER A 290, LYS A 292, 290(ALK6 = T ALK3 = S ALK2 = P),
    ALA A 293 292(na), 293(na)
    108 GLN ASP D 36 36(ActRII, ActRIIb D, BMPRII N)
    110 ASN LYS D 37, ASP D 62, 36(ActRII, ActRIIb D, BMPRII
    ASP D 36 N), 37(ActRII, ActRIIa K, BMPRII na),
    62 D conserved
    111 ALA LEU D 61, LYS D 37 61(ActRIIa, ActRIIb L, BMPRII G),
    37(ActRII, ActRIIa K, BMPRII na)
    112 ILE LEU D 61 61(ActRIIa, ActRIIb L, BMPRII G)
    113 SER LEU D 61, TRP D 60, 61(ActRIIa, ActRIIb L, BMPRII G), 60
    LEU N 43, VAL N 44, W conserved
    ASP N 45, LEU N 46
    114 VAL TRP D 60, LEU N 46 60 W conserved
    115 LEU PHE D 83, TRP D 60, 83 F conserved, 60 W conserved, 56
    PHE D 42, THR D 44, K conserved, 42(ActRIIb, BMPRII = Y,
    LYS D 56, LEU N 46, ActRIIa = F), 44(ActRIIb = S, ActRIIa = T,
    PHE N 168, ARG N 204, BMPRII = L)
    ILE N 220
    116 TYR ASP B 284, PRO N 37 284(ALK6, ALK3 = D ALK2 = K)
    117 PHE VAL D 81, GLU D 80, 81(ActRIIa, ActRIIb V, BMPRII na),
    ARG N 206, ILE N 218 80(ActRIIb = Q, ActRIIa = E, BMPRII
    na)
    119 ASP HIS N 29
    122 ASN ARG D 20, ASN D 17, 20(ActRIIb = L, ActRIIa = K, BMPRII
    GLN N 221 na), 17(ActRIIa, ActRIIb N, BMPRII
    na)
    123 VAL VAL D 81, VAL D 55, 81(ActRIIa, ActRIIb V, BMPRII na),
    LYS D 56, THR D 44, 55 V conserved, 56 K conserved,
    LYS D 46, ILE N 218, 44(ActRIIb = S, ActRIIa = T, BMPRII = L),
    PRO N 219, ILE N 220, 46(ActRIIb = A, ActRIIa = K,
    GLN N 221 BMPRII = E),
    124 ILE HIS N 199, GLN N 221
    125 LEU TRP D 60, PHE D 42, 60 W conserved, 56 K conserved,
    LYS D 56, LEU N 43, 42(ActRIIb, BMPRII = Y, ActRIIa = F)
    ASP N 45, LEU N 46,
    GLN N 221, TYR N 222,
    PRO N 223
    126 LYS TYR B 280, GLU B 281, 280(ALK6 = L ALK3 = Y ALK2 na),
    ASP B 284, PRO N 37, 281(ALK2 na), 284(ALK6, ALK3 = D
    SER N 38, ASP N 39, ALK2 = K)
    LEU N 43, HIS N 199
    127 LYS LEU D 61, LYS D 37, 37(ActRII, ActRIIa K, BMPRII na),
    ALA N 36, PRO N 37, 61(ActRIIa, ActRIIb L, BMPRII G),
    SER N 38, ASN N 40, 36(ActRII, ActRIIb D, BMPRII N)
    LEU N 41, PRO N 42,
    LEU N 43
    128 TYR ASP B 284, PHE B 285, 284(ALK6, ALK3 = D ALK2 = K),
    PRO N 35, ALA N 36, 285(ALK6, ALK3 = F ALK2 = M)
    PRO N 37, SER N 38
    129 ARG GLU B 281, ASN E 83, 281(ALK3, ALK6 E, ALK2 na)
    ALA N 36, SER N 38,
    ASN N 40
    130 ASN GLU B 281 281(ALK3, ALK6 E, ALK2 na)
    131 MET PHE B 285, PRO N 35 285(ALK6, ALK3 = F ALK2 = M)
    134 ARG ASP D 36 36(ActRII, ActRIIb D, BMPRII N)
    • Example 4 Identification of Regions of High Electrostatic Potential in BMP-7
  • The electrostatic potential at each position in BMP-7 was determined using the Dybye-Huckel equation in the context of the BMP-7 dimer. Positions with electrostatic potential greater than 0.5 or less than −0.5 are listed in the table below; modifications at these positions may confer increased stability or receptor binding specificity.
    TABLE 3
    Regions of high electrostatic potential in BMP-7
    Residue Residue Electrostatic
    number name potential
    46 SER −0.72
    67 CYS 0.73
    68 GLU 0.50
    69 GLY 0.58
    70 GLU 0.55
    71 CYS 0.50
    72 ALA 0.62
    82 THR 0.57
    105 ALA 0.54
    106 PRO 0.67
    107 THR 0.65
    108 GLN 0.68
    109 LEU 0.79
    110 ASN 1.00
    111 ALA 1.51
    113 SER 0.68
    122 ASN −0.64
    133 VAL 0.68
    135 ALA 0.53
    136 CYS 0.62
    • Example 5 Identification of Preferred Substitutions to BMPs
  • Analogous contact environment (ACE) calculations, were performed on BMP-7 using complete PFAM alignment for BMP-7. ACE calculations identify alternate residues for each position that are observed in structurally similar contexts in homologous proteins. The calculations were performed using a low stringency threshold of 0.8 and a high stringency threshold of 0.5.
    TABLE 4
    Residues observed in analogous structural
    contexts in BMP-7 homologs.
    ACE, low ACE, high
    residue Wt stringency stringency
    36 GLN E Q T Q T
    37 ALA A G S V A G
    38 CYS C C
    39 LYS K R K
    40 LYS K R T K
    41 HIS H K R H
    42 GLU E S E
    43 LEU F L M P L P
    44 TYR F Y F Y
    45 VAL I R V V
    46 SER D E N S S
    47 PHE E L S F
    48 ARG K Q R K Q R
    49 ASP A D E Q D
    50 LEU F I L M V L V
    51 GLY D G N G N
    52 TRP W W
    53 GLN D H L N Q R S D H L N Q S
    54 ASP D N R D N
    55 TRP W W
    56 ILE I V I
    57 ILE I V I
    58 ALA A K Q S Y A
    59 PRO P P
    60 GLU A E G H K M A E K M P
    M P Q R S T Q R S
    61 GLY G G
    62 TYR F Y Y
    63 ALA A D E G H A M Q S
    M N Q S
    64 ALA A G A
    65 TYR F N Y F N Y
    66 TYR F Y Y
    67 CYS C C
    68 GLU A D E H K Q R D E
    69 GLY G G
    70 GLU E E
    71 CYS C C
    72 ALA A D N P S V A N S V
    73 PHE F F
    74 PRO P P
    75 LEU L L
    76 ASN A D N S N
    77 SER A S A S
    78 TYR C F H Y C F H Y
    79 MET A M M
    80 ASN N N
    81 ALA A F G P S T A
    82 THR T T
    83 ASN K N S N
    84 HIS H H
    85 ALA A A
    86 ILE I L V I
    87 VAL I L M V V
    88 GLN K Q Q
    89 THR L T T
    90 LEU L L
    91 VAL V V
    92 HIS H N H
    93 PHE A F L S F S
    94 ILE F I I
    95 ASN N N
    96 PRO P P
    97 GLU A D E G K N D E
    Q R S
    98 THR A K R T T Y
    99 VAL T V V
    100 PRO G P P
    101 LYS K L Q K Q
    102 PRO A P S T V W P
    103 CYS C K C
    104 CYS C W C
    105 ALA A G H I Q R A
    S T V
    106 PRO N P P
    107 THR T T
    108 GLN K Q K Q
    109 LEU L L
    110 ASN H N N
    111 ALA A G S A
    112 ILE I L T I
    113 SER P S T P S
    114 VAL I L M V L M V
    115 LEU L L
    116 TYR F Y Y
    117 PHE F I K L Q Y F Y
    118 ASP D D
    119 ASP D E N S D E N S
    120 SER D E G H N S N S
    121 SER A D E H K N R S A D S
    122 ASN A N S N
    123 VAL I L V V
    124 ILE I V I V
    125 LEU I K L Y L Y
    126 LYS K N R Y K R
  • PDA® technology calculations were performed to identify alternate residues that are compatible with the structure and function of BMP-7. At each variable position, energies were calculated for the wild type residue and alternate residues with decreased hydrophobic or increased polar character. First, point mutation calculations were run for each template. The energy of each alternate amino acid in its most favorable rotameric conformation was compared to the energy of the wild type residue in the crystallographically observed rotameric conformation; all reported energies in the table below are [E(wild type)−E(variant)]. For residues that are within 5 Å of at least one atom in the type I or type II receptor, calculations were also performed using templates consisting of the BMP-7 dimer bound to receptor.
    TABLE 5
    Energies of most favorable alternate residues in each variable position in BMP-7
    # Wt dimer ALK2 ALK3 ALK6 ActRIIa ActRIIb
    36 GLN N: −4.8 N: 0.4 N: −6.6
    D: −3.7 Q: 0.8 Q: −5.6
    S: −3.0 D: 0.8 D: −5.2
    39 LYS E: −11.9 T: 0.0 T: 1.4 S: 2.7 E: −2.0 E: −1.8
    K: −10.5 E: 0.2 A: 1.6 E: 3.3 S: −0.4 K: −0.3
    Q: −10.0 S: 0.8 S: 2.6 T: 4.1 K: −0.2 Q: 0.4
    42 GLU Q: −3.2 Q: −5.0 Q: −6.2
    E: −2.3 E: −4.0 R: −5.7
    N: −0.9 N: −2.9 E: −5.5
    44 TYR Q: −6.6 Q: −3.5 Q: −3.5 Q: −3.5 Q: 0.8 Q: −3.1
    E: −5.6 E: −2.6 E: −2.6 E: −2.6 R: 1.1 R: −2.5
    N: −4.6 N: −1.5 D: −1.5 N: −1.5 E: 1.9 E: −2.2
    48 ARG E: −5.4 N: −3.3 Q: −3.9 N: −3.2 N: −8.4 N: −3.9
    Q: −4.3 Q: −3.2 N: −3.3 Q: −2.9 Q: −7.5 Q: −3.7
    N: −3.8 R: −2.6 R: −2.9 R: −2.5 D: −7.1 E: −2.9
    49 ASP S: −1.4 D: −0.3 N: −3.4
    D: −0.6 R: 0.0 D: −2.5
    N: −0.5 Q: 0.2 Q: −1.9
    52 TRP Q: 2.3 K: 14.5 E: 14.5 E: 14.5 K: 1.8 K: 0.6
    K: 3.2 E: 15.0 K: 15.0 K: 15.0 Q: 2.3 Q: 1.4
    E: 3.4 A: 16.7 Q: 16.7 Q: 16.7 E: 3.5 E: 2.6
    53 GLN D: −6.1 D: 6.2 A: 7.0 D: 5.9 E: −7.5 D: −6.9
    A: −5.7 A: 6.3 H: 7.3 A: 6.4 S: −6.3 S: −6.4
    S: −5.7 T: 6.6 T: 7.8 H: 6.6 Q: −6.2 Q: −6.4
    54 ASP D: −0.3 N: −6.4 N: −6.4 N: −6.3 N: −3.6 N: 0.0
    S: 0.2 D: −5.5 D: −5.6 D: −5.5 Q: −3.4 D: 0.7
    N: 0.6 Q: −4.9 Q: −4.5 Q: −5.4 D: −2.8 Q: 1.4
    55 TRP N: −19.6 R: 11.3 H: 11.3 H: 11.3 Q: −18.3 Q: −17.4
    R: −19.3 H: 13.0 S: 13.0 Q: 13.0 N: −16.7 E: −15.9
    D: −18.8 Q: 13.9 T: 13.9 R: 13.9 E: −16.6 N: −15.9
    57 ILE E: 1.0 T: −4.9 T: −4.9 T: −4.9 E: 9.0 E: 8.8
    K: 1.1 D: −3.1 D: −3.1 D: −3.1 T: 11.6 D: 9.3
    Q: 2.2 R: −2.5 Q: −2.5 R: −2.5 D: 12.0 T: 9.4
    60 GLU Q: −1.9 E: −1.8 E: 0.6 E: −1.7 E: 0.2 T: −0.3
    N: −1.4 Q: 3.9 Q: 4.5 Q: 4.1 T: 1.7 E: 0.2
    R: −1.3 N: 4.5 N: 5.3 N: 4.7 D: 2.8 K: 0.8
    63 ALA R: −5.1 A: 0.0 E: −4.0
    Q: −4.8 S: 0.8 Q: −1.6
    E: −3.9 T: 2.2 A: 0.2
    65 TYR A: 7.9
    E: 8.5
    H: 8.5
    70 GLU E: 2.8 D: −2.3 E: −5.6
    Q: 4.7 Q: −1.5 Q: −3.0
    D: 4.9 E: −0.7 T: 0.4
    73 PHE R: 0.4 H: 11.2 H: 11.2 H: 11.2 H: −6.5 H: −6.5
    Q: 1.8 E: 18.6 A: 18.6 D: 18.6 D: −5.7 D: −5.7
    E: 2.4 D: 21.2 S: 21.1 A: 21.1 S: −4.0 A: −4.1
    76 ASN N: −6.6 A: −3.9 A: −5.2 N: −4.0 D: −6.2 S: −4.5
    Q: −6.4 T: −2.2 S: −2.4 S: −1.2 Q: −5.3 Q: −4.4
    D: −6.4 S: −1.1 T: 3.5 T: 1.6 N−5.2 D: −4.2
    77 SER N: −5.7 S: −1.8 A: −4.5 K: −3.0 N: −8.9 N: −6.9
    D: −4.6 A: 1.3 S: −0.2 D: −0.9 D: −7.9 D: −5.8
    S: −3.9 T: 10.1 T: 0.1 A: −0.3 S: −6.8 S: −4.8
    78 TYR N: −15.6 S: 3.2 S: 3.2 S: 3.2 N: −13.2 R: −12.8
    D: −14.6 D: 6.4 A: 6.4 T: 6.4 D: −12.8 N: −12.4
    S: −13.9 Q: 6.5 H: 6.5 A: 6.5 S: −11.6 D: −12.1
    86 ILE K: −5.0 T: 9.9 T: 9.9 D: 9.9 E: −3.6 K: −5.1
    E: −4.3 D: 10.9 D: 10.9 A: 10.9 K: −2.2 E: −3.6
    Q: −4.0 A: 11.6 A: 11.6 T: 11.6 Q: −1.9 Q: −2.1
    88 GLN E: −0.1
    T: 1.6
    Q: 2.4
    90 LEU K: −3.3 E: 6.3 E: 6.3 E: 6.3 E: −0.8 E: −2.2
    E: −0.6 D: 9.4 T: 9.4 T: 9.4 Q: −0.7 Q: −2.1
    Q: 0.5 T: 9.5 D: 9.5 D: 9.5 R: −0.6 R: −0.1
    93 PHE S: −18.0 E: 0.3 S: 0.3 E: 0.3 D: −15.3 D: −15.1
    D: −17.4 T: 2.3 D: 2.3 D: 2.3 S: −15.1 S: −14.8
    R: −17.4 D: 3.0 E: 3.0 Q: 3.0 N: −13.8 N: −13.6
    94 ILE K: −2.7 E: 4.1 T: 4.1 H: 4.1 E: −2.0 K: −2.0
    E: −2.0 D: 4.3 N: 4.3 D: 4.7 Q: −.06 E: −1.9
    Q: −0.8 A: 4.7 D: 4.7 E: 5.9 K: −0.4 Q: −0.4
    95 ASN Q: 3.4 N: 5.9 Q: −2.6
    D: 3.9 D: 6.6 N: 0.3
    S: 4.4 Q: 7.3 D: 0.4
    97 GLU N: −5.8 — N: −3.6
    D: −4.9 D: −2.6
    S: −4.1 S: −2.6
    98 THR D: −0.8 N: −2.1 Q: −9.3
    E: −0.7 D: −1.4 R: −8.3
    K: −0.3 Q: −1.1 E: −8.0
    108 GLN N: −5.7 Q: −2.6 S: −6.8
    D: −5.2 D: −0.7 N: −5.8
    Q: −5.1 S: 0.4 D: −4.8
    110 ASN E: 1.0 A: −7.1 Q: −8.1
    Q: 4.0 E: −5.7 E: −6.7
    S: 8.3 D: −4.6 A: −4.6
    111 ALA A: 0.0 A: −4.7 A: −6.4
    S: 1.7 S: −2.1 S: −3.3
    H: 9.2 T: 26.2 D: 46.3
    115 LEU K: −3.4 K: −3.8 E: −3.8 K: −3.8 E: 8.9 E: 6.7
    E: −3.2 E: −3.3 K: −3.3 E: −3.3 T: 11.5 A: 10.1
    D: −1.3 D: −1.5 D: −1.5 D: −1.5 D: 12.1 Q: 10.4
    116 TYR H: 4.5 H: 4.6 H: 4.6 H: 4.6 H: 1.7 H: 1.5
    S: 6.0 T: 8.8 T: 8.8 A: 8.8 T: 4.3 T: 4.6
    T: 7.5 A: 9.3 A: 9.3 S: 9.3 S: 6.4 S: 6.7
    117 PHE Q: −7.3 K: −4.1 R: −4.1 R: −4.1 K: 6.7 H: 7.1
    R: −7.2 Q: −3.9 K: −3.9 Q: −3.9 E: 9.1 K: 8.0
    E: −6.9 R: −3.7 Q: −3.7 K: −3.7 H: 10.3 E: 8.1
    119 ASP R: −2.5 N: −0.4 N: −5.2
    Q: −2.3 S: 0.7 S: −4.1
    N: −1.9 D: 0.8 D: −3.8
    120 SER N: −5.8 S: −1.7 N: −7.4
    S: −4.6 N: −1.6 Q: −6.6
    D: −4.4 D: −0.1 S: −5.9
    121 SER N: −4.7 N: −4.8 Q: −7.0
    Q: −4.0 D: −3.4 E: −6.2
    S: −3.7 Q: −3.2 K: −5.9
    122 ASN R: −2.6 N: 5.3 Q: −6.0 R: 0.0
    N: −2.5 Q: 6.3 E: −5.7 Q: 0.6
    Q: −2.4 D: 7.6 R: −5.6 N: 0.7
    123 VAL Q: −5.4 T: −9.2 T: −9.2 T: −9.2 D: 4.8 T: 4.8
    E: −4.5 R: −8.6 R: −8.6 R: −8.6 T: 5.1 A: 6.0
    S: −4.1 E: −8.3 E: −8.3 E: −8.3 A: 6.4 D: 7.6
    125 LEU Q: −10.7 Q: −9.0 Q: −9.0 Q: −9.0 H: −1.0 H: −0.6
    E: −9.8 E: −8.4 E: −8.4 E: −8.4 A: 3.8 E: 3.2
    S: −9.3 S: −7.3 S: −7.3 S: −7.3 D: 3.8 K: 3.2
    126 LYS T: −1.2 D: −10.8 Q: −2.2 D: −4.6 Q: −9.9 Q: −9.2
    D: 1.0 S: −7.4 R: −1.5 E: −4.6 E: −9.3 E: −8.5
    E: 1.0 N: −5.9 D: −1.3 K: −4.2 R: −7.9 R: −7.3
    127 LYS Q: −13.7 N: −17.3 Q: −7.9 N: −17.8 D: −12.5 T: −5.2
    E: −12.8 D: −16.7 E: −7.2 D: −17.5 T: −11.7 S: −2.5
    R: −12.0 Q: −13.7 S: −5.9 Q: −13.5 S: −10.2 D: −0.9
    128 TYR K: 1.2 E: 4.9 H: 4.9 H: 4.9 E: 2.5 E: 0.7
    E: 2.3 A: 7.1 D: 9.9 K: 9.9 D: 3.9 D: 3.6
    Q: 4.1 H: 9.9 K: 10.5 D: 10.5 K: 5.9 K: 5.2
    129 ARG Q: −21.5 D: −8.3 D: −4.3 D: −6.6 N: −10.3 E: −9.9
    E: −21.1 E: −6.6 S: −4.1 S: −6.6 D: −9.7 N: −8.9
    N: −19.1 N: −6.0 Q: −2.9 Q: −6.1 E: −9.4 Q: −8.3
    130 ASN E: −0.9 D: −4.3 D: −2.1 D: −2.0
    Q: −0.7 E: −3.5 R: −1.7 R: −1.7
    R: −0.4 Q: −3.3 E: −1.7 Q: −0.9
    134 ARG Q: −7.6 Q −6.7 Q: −4.0 S: −1.1 R: −0.8 R: −1.0
    E: −7.1 E: −6.0 D: −3.8 D: −1.0 S: 0.0 S: 0.5
    R: −6.5 R: −5.2 S: −3.7 Q: −1.0 D: 1.3 D: 1.7
    135 ALA E: −3.4
    D: −3.4
    Q: −3.0
  • Next, combinatorial calculations were performed in which multiple variable positions located close in space were allowed to vary. The most favorable amino acid sequence was first identified with DEE, and then Monte Carlo calculations were performed to identify 10,000 favorable energies. All residues that were selected for a given position in at least 500 of the top 10,000 sequences were noted, and the number of occurrences is given in the table below. For residues that are within 5 Å of at least one atom in the type I or type II receptor, calculations were also performed using templates consisting of the BMP-7 dimer bound to receptor.
    TABLE 6
    Preferred alternate residues identified using combinatorial PDA ® calculations
    # wt dimer ALK2 ALK3 ALK6 ActRII ActRIIb
    36 GLN Q: 7809 M: 9996 Q: 10000
    N: 1884
    39 LYS S: 9842 S: 8163 S: 9997 D: 5917 S: 10000 S: 10000
    D: 1118 M: 3085
    T: 572
    42 GLU D: 4594 D: 4405 L: 9999
    N: 4513 F: 3105
    L: 893 N: 2490
    48 ARG H: 9950 R: 9994 Q: 7431 R: 10000 E: 9274 R: 6089
    E: 2530 Q: 649 Q: 1849
    N: 1072
    K: 936
    49 ASP S: 5123 R: 10000 N: 8591
    N: 4554 M: 766
    R: 589
    52 TRP W: 9937 W: 10000 W: 10000 W: 10000 W: 10000 W: 10000
    53 GLN Q: 5056 D: 9292 W: 6190 D: 9673 S: 9247 R: 9596
    E: 4894 Q: 695 D: 3771 Q: 753
    54 ASP D: 9422 N: 7578 N: 9326
    S: 578 D: 1217 S: 606
    S: 1205
    55 TRP F: 9234 W: 10000 W: 10000 W: 10000 K: 7426 Q: 4838
    Q: 2063 K: 2656
    N: 1596
    57 ILE Q: 4803 V: 7154 V: 9029 T: 6435 I: 10000 I: 10000
    E: 4362 T: 1771 E: 940 V: 2518
    Q: 928
    60 GLU K: 4894 Q: 6658 R: 6190 Q: 8619 E: 10000 E: 9727
    Q: 4752 E: 1911 Q: 3243 E: 878
    N: 1072
    70 GLU E: 10000 M: 7656 E: 10000
    E: 1051
    T: 840
    73 PHE M: 9998 F: 9569 F: 10000 F: 9968
    76 ASN N: 7622 A: 9496 A: 10000 A: 9309 D: 8520 D: 9528
    D: 2269 S: 504 S: 658 K: 1480
    77 SER N: 9226 A: 9989 D: 10000 D: 10000 N: 4869 N: 5705
    S: 2426 D: 2067
    D: 2247 S: 1703
    86 ILE L: 5322 V: 3799 I: 10000 D: 4757
    F: 4678 M: 2956 I: 3625
    I: 2197 H: 737
    D: 757 V: 548
    90 LEU I: 7320 L: 7909 I: 10000 L: 8453
    L: 1971 I: 2091 I: 1547
    93 PHE R: 10000 M: 9971 F: 10000 F: 9422
    94 ILE K: 6521 I: 10000 I: 8908 I: 5328
    I: 3472 V: 705 V: 3624
    H: 636
    95 ASN N: 10000 N: 10000 E: 6756
    M: 2423
    R: 821
    97 GLU E: 8909 R: 6746
    N: 565 W: 1317
    F: 968
    E: 681
    98 THR K: 9813 E: 9849 R: 8142
    K: 1037
    Q: 659
    108 GLN W: 10000 W: 5051 E: 8219
    L: 4949 M: 1368
    115 LEU E: 9073 E: 5297 E: 9835 E: 5464 I: 9494 I: 8877
    K: 1647 K: 2112 L: 506 L: 865
    D: 857 D: 1598
    Q: 682
    L: 611
    116 TYR S: 7525 T: 8380 Y: 10000 Y: 10000 Y: 9428 Y: 6205
    H: 1972 S: 734 F: 3186
    T: 577
    117 PHE K: 10000 R: 5996 K: 5592 K: 5038 F: 10000 F: 9956
    S: 734 Q: 2504 E: 4955
    E: 1856
    119 ASP N: 3258 N: 4613 N: 9068
    R: 2589 D: 4434 D: 842
    Q: 1910 S: 665
    D: 1614
    120 SER R: 9814 Q: 9548 E: 10000
    121 SER N: 8165 N: 8910 W: 10000
    Q: 1581 Q: 791
    122 ASN Q: 9767 R: 7212 Q: 10000
    Q: 2768
    123 VAL R: 4692 Q: 3725 R: 10000 K: 4955 V: 10000 V: 9965
    N: 4665 K: 3427 Q: 2595
    E: 2351 E: 1252
    R: 999
    125 LEU Q: 2247 Q: 2148 Q: 2688 Q: 2618 L: 10000 E: 7583
    E: 2234 E: 2024 E: 2252 E: 1838 L: 1122
    N: 2103 D: 1558 D: 1815 T: 1591 Q: 540
    D: 1840 N: 925 R: 1215 D: 1522
    R: 854 N: 828 R: 897
    T: 681
    S: 553
    126 LYS E: 10000 D: 10000 E: 7981 E: 10000 Q: 8882 Q: 7360
    Q: 2019 E: 904 R: 2587
    127 LYS Q: 10000 Q: 7702 Q: 10000 Q: 7301 T: 8654 Q: 10000
    N: 2120 N: 1850 D: 1346
    D: 849
    128 TYR K: 7798 M: 10000 M: 10000 M: 10000 W: 10000 W: 10000
    M: 2139
    129 ARG D: 9142 E: 7628 E: 10000 E: 7301 N: 8799 N: 7847
    N: 858 D: 1971 R: 2699 D: 1201 Q: 1495
    D: 541
    134 ARG M: 6832 E: 9900 E: 10000 E: 9997 E: 9996 Q: 5893
    E: 3143 Y: 2281
    E: 1787
  • PDA® technology calculations were also performed to identify mutations that are likely to either increase or substantially eliminate binding to the BMP inhibitor protein Noggin. At each position in BMP-7 that is within 5 A of at least one atom in Noggin (see table above), energies were calculated for alternate residues using a template comprising (1) BMP-7 only, and (2) BMP-7 bound to Noggin. Preferred substitutions include, but are not limited to, those listed in the tables below.
    TABLE 7
    Preferred substitutions to substantially eliminate Noggin binding
    Energy Energy
    Residue Alternate (BMP-7 (BMP-7-
    number amino acid only) noggin) Δ(Energy)
    55 ILE 5.38 109.30 103.91
    55 LEU 4.01 421.61 417.60
    55 LYS 0.94 2576.09 2575.15
    55 ARG −1.82 1012.10 1013.92
    57 MET 4.30 219.47 215.17
    57 TYR 7.74 42890.27 42882.53
    57 GLU −3.05 119.37 122.42
    57 HIS 6.53 2905.10 2898.57
    57 HSP 5.72 3035.01 3029.29
    57 LYS 0.40 114.98 114.58
    57 GLN −4.66 150.57 155.23
    57 ARG −3.67 4086.31 4089.97
    58 ILE 9.42 322.50 313.09
    58 LEU 9.30 84822.06 84812.76
    58 MET 8.88 754.69 745.81
    58 TYR 4.94 1105.51 1100.57
    58 VAL 6.66 226.71 220.05
    58 GLU −1.90 199.69 201.59
    58 HIS 5.03 1385.50 1380.47
    58 HSP 4.31 1951.88 1947.58
    58 LYS 3.52 987.81 984.28
    58 GLN −3.02 181.68 184.70
    58 ARG −3.00 221.94 224.94
    59 TYR 9.57 15040.62 15031.05
    76 GLU 3.88 210.29 206.41
    76 GLN 2.78 304.90 302.12
    76 ARG 8.02 9204.62 9196.60
    77 GLU 9.73 5019.33 5009.59
    77 GLN 8.40 4804.74 4796.34
    83 PHE 3.55 2730.52 2726.97
    83 TRP 1.99 4103.04 4101.05
    83 TYR −3.56 1606.78 1610.35
    83 HSP −1.42 110.31 111.73
    83 LYS 0.82 275.49 274.67
    83 ARG −4.14 114.90 119.04
    86 LEU 6.41 177.93 171.52
    86 MET 3.76 182.42 178.66
    86 PHE 4.06 510.92 506.87
    86 TYR 0.29 486.51 486.22
    86 ARG −1.29 360.80 362.09
    87 HIS 4.35 722.22 717.87
    87 HSP 9.18 650.44 641.27
    113 ILE 9.08 220.54 211.47
    113 LEU 4.06 1142.97 1138.91
    113 MET 6.10 1203.71 1197.61
    113 PHE 5.50 *****
    113 TYR 5.35 *****
    113 GLU −2.87 199.31 202.17
    113 HIS −0.15 219.95 220.09
    113 HSP 2.62 294.44 291.82
    113 LYS 2.39 219.74 217.35
    113 GLN −3.68 419.42 423.10
    113 ARG −0.22 31582.79 31583.01
    115 MET 0.59 433.33 432.74
    115 LYS −4.58 104.47 109.05
    115 ARG −2.89 629.82 632.71
    123 MET 2.17 186.71 184.54
    123 TYR 7.81 *****
    123 HIS 6.31 2238.61 2232.29
    123 HSP 5.63 11040.76 11035.13
    127 ILE 7.26 270.14 262.88
    127 VAL 5.22 223.61 218.39
    127 HIS 8.31 1012.09 1003.79
    127 HSP 8.00 1708.17 1700.17
    128 ILE 0.25 401.32 401.07
    128 ARG −3.86 124.31 128.17
  • TABLE 8
    Preferred substitutions to increase Noggin binding affinity
    Energy Energy
    Residue Alternate (BMP-7 (BMP-7-
    number amino acid only) noggin) Δ(Energy)
    48 MET 8.38 −3.60 −11.99
    57 VAL −3.57 −14.50 −10.92
    59 MET 7.34 −7.13 −14.47
    60 ILE 14.56 −0.05 −14.61
    60 LEU 13.50 2.97 −10.52
    60 MET 15.34 2.70 −12.64
    60 VAL 13.08 0.51 −12.58
    74 MET 13.88 1.04 −12.84
    76 ILE 13.60 −1.47 −15.07
    76 VAL 11.19 −6.60 −17.79
    76 ALA 9.97 −3.48 −13.45
    77 ALA 13.76 −2.23 −15.99
    77 HIS 16.02 2.66 −13.36
    77 THR 12.53 −7.56 −20.09
    86 VAL 4.41 −10.60 −15.02
    113 ALA 2.89 −7.70 −10.58
    119 ILE 28.27 18.21 −10.06
    119 LEU 29.23 17.25 −11.99
    124 VAL −4.30 −14.52 −10.22
    125 ILE 247.94 228.79 −19.16
    125 MET 10.73 −17.18 −27.91
    125 ALA 4.10 −7.22 −11.32
    126 MET 8.64 −9.57 −18.21
    126 TRP 64.98 35.09 −29.89
    126 HIS 49.02 38.84 −10.18
    126 HSP 47.75 37.16 −10.59
    126 THR 6.31 −5.14 −11.45
    127 MET 7.52 −11.44 −18.95
    127 ALA 3.79 −6.37 −10.16
  • A number of alternate residues were selected for each variable position. In all cases, the alternate residues are predicted to be compatible with the structure of BMP-7 dimer. The alternate residues are predicted to interact with the receptors in a diverse manner, encompassing competitive inhibitor variants, receptor specific variants, and high affinity variants. The table shown below indicates preferred substitutions that were identified using sequence alignment data, ACE calculations, and PDA® technology calculations. Note that “X” indicates a one-residue deletion.
    TABLE 9
    BMP-7 variants in Library 1.
    Residue wt calculation Library 1.1 Library 1.2 Library 1.3 # variants
    21 LEU expH DKS 3
    23 MET expH DKS 3
    26 VAL expH DKS 3
    36 GLN adtl. surf ENR 3
    39 LYS specificity DERST 5
    42 GLU adtl. surf DQRT 4
    44 TYR expH AEHKQR 6
    48 ARG specificity EKNQ 4
    49 ASP adtl. surf ES 2
    52 TRP expH AEKQ 4
    53 GLN specificity ADERS H 6
    54 ASP adtl. surf KNRS 4
    55 TRP expH AEHKNQ R 7
    57 ILE expH AEHKTV D 7
    60 GLU specificity KQRST 5
    63 ALA adtl. surf EQRS 4
    65 TYR electrostatic DEN 3
    70 GLU adtl. surf AQ 2
    73 PHE expH AEHQRS D 7
    76 ASN specificity ADST 4
    77 SER specificity ADKQT 5
    78 TYR expH DGHNST 6
    80 ASN glycosylation DQST 4
    82 THR glycosylation V 1
    83 ASN glycosylation P 1
    86 ILE expH EKQT AD 6
    88 GLN electrostatic E 1
    90 LEU expH EKNQRST 7
    93 PHE expH ADEQRST 7
    94 ILE expH AEKQRT H 7
    95 ASN adtl. surf DKQR 4
    97 GLU adtl. surf DKR 3
    98 THR adtl. surf AEKRX 5
    108 GLN adtl. surf DKS 3
    110 ASN electrostatic DEH 3
    111 ALA electrostatic DS 2
    115 LEU expH EKT 3
    116 TYR expH DEHKST A 7
    117 PHE expH ADEKQR H 7
    120 SER adtl. surf DERN 4
    121 SER adtl. surf DEKNT 5
    122 ASN adtl. surf EQR 3
    123 VAL expH ADNRT 5
    125 LEU expH AEKQ Y 5
    126 LYS specificity DEQR 4
    127 LYS specificity DQST E 5
    128 TYR expH DEHKQ 5
    129 ARG specificity DES 3
    130 ASN electrostatic D 1
    134 ARG specificity EKQS D 5
    135 ALA electrostatic DES 3
  • As may easily be appreciated, many of these preferred substitutions may easily be incorporated into the analogous positions in other BMPs and TGF-β family members. A sequence alignment of human BMPs is given in FIG. 3 (SEQ ID NOS:7-12). In order to identify which substitutions may be incorporated into BMP-2, BMP-4, BMP-5, BMP-6, and BMP-8, the energy of each of the above substitutions was calculated in the context of each dimer structure. Substitutions with similar energies in two different structures are likely to produce similar effects in the two proteins.
    TABLE 10
    Energies of library mutations in the context of the BMP-2, 4, 5, 6, 7, and 8
    structures.
    BMP-7
    Residue substitution BMP2 E(tot) BMP4 E(tot) BMP5 E(tot) BMP6 E(tot) E(tot) BMP8 E(tot)
    Q 36 GLU 5.6 3.4 6.0 6.4 5.8 5.6
    Q 36 ASN 4.2 5.1 2.5 3.0 2.4 2.2
    Q 36 ARG 8.0 5.2 5.4 5.7 5.3 5.0
    A 37 ASP −3.0 −3.1 −0.2 1.7 −0.3 −3.4
    A 37 GLU −1.8 −2.4 5.0 3.5 2.9 1.3
    A 37 HIS 2.3 2.5 10.6 7.1 8.5 5.1
    A 37 LYS 2.5 2.7 2.9 1.1 2.7 −0.8
    A 37 ARG 1.0 1.1 4.2 2.8 4.1 4.7
    K 39 ASP 1.7 1.7 3.6 1.7 2.2 3.9
    K 39 GLU 0.7 0.6 −0.7 −2.7 −0.4 0.9
    K 39 ARG 2.5 2.5 1.8 0.0 3.2 2.1
    K 39 SER −0.2 −0.3 2.0 0.0 1.8 2.9
    K 39 THR −0.7 −0.7 1.2 1.2 2.3 1.6
    E 42 ASP 4.2 1.3 2.7 3.4 2.7 2.5
    E 42 GLN 1.3 0.0 −0.8 1.4 −0.7 0.0
    E 42 ARG 1.9 1.3 2.2 4.6 1.9 1.5
    E 42 THR 4.4 3.3 4.2 5.0 4.1 3.7
    Y 44 ALA 2.6 2.0 7.3 7.3 7.3 8.3
    Y 44 GLU −3.5 −4.1 −0.2 −0.2 −0.1 1.3
    Y 44 HIS −2.4 −2.6 3.0 2.9 3.0 3.9
    Y 44 LYS −2.6 −2.9 3.3 3.4 3.2 5.5
    Y 44 GLN −4.4 −4.9 −1.1 −1.1 −1.0 0.4
    Y 44 ARG −2.8 −2.9 2.6 2.7 2.6 4.5
    R 48 GLU 2.0 2.0 −1.5 −1.7 −1.5 1.2
    R 48 LYS 7.0 7.0 2.2 2.9 2.2 7.0
    R 48 ASN −0.6 −0.6 −0.1 −0.1 0.1 −1.7
    R 48 GLN 0.3 0.4 −0.4 −0.4 −0.4 −0.2
    D 49 GLU 4.3 4.3 2.2 2.2 2.1 1.8
    D 49 SER 4.3 4.3 −0.7 −0.7 −0.9 −1.0
    W 52 ALA −4.1 −4.0 2.7 2.7 2.4 2.1
    W 52 GLU −6.4 −6.4 −2.3 −2.3 −2.5 −3.4
    W 52 LYS −5.1 −5.0 −2.6 −2.6 −2.8 −5.0
    W 52 GLN −5.2 −5.0 −3.5 −3.5 −3.7 −4.8
    Q 53 ALA 2.0 1.9 0.1 −1.4 0.1 −3.9
    Q 53 ASP −1.2 −1.2 −0.3 −2.0 −0.3 −5.3
    Q 53 GLU 0.3 0.3 9.1 −1.5 9.1 −6.8
    Q 53 HIS 2.8 2.8 1.4 0.5 1.4 1.6
    Q 53 ARG −1.6 −1.5 3.5 0.7 3.3 −3.6
    Q 53 SER 0.2 0.2 0.2 −1.8 0.2 −3.4
    D 54 LYS 12.3 12.4 4.3 4.4 5.5 6.0
    D 54 ASN 4.5 4.4 −1.9 −1.9 0.1 −1.6
    D 54 ARG 8.6 8.7 −0.3 −0.3 1.6 1.2
    D 54 SER 6.1 6.1 −0.2 −0.2 −0.3 0.1
    W 55 ALA 1.9 2.0 1.9 1.9 1.8 2.2
    W 55 GLU −2.5 −2.4 −1.8 −1.8 −1.8 −1.7
    W 55 HIS 0.6 1.4 4.0 4.0 3.7 4.4
    W 55 LYS 0.2 0.3 2.7 2.7 2.6 3.0
    W 55 ASN −4.0 −3.9 −3.9 −3.9 −3.9 −3.6
    W 55 GLN −3.7 −3.7 −2.7 −2.7 −2.8 −2.5
    W 55 ARG −5.0 −4.8 −3.6 −3.6 −3.7 −3.2
    I 57 VAL −3.9 −3.6 −2.7 −3.9 −2.8 −2.2
    I 57 ALA 1.1 1.5 −0.5 −1.3 −0.6 −0.7
    I 57 ASP −2.8 −2.7 −4.2 −5.3 −4.2 −4.3
    I 57 GLU −4.8 −4.5 −6.2 −7.1 −6.1 −5.4
    I 57 HIS 2.7 2.9 4.2 2.8 4.3 3.5
    I 57 LYS −1.0 −0.9 −5.8 −6.5 −6.1 −2.0
    I 57 THR −7.3 −7.1 −1.2 −2.0 −1.2 −0.7
    E 60 LYS 5.3 5.1 5.9 6.1 5.4 6.1
    E 60 GLN 0.3 0.2 2.8 2.5 0.7 1.3
    E 60 ARG 2.0 1.9 3.6 3.7 1.3 5.1
    E 60 SER 2.2 2.1 3.5 2.7 2.9 3.2
    E 60 THR 3.2 3.1 5.2 5.1 2.7 5.7
    A 63 GLU −2.0 −2.0 −0.9 −0.6 −2.2 −4.5
    A 63 GLN −2.7 −2.7 −1.7 −1.5 −3.1 −4.7
    A 63 ARG −2.3 −2.3 −1.0 −0.3 −3.4 −1.4
    A 63 SER −0.4 −0.4 0.5 1.1 1.4 1.4
    Y 65 ASP −4.1 −6.0 −3.4 −3.5 −3.4 −3.7
    Y 65 GLU 21.7 19.5 −3.7 −3.8 −3.9 73.9
    Y 65 ASN −0.7 −2.4 −0.3 −0.3 −0.4 −0.7
    E 70 ALA 4.3 2.2 2.6 4.6 2.6 1.9
    E 70 GLN −0.7 −0.9 0.4 1.1 −0.3 −0.3
    A 72 ASP 10.7 −1.8 −1.3 −1.3 −1.1 −1.7
    A 72 GLU −0.1 −3.6 −1.3 −1.2 −3.1 −1.5
    A 72 HIS 3.7 −0.6 2.9 2.9 2.4 2.6
    A 72 LYS 1.9 −2.4 1.1 1.1 0.5 0.8
    A 72 ASN 9.0 −0.3 2.3 2.3 2.4 1.9
    A 72 ARG −4.4 −2.2 −2.9 −2.9 −3.1 −3.1
    A 72 SER 2.0 −1.0 −4.3 −4.3 −4.4 −4.6
    F 73 ALA 0.2 0.3 4.0 4.0 6.0 4.0
    F 73 ASP −1.9 −1.8 3.4 3.4 4.0 3.6
    F 73 GLU −3.2 −3.0 1.1 1.1 1.2 1.3
    F 73 HIS −0.7 −0.6 3.7 3.7 5.6 2.7
    F 73 GLN −4.0 −3.9 0.3 0.3 0.6 0.6
    F 73 ARG −4.7 −4.5 −1.2 −1.2 −0.8 −1.0
    F 73 SER −1.2 −1.1 1.8 1.8 1.2 1.8
    N 76 ALA 4.1 4.0 6.2 6.2 5.9 4.8
    N 76 ASP −0.3 −0.3 1.1 1.1 0.9 0.1
    N 76 SER 0.4 0.4 2.5 2.5 2.3 1.1
    N 76 THR 8.2 7.8 5.9 5.9 5.4 4.0
    S 77 ALA 13.7 13.7 15.1 15.1 15.1 14.7
    S 77 ASP 6.3 6.4 7.8 7.8 7.9 7.5
    S 77 LYS 18.2 18.2 19.4 19.4 19.3 18.8
    S 77 GLN 8.9 9.0 9.8 9.8 9.8 9.3
    S 77 THR 12.6 12.8 13.7 13.7 13.6 12.0
    Y 78 ASP 3.5 3.7 3.4 3.4 5.0 5.7
    Y 78 HIS 11.4 10.4 11.7 11.7 12.5 11.2
    Y 78 ASN 2.2 2.4 2.6 2.6 4.0 4.8
    Y 78 SER 4.2 4.3 4.5 4.5 5.7 6.3
    Y 78 THR 8.1 8.2 8.2 8.2 9.3 9.1
    I 86 ALA 1.0 0.9 0.2 0.2 −0.1 −0.4
    I 86 ASP −1.1 −1.4 −4.8 −4.8 −4.9 −5.5
    I 86 GLU −4.2 −4.1 −6.5 −6.5 −6.5 −6.6
    I 86 LYS −0.8 −0.8 −7.0 −7.0 −7.2 −7.7
    I 86 GLN −2.7 −2.4 −6.2 −6.2 −6.3 −6.6
    I 86 THR 2.2 2.3 −1.0 −1.0 −1.1 −1.4
    Q 88 GLU −11.9 −9.9 −10.8 −10.8 −10.9 −9.9
    L 90 GLU −7.9 −7.8 −6.4 −6.4 −7.1 −8.4
    L 90 LYS −4.4 −4.2 −7.0 −6.9 −9.8 −8.5
    L 90 ASN −1.7 −1.6 −3.6 −3.6 −2.1 −1.7
    L 90 GLN −6.0 −5.9 −5.4 −5.4 −6.0 −7.0
    L 90 ARG −1.4 −1.2 −4.7 −4.7 −5.6 −5.5
    L 90 SER −5.4 −5.4 −2.4 −2.4 −2.6 −2.7
    L 90 THR −4.0 −3.9 −1.5 −1.5 −2.6 −3.8
    F 93 ALA 1.9 2.1 1.3 1.3 1.2 1.2
    F 93 ASP −2.1 −2.0 −2.9 −2.8 −3.0 −3.2
    F 93 GLU −4.5 −4.4 0.7 0.8 0.4 0.2
    F 93 GLN −4.9 −4.8 −0.6 −0.6 −0.9 −1.1
    F 93 ARG −3.4 −3.2 −2.6 −2.6 −3.0 −2.9
    F 93 SER −2.9 −2.8 −3.7 −3.7 −3.6 −3.6
    F 93 THR 3.9 4.0 6.7 6.7 6.3 6.2
    I 94 ALA 1.8 1.9 −1.9 0.5 0.6 −2.4
    I 94 GLU −4.9 −4.8 −7.6 −5.2 −5.0 −7.8
    I 94 HIS −1.7 −1.6 6.1 −0.2 2.9 5.8
    I 94 LYS −5.0 −5.0 −8.4 −5.2 −5.7 −8.4
    I 94 GLN −3.7 −3.6 −6.1 −4.0 −3.8 −6.2
    I 94 ARG −0.4 −0.2 −5.9 −3.4 −3.5 −4.2
    I 94 THR 0.4 0.4 −1.7 0.5 1.0 −1.1
    N 95 ASP 0.8 2.8 −4.1 2986.4 −1.7 −2.1
    N 95 LYS 3.8 9.2 −1.2 4982.8 3.9 2.7
    N 95 GLN 0.6 3.4 −4.9 3497.0 −2.2 0.0
    N 95 ARG 2.6 6.3 −2.5 4116.5 3.7 2.4
    E 97 ASP 3.2 3.6 6.6 3.3 3.5 6.1
    E 97 LYS 3.7 3.9 15.6 12.9 13.1 15.9
    E 97 ARG 4.3 4.2 11.4 8.0 8.2 11.1
    T 98 ALA 8.5 8.2 0.4 −0.4 −0.4 −0.6
    T 98 GLU 4.3 5.6 −5.5 −3.7 −2.8 −4.3
    T 98 LYS 9.5 11.1 −5.8 −3.4 −2.4 −2.2
    T 98 ARG 6.0 7.9 0.6 3.1 3.5 3.1
    A 105 VAL −11.4 −14.8 −4.2 −4.2 0.4 −4.2
    Q 108 ASP −1.6 −1.6 −3.3 −3.4 −3.3 −2.2
    Q 108 LYS 4.4 4.4 2.8 3.0 2.8 3.3
    Q 108 SER −0.6 −0.7 −2.6 −2.6 −2.6 −1.3
    N 110 ASP −0.9 −0.7 7.5 7.5 12.8 −0.5
    N 110 GLU −0.6 −0.5 −1.6 −1.7 −1.4 0.0
    N 110 HIS 10.3 10.8 11.8 11.8 12.4 8.9
    A 111 ASP 266.0 263.9 1199.6 1199.6 1155.7 1201.4
    A 111 SER 2.5 2.5 1.4 1.4 1.4 3.4
    L 115 GLU −7.9 −7.9 −7.8 −7.9 −7.7 −7.8
    L 115 LYS −7.2 −7.2 −7.6 −7.5 −7.8 −7.5
    L 115 THR −1.3 −2.6 −5.4 −5.4 −5.4 −5.4
    Y 116 ASP 22.1 24.7 275.0 274.9 278.8 274.6
    Y 116 GLU 76.1 65.5 125.3 125.2 126.5 122.8
    Y 116 HIS −9.2 −9.5 −7.5 −7.5 −7.1 −6.7
    Y 116 LYS 4301.8 3766.9 198.7 198.7 211.7 203.6
    Y 116 SER −2.3 −2.3 −5.6 −5.6 −5.6 −4.3
    Y 116 THR −4.8 −4.8 −4.2 −4.3 −4.1 −2.5
    F 117 ALA −3.5 −2.5 −0.1 −0.1 −2.0 −2.7
    F 117 ASP −5.1 −4.7 −2.4 −2.5 −2.2 −4.7
    F 117 GLU −7.2 −7.1 −4.6 −4.7 −4.4 −6.8
    F 117 LYS −6.4 −7.6 −2.9 −2.8 −2.7 −5.5
    F 117 GLN −8.1 −8.0 −4.7 −4.7 −4.8 −8.0
    F 117 ARG −6.5 −5.8 −4.8 −4.7 −4.7 −5.8
    D 119 GLU 10.2 12.8 6.8 5.6 6.9 6.7
    D 119 ASN 4.5 7.3 6.0 4.9 6.1 6.0
    D 119 SER 6.5 9.3 8.0 6.9 8.0 7.9
    D 119 THR 12.2 14.3 10.4 10.3 10.5 10.4
    S 120 ASP 1.9 1.8 1.5 1.5 1.6 1.0
    S 120 GLU 1.1 1.0 3.5 3.5 3.6 2.9
    S 120 ASN 0.5 0.3 0.1 0.1 0.2 0.0
    S 120 ARG 1.6 1.4 5.3 5.3 5.4 5.0
    S 121 ASP 3.2 3.4 3.2 3.2 3.2 2.5
    S 121 GLU 4.2 4.4 3.9 3.8 3.9 3.2
    S 121 LYS 9.7 9.8 7.9 8.0 7.8 8.1
    S 121 ASN 1.8 1.9 1.7 1.7 1.7 1.1
    S 121 THR 8.2 8.4 6.5 6.5 6.4 5.7
    N 122 GLU −0.3 −0.1 −1.0 −1.1 2.9 −1.1
    N 122 GLN −2.0 −1.8 −2.6 −2.6 1.4 −2.6
    N 122 ARG −0.8 −0.5 −2.6 −2.9 1.2 −2.6
    V 123 ALA 0.7 0.9 1.9 1.9 1.7 1.7
    V 123 ASP −1.8 −1.8 −1.0 −1.1 −0.8 −1.2
    V 123 ASN −2.9 −2.8 0.1 0.1 0.3 0.0
    V 123 ARG −3.3 −2.9 −2.7 −2.6 −2.4 −3.0
    V 123 THR −2.6 −2.3 −2.2 −2.2 −2.4 −3.2
    L 125 ALA 5.0 5.2 4.7 4.7 4.5 4.7
    L 125 GLU −0.8 −0.8 −1.2 −1.3 −1.3 −1.2
    L 125 LYS 4.2 4.2 3.6 3.7 3.4 3.7
    L 125 GLN −1.8 −1.7 −2.2 −2.2 −2.3 −2.2
    K 126 ASP −1.6 −3.4 −5.5 −5.5 −5.5 −5.2
    K 126 GLU −1.4 −3.0 −3.3 −3.4 −5.4 −2.7
    K 126 GLN −2.4 −4.3 −1.4 −1.4 −3.6 −3.3
    K 126 ARG −2.7 −5.7 0.5 0.5 −0.7 9.9
    K 127 ASP 5.9 4.0 0.7 0.7 0.6 0.9
    K 127 GLN 2.0 0.2 −2.5 −2.5 −3.1 −2.3
    K 127 SER 3.0 1.2 0.1 0.1 −0.1 0.1
    K 127 THR 5.6 3.7 1.5 1.5 −0.5 1.7
    Y 128 ASP −6.4 −6.6 −5.5 −5.5 −5.6 −5.3
    Y 128 GLU −3.3 −3.0 −7.4 −7.5 −7.6 −8.9
    Y 128 HIS −10.0 −9.8 −4.3 −4.3 −4.4 −7.3
    Y 128 LYS 8.1 10.0 −8.7 −8.6 −8.8 −5.9
    Y 128 GLN 3.6 3.6 −5.7 −5.7 −5.8 −4.6
    R 129 ASP −0.5 −0.5 0.1 0.0 0.1 0.1
    R 129 GLU −0.3 1.6 −2.0 −2.0 −2.0 −1.9
    R 129 SER −0.4 1.5 1.5 1.5 1.5 1.5
    N 130 ASP −6.6 −4.6 −2.8 −2.8 −2.6 −2.7
    R 134 GLU −6.9 −6.9 −7.1 −7.1 −6.9 −6.9
    R 134 LYS 12.3 18.6 −4.3 −4.1 −2.2 −4.1
    R 134 GLN −4.3 −4.2 −7.5 −7.4 −7.4 −6.6
    R 134 SER −2.4 −2.4 −3.8 −3.8 −3.9 −3.2
    A 135 ASP 1.6 1.2 −5.1 −5.1 −5.9 −1.7
    A 135 GLU 2.2 1.2 −4.8 −4.8 −5.9 −2.6
    A 135 SER 3.7 2.4 −4.0 −4.0 −5.2 −2.1
    H 139 ARG −4.4 −4.4 −0.6 −0.6 −2.6 −0.6
  • Correlation coefficients (R2) for energies calculated using the BMP-2 template versus other BMP templates are as follows: BMP2 vs BMP4=0.93, BMP2 vs BMP5=0.52, BMP2 vs BMP6=0.44, BMP2 vs BMP-7=0.64, and BMP2 vs BMP8=0.52. Correlation coefficients (R2) for energies calculated using the BMP-7 template versus other BMP templates are as follows: BMP-7 vs BMP2=0.54, BMP-7 vs BMP4=0.54, BMP-7 vs BMP5=0.95, BMP-7 vs BMP6=0.71, and BMP-7 vs BMP8=0.76. These trends correlate with the sequence similarity of the pair. Modifications to BMP-7 have substantially similar effects on other BMPs if the energy difference between the modification in the BMP-7 template and another BMP template are less than 1 kcal/mol, or if both energies are higher than 50 kcal/mol. The following BMP-7 modifications have substantially similar effects in BMP-2: Q36E, A37K, K39D, E42R, E42T, R48N, R48Q, Q53D, Q53S, W55A, W55E, W55N, W55Q, E60K, E60Q, E60R, E60S, E60T, A63E, A63Q, Y65D, Y65N, E70Q, S77Q, S77T, Q88E, L90E, L90N, L90Q, F93A, F93D, F93R, F93S, I94E, I94K, I94Q, I94T, N95K, E97D, N110E, A111D, L115E, L115K, Y116D, Y116E, Y116K, Y116T, S120D, S120N, S121D, S121E, S121N, V123A, V123D, V123R, V123T, L125A, L125E, L125K, L125Q, Y128D, R129D, and R134E. The following BMP-7 modifications have substantially similar effects in BMP-4: Q36R, A37K, K39D, K39E, E42Q, E42R, E42T, R48N, R48Q, Q53D, Q53S, W55A, W55E, W55N, W55Q, 157V, E60K, E60Q, E60R, E60S, E60T, A63E, A63Q, E70A, E70Q, A72D, A72E, A72R, S77Q, S77T, Q88E, L90E, L90N, L90Q, F93A, F93D, F93R, F93S, I94E, I94K, I94Q, I94T, E97D, N110E, A111D, L115E, L115K, Y116D, Y116E, Y116K, Y116T, F117A, S120D, S120N, S121D, S121E, S121N, V123A, V123D, V123R, V123T, L125A, L125E, L125K, L125Q, K126Q, Y128D, R129D, R129S, and R134E. The following BMP-7 modifications have substantially similar effects in BMP-5: Q36E, Q36N, Q36R, A37D, A37K, A37R, K39E, K39S, E42D, E42Q, E42R, E42T, Y44A, Y44E, Y44H, Y44K, Y44Q, Y44R, R48E, R48K, R48N, R48Q, D49E, D49S, W52A, W52E, W52K, W52Q, Q53A, Q53D, Q53E, Q53H, Q53R, Q53S, D54S, W55A, W55E, W55H, W55K, W55N, W55Q, W55R, I57V, I57A, I57D, I57E, I57H, I57K, I57T, E60K, E60S, A63S, Y65D, Y65E, Y65N, E70A, E70Q, A72D, A72H, A72K, A72N, A72R, A72S, F73D, F73E, F73Q, F73R, F73S, N76A, N76D, N76S, N76T, S77A, S77D, S77K, S77Q, S77T, Y78H, I86A, I86D, I86E, I86K, I86T, I86T, Q88E, L90E, L90Q, L90R, L90S, F93A, F93D, F93E, F93Q, F93R, F93S, F93T, T98A, Q108D, Q108K, Q108S, N110E, N110H, A111D, A111S, L115E, L115K, L115T, Y116D, Y116E, Y116H, Y116K, Y116S, Y116T, F117D, F117E, F117K, F117Q, F117R, D119E, D119N, D119S, D119T, S120D, S120E, S120N, S120R, S121D, S121E, S121K, S121N, S121T, V123A, V123D, V123N, V123R, V123T, L125A, L125E, L125K, L125Q, K126D, K127D, K127Q, K127S, Y128D, Y128E, Y128H, Y128K, Y128Q, R129D, R129E, R129S, N130D, R134E, R134Q, R134S, and A135D. The following BMP-7 modifications have substantially similar effects in BMP-6: Q36E, Q36N, Q36R, A37E, K39D, E42D, E42T, Y44A, Y44E, Y44H, Y44K, Y44Q, Y44R, R48E, R48K, R48N, R48Q, D49E, D49S, W52A, W52E, W52K, W52Q, Q53H, D54S, W55A, W55E, W55H, W55K, W55N, W55Q, W55R, I57A, I57E, I57K, I57T, E60K, E60S, Y65D, Y65E, Y65N, A72D, A72H, A72K, A72N, A72R, A72S, F73D, F73E, F73Q, F73R, F73S, N76A, N76D, N76S, N76T, S77A, S77D, S77K, S77Q, S77T, Y78H, I86A, I86D, I86E, I86K, I86T, I86T, Q88E, L90E, L90Q, L90R, L90S, F93A, F93D, F93E, F93Q, F93R, F93S, F93T, I94A, I94E, I94K, I94Q, I94R, I94T, E97D, E97K, E97R, T98A, T98E, T98K, T98R, Q108D, Q108K, Q108S, N110E, N110H, A111D, A111S, L115E, L115K, L115T, Y116D, Y116E, Y116H, Y116K, Y116S, Y116T, F117D, F117E, F117K, F117Q, F117R, D119T, S120D, S120E, S120N, S120R, S121D, S121E, S121K, S121N, S121T, V123A, V123D, V123N, V123R, V123T, L125A, L125E, L125K, L125Q, K126D, K127D, K127Q, K127S, Y128D, Y128E, Y128H, Y128K, Y128Q, R129D, R129E, R129S, N130D, R134E, R134Q, R134S, and A135D. The following BMP-7 modifications have substantially similar effects in BMP-8: Q36E, Q36N, Q36R, A37R, K39T, E42D, E42Q, E42R, E42T, Y44A, Y44H, R48Q, D49E, D49S, W52A, W52E, Q53H, D54K, D54R, D54S, W55A, W55E, W55H, W55K, W55N, W55Q, W55R, 157V, 157A, 157D, 157E, 157H, 157T, E60K, E60Q, E60S, A63S, Y65D, Y65N, E70A, E70Q, A72D, A72H, A72K, A72N, A72R, A72S, F73D, F73E, F73Q, F73R, F73S, N76D, S77A, S77D, S77K, S77Q, Y78D, Y78N, Y78S, Y78T, I86A, I86D, I86E, I86K, I86T, I86T, Q88E, L90N, L90Q, L90R, L90S, F93A, F93D, F93E, F93Q, F93R, F93S, F93T, I94R, N95D, T98A, T98K, T98R, Q108K, A111D, L115E, L115K, L115T, Y116D, Y116E, Y116H, Y116K, F117A, D119E, D119N, D119S, D119T, S120D, S120E, S120N, S120R, S121D, S121E, S121K, S121N, S121T, V123A, V123D, V123N, V123R, V123T, L125A, L125E, L125K, L125Q, K126D, K126Q, K127D, K127Q, K127S, Y128D, R129D, R129E, R129S, N130D, R134E, R134Q, and R134S.
  • ACE calculations were also performed to assess the similarity of the structural environment at each variable position in BMP-7 vs. BMP-2, BMP-4, BMP-5, BMP-6, and BMP-8. At positions with an ACE similarity score of 0.4 or higher in the table below, mutations will have similar effects in BMP-7 vs. the other BMP. ACE similarity scores between 0.6 and 0.8 indicate that the effects of mutations are highly likely to have similar effects, and ACE similarity scores greater than 0.8 indicate that the effects of mutations should be substantially identical.
    TABLE 11
    ACE similarity scores for BMP-7 versus selected additional human TGF-β proteins
    BMP- BMP-
    BMP-2 BMP-3 3B BMP-4 BMP-5 BMP-6 BMP-8 BMP-9 10
     36 0.58 0.11 0.14 0.23 0.85 0.81 0.60 0.10 0.10
     37 0.12 0.02 0.02 0.07 0.72 0.27 0.30 0.02 0.05
     39 0.35 0.03 0.04 0.24 0.75 0.67 0.38 0.02 0.02
     42 0.30 0.37 0.37 0.33 0.56 0.27 0.69 0.36 0.36
     44 0.19 0.04 0.04 0.22 0.95 0.82 0.59 0.04 0.21
     48 0.17 0.17 0.17 0.17 1.00 0.74 0.26 0.19 0.16
     49 0.11 0.09 0.09 0.12 0.56 0.50 0.40 0.07 0.07
     52 0.37 0.32 0.34 0.37 0.99 0.98 0.46 0.41 0.39
     53 0.28 0.11 0.11 0.28 1.00 0.49 0.48 0.09 0.12
     54 0.29 0.30 0.29 0.29 1.00 0.96 0.19 0.29 0.30
     55 0.59 0.30 0.26 0.58 1.00 0.99 0.52 0.26 0.17
     57 0.20 0.45 0.11 0.20 1.00 0.96 0.43 0.05 0.08
     60 0.48 0.18 0.18 0.48 1.00 0.74 0.65 0.21 0.61
     63 0.19 0.04 0.03 0.21 0.35 0.10 0.81 0.06 0.31
     65 0.04 0.01 0.01 0.05 0.96 0.99 0.20 0.03 0.02
     70 0.04 0.02 0.02 0.04 0.38 0.12 0.22 0.03 0.02
     72 0.23 0.01 0.01 0.08 0.93 0.80 0.23 0.03 0.01
     73 0.18 0.02 0.02 0.17 0.41 0.41 0.12 0.18 0.05
     76 0.21 0.12 0.11 0.17 0.58 0.58 0.50 0.10 0.15
     77 0.26 0.12 0.12 0.26 0.76 0.76 0.37 0.12 0.16
     78 0.34 0.13 0.13 0.28 0.77 0.75 0.61 0.14 0.17
     80 0.09 0.01 0.01 0.09 0.32 0.46 0.37 0.04 0.07
     82 0.02 0.01 0.01 0.01 0.99 0.99 0.68 0.00 0.00
     83 0.41 0.14 0.14 0.36 1.00 1.00 0.44 0.26 0.25
     86 0.36 0.09 0.09 0.36 0.97 0.97 0.39 0.10 0.04
     88 0.04 0.15 0.15 0.04 0.82 0.82 0.05 0.01 0.00
     90 0.18 0.11 0.11 0.18 0.33 0.33 0.18 0.11 0.04
     93 0.37 0.39 0.39 0.38 0.59 0.63 0.54 0.32 0.14
     94 0.11 0.07 0.07 0.12 0.18 0.34 0.22 0.15 0.16
     95 0.00 0.01 0.01 0.00 0.05 0.11 0.05 0.02 0.00
     97 0.02 0.05 0.05 0.02 0.06 0.59 0.15 0.06 0.02
     98 0.20 0.02 0.02 0.20 0.05 0.88 0.11 0.02 0.07
    105 0.03 0.01 0.01 0.03 0.95 0.98 0.69 0.03 0.03
    108 0.09 0.03 0.02 0.09 0.37 0.98 0.45 0.05 0.04
    110 0.11 0.03 0.01 0.10 0.69 0.70 0.30 0.01 0.02
    111 0.02 0.00 0.00 0.01 1.00 1.00 0.23 0.00 0.03
    115 0.45 0.39 0.30 0.45 1.00 0.99 0.82 0.08 0.07
    116 0.38 0.65 0.55 0.38 1.00 0.98 0.38 0.09 0.04
    117 0.36 0.43 0.37 0.35 1.00 0.98 0.61 0.20 0.14
    119 0.53 0.58 0.54 0.37 1.00 0.69 0.89 0.38 0.41
    120 0.07 0.37 0.32 0.07 1.00 1.00 0.33 0.04 0.01
    121 0.13 0.62 0.25 0.10 1.00 0.72 0.53 0.05 0.07
    122 0.21 0.22 0.18 0.09 1.00 0.42 0.62 0.08 0.07
    123 0.16 0.64 0.21 0.15 1.00 0.99 0.52 0.07 0.09
    125 0.69 0.62 0.27 0.69 1.00 1.00 0.84 0.50 0.43
    126 0.60 0.33 0.29 0.60 1.00 1.00 0.28 0.46 0.38
    127 0.37 0.07 0.03 0.37 1.00 1.00 0.61 0.04 0.03
    128 0.55 0.38 0.38 0.55 1.00 1.00 0.30 0.07 0.05
    129 0.10 0.05 0.06 0.09 0.99 0.99 0.61 0.01 0.03
    130 0.26 0.02 0.03 0.26 0.98 0.98 0.77 0.06 0.07
    134 0.07 0.05 0.12 0.07 0.36 0.38 0.12 0.04 0.03
    135 0.10 0.00 0.00 0.10 0.23 0.22 0.10 0.04 0.03
    139 0.19 0.01 0.00 0.18 0.94 0.97 0.80 0.10 0.10
    BMP- TGF- TGF- TGF- TGF-
    15 GDF-1 GDF-3 GDF-5 GDF-8 GDF-9 β1 β2 β3 β4
     36 0.14 0.42 0.41 0.10 0.36 0.24 0.10 0.10 0.10 0.09
     37 0.02 0.02 0.03 0.03 0.01 0.02 0.01 0.01 0.01 0.00
     39 0.19 0.07 0.23 0.04 0.06 0.19 0.02 0.02 0.03 0.02
     42 0.11 0.11 0.15 0.21 0.11 0.09 0.09 0.09 0.09 0.34
     44 0.03 0.29 0.19 0.04 0.03 0.03 0.18 0.17 0.17 0.12
     48 0.24 0.28 0.21 0.15 0.16 0.22 0.21 0.21 0.21 0.15
     49 0.40 0.27 0.20 0.12 0.06 0.12 0.09 0.15 0.14 0.06
     52 0.62 0.26 0.49 0.42 0.08 0.15 0.36 0.37 0.34 0.01
     53 0.18 0.14 0.17 0.45 0.03 0.01 0.07 0.04 0.06 0.01
     54 0.30 0.31 0.30 0.30 0.30 0.09 0.39 0.38 0.38 0.12
     55 0.10 0.14 0.16 0.45 0.08 0.11 0.07 0.07 0.07 0.12
     57 0.12 0.73 0.10 0.17 0.62 0.11 0.01 0.03 0.03 0.00
     60 0.32 0.90 0.72 0.27 0.20 0.22 0.51 0.41 0.50 0.31
     63 0.00 0.03 0.02 0.06 0.01 0.00 0.05 0.04 0.04 0.18
     65 0.01 0.02 0.05 0.03 0.02 0.01 0.02 0.01 0.01 0.02
     70 0.02 0.05 0.01 0.01 0.01 0.02 0.01 0.01 0.01 0.00
     72 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00
     73 0.02 0.04 0.02 0.12 0.00 0.01 0.00 0.00 0.00 0.00
     76 0.01 0.05 0.02 0.25 0.01 0.01 0.00 0.00 0.00 0.05
     77 0.22 0.11 0.24 0.20 0.07 0.13 0.11 0.11 0.11 0.14
     78 0.23 0.11 0.24 0.21 0.08 0.10 0.08 0.12 0.10 0.14
     80 0.00 0.01 0.04 0.11 0.03 0.00 0.00 0.00 0.00 0.01
     82 0.00 0.01 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00
     83 0.13 0.10 0.08 0.26 0.01 0.08 0.02 0.02 0.03 0.01
     86 0.09 0.04 0.11 0.21 0.00 0.01 0.00 0.00 0.00 0.00
     88 0.07 0.02 0.00 0.01 0.00 0.04 0.00 0.00 0.00 0.00
     90 0.05 0.02 0.10 0.09 0.01 0.01 0.02 0.06 0.04 0.00
     93 0.14 0.22 0.62 0.40 0.34 0.06 0.15 0.43 0.30 0.07
     94 0.07 0.07 0.11 0.09 0.12 0.04 0.08 0.10 0.10 0.01
     95 0.01 0.02 0.01 0.14 0.02 0.01 0.01 0.11 0.09 0.00
     97 0.01 0.08 0.18 0.15 0.50 0.01 0.43 0.44 0.44 0.01
     98 0.01 0.01 0.05 0.03 0.11 0.01 0.03 0.06 0.05 0.00
    105 0.00 0.02 0.00 0.03 0.02 0.00 0.00 0.00 0.00 0.00
    108 0.02 0.02 0.05 0.10 0.03 0.01 0.05 0.03 0.04 0.03
    110 0.03 0.03 0.03 0.05 0.02 0.02 0.14 0.06 0.08 0.01
    111 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00
    115 0.15 0.73 0.55 0.23 0.22 0.09 0.00 0.00 0.00 0.01
    116 0.22 0.42 0.31 0.46 0.07 0.10 0.01 0.01 0.01 0.01
    117 0.23 0.43 0.51 0.51 0.29 0.16 0.01 0.01 0.01 0.04
    119 0.34 0.84 0.57 0.58 0.29 0.29 0.16 0.19 0.17 0.21
    120 0.02 0.33 0.32 0.31 0.01 0.02 0.00 0.00 0.00 0.01
    121 0.09 0.83 0.16 0.24 0.17 0.08 0.04 0.04 0.04 0.05
    122 0.04 0.52 0.21 0.21 0.03 0.02 0.00 0.00 0.00 0.01
    123 0.11 0.67 0.17 0.21 0.43 0.06 0.01 0.03 0.03 0.00
    125 0.62 0.67 0.65 0.71 0.32 0.47 0.05 0.14 0.14 0.01
    126 0.15 0.39 0.61 0.31 0.07 0.08 0.03 0.03 0.03 0.01
    127 0.05 0.05 0.05 0.05 0.01 0.04 0.01 0.02 0.01 0.01
    128 0.45 0.25 0.20 0.49 0.03 0.15 0.05 0.06 0.06 0.02
    129 0.01 0.02 0.01 0.02 0.02 0.01 0.03 0.03 0.03 0.01
    130 0.01 0.03 0.04 0.14 0.01 0.00 0.01 0.01 0.01 0.00
    134 0.01 0.03 0.04 0.07 0.04 0.02 0.02 0.02 0.02 0.01
    135 0.00 0.00 0.05 0.03 0.02 0.00 0.00 0.00 0.00 0.01
    139 0.00 0.01 0.03 0.11 0.02 0.00 0.00 0.00 0.00 0.00
  • Based on the above ACE analysis, BMP-7 variants at the following positions are transferable to BMP-2: 36, 55, 60, 83, 115, 119, 125, 126, and 128. BMP-7 variants at the following positions are transferable to BMP-3: 57, 116, 117, 119, 121, 123, and 125. BMP-7 variants at the following positions are transferable to BMP-3b: 116 and 119. BMP-7 variants at the following positions are transferable to BMP-4: 55, 60, 115, 125, 126, and 128. BMP-7 variants at the following positions are transferable to BMP-5: 36, 37, 39, 42, 44, 48, 49, 52, 53, 54, 55, 57, 60, 65, 72, 73, 76, 77, 78, 82, 83, 86, 88, 93, 105, 110, 111, 115, 116, 117, 119, 120, 121, 122, 123, 125, 126, 127, 128, 129, 130, and 139. BMP-7 variants at the following positions are transferable to BMP-6: 36, 39, 44, 48, 49, 52, 53, 54, 55, 57, 60, 65, 72, 73, 76, 77, 78, 80, 82, 83, 86, 88, 93, 97, 98, 105, 108, 110, 111, 115, 116, 117, 119, 120, 121, 122, 123, 125, 126, 127, 128, 129, 130, and 139. BMP-7 variants at the following positions are transferable to BMP-9: 36, 42, 44, 49, 52, 53, 55, 57, 60, 63, 75, 78, 82, 83, 93, 105, 108, 115, 117, 119, 121, 122, 123, 125, 127, 129, 130, and 139. BMP-7 variants at the following positions are transferable to BMP-9: 52, 125, and 126. BMP-7 variants at the following positions are transferable to BMP-10: 60, 119, and 125. BMP-7 variants at the following positions are transferable to BMP-15: 49, 52, 125, and 128. BMP-7 variants at the following positions are transferable to GDF-1: 36, 57, 60, 115, 116, 117, 119, 121, 123, and 125. BMP-7 variants at the following positions are transferable to GDF-3: 36, 52, 60, 93, 115, 117, 119, 125, and 126. BMP-7 variants at the following positions are transferable to GDF-5: 52, 53, 55, 93, 116, 117, 119, 125, and 128. BMP-7 variants at the following positions are transferable to GDF-8: 57, 97, and 123. BMP-7 variants at the following positions are transferable to GDF-9: 125. BMP-7 variants at the following positions are transferable to TGF-β1: 60 and 97. BMP-7 variants at the following positions are transferable to TGF-β2: 60, 93 and 97. BMP-7 variants at the following positions are transferable to TGF-β3: 60 and 97.
    • Example 6 Generation of DNA Encoding the Parent BMP-7
  • A number of constructs for the expression of wild type human BMP-7 were made and tested: (1) native BMP-7 Image clone in pSport6 vector (obtained from ATCC), (2) FLAG-tagged BMP-7, with G4S linker and FLAG tag located just after the RXXR (SEQ ID NO:87) cleavage site in pCMVTnT vector (Promega), (3) FLAG-tagged BMP-7 with a perfect Kozak sequence (MAV rather than MHV) in pCMVTnT vector, (4) FLAG-tagged BMP-7 using native BMP-2 Kozak sequence, signal sequence, and pro-domain in pCMVTnT vector, (5) FLAG-tagged BMP-7 using native MIC-1 Kozak sequence, signal sequence, and pro-domain in pCMVTnT vector, and (6) native BMP-7 Image clone in pSport6 vector (obtained from ATCC) with 6×His tag at the N-terminus of the pro-domain. The untagged native Image clone in the pSport6 vector was found to produce the highest expression yields and was used as the template for variant construction.
  • Additional constructs were prepared for yeast expression: (1) pYES vector negative control, (2) BMP-7 mature domain in pYES vector, (3) E-BMP-7 mature domain in pYES vector, (4) AEAE-BMP-7 mature domain in pYES vector, (5) full length BMP-7 in pYES vector, and (6) REKR-full length BMP-7 in pYES vector.
    • Example 7 Generation of DNA Encoding BMP Variants
  • Constructs for the BMP-7 variants shown in the above table were prepared by site directed mutagenesis. The pSport6 Image clone (ATCC) was used as a template for all of the variants. DNA corresponding to each desired construct was prepared using Qiagen Miniprep or Maxiprep kits. As some of the BMP-7 variants were constructed using degenerate oligos, variants in addition to those explicitly included in Library 1 above were generated. Such variants include the following: L21E, L21G, L21N, L21R, M23G, M23N, M23R, V26E, V26G, V26N, K39A, K39G, K39N, Y44D, Y44G, Y44N, Y44P, Y44S, Y44T, R48D, R48H, W52P, W52T, Q53G, Q53K, Q53T, W55P, W55T, 157L, 157P, 157Q, E60H, E60N, E60P, F73G, F73K, F73N, F73T, N76Y, S77E, S77H, S77N, S77P, Y78P, Y78R, 186P, L90G, L90H, L90P, F93G, F93H, F93P, L115A, L115Q, Y116A, Y116Q, F117S, F117Y, V123G, I125P, I125T, K126G, K127A, K127H, K127N, K127P, K127Y, R129K, R129N, R134L, and R134P. Furthermore, silent mutations (that is, changes in DNA codon sequence that do not change the corresponding amino acid sequence) were introduced at I57, N76, Y116, V123, and R134.
    • Example 8 In Vitro Translation of Wild Type BMP-7
  • The following constructs were generated and used for in vitro translation experiments: (1) full length BMP-7 with FLAG tag at N-terminus of mature domain, (2) full length MIC-1 with FLAG tag at the N-terminus of the mature domain, (3) BMP-7 pro-domain with N-terminal FLAG tag, (4) MIC-1 pro-domain with N-terminal FLAG tag, (5) BMP-7 mature domain with N-terminal FLAG tag, (6) MIC-1 mature domain with N-terminal FLAG tag, (7) full length BMP-7 with C-terminal FLAG tag, (8) full length MIC-1 with C-terminal FLAG tag, (9) BMP-7 pro-domain with C-terminal FLAG tag, (10) MIC-1 pro-domain with C-terminal FLAG tag, (11) BMP-7 mature domain with C-terminal FLAG tag, and (12) MIC-1 mature domain with C-terminal FLAG tag. The 5′ end of each construct had a spacer, T7 promoter, globin UTR, and optimized ribosomal binding site preceeding the gene. Luciferase was used as a positive control. A coupled transcription/translation off the PCR product was used (TnT, Promega). Protein expression comparable to luciferase was obtained for all of the BMP-7 constructs other than (11) above.
    • Example 9 Expression of Wild Type and Variant BMP-7
  • The following small-scale expression protocol was used for initial library screening. 293T cells were plated into 6-well dishes (1-5×105 cells/mL in 4 mL DMEM 10% FBS). The next day, the cells were transfected using 5 ug DNA/well. As an internal control for transformation efficiency, several mini-preps of the native Image clone were used. After three days, the conditioned media was harvested and screened. Expression yields were determined using ELISA (all variants, not corrected for changes in antibody binding affinity, using R&D Systems ELISA Duoset Cat#DY354) and Western blotting (selected variants).
    TABLE 12
    Expression yields of
    Library 1 variants in 293T cells
    Fold
    change
    ELISA relative to Western
    Variant concentration image blot band
    name (ng/mL) clone intensity
    L21D 999 1.34
    L21E 332 0.45
    L21G 4917 0.78 ++
    L21K 495 0.50
    L21N 414 2.97 −
    L21R 682 0.92
    M23D 565 0.56 +
    M23G 4 0.03 +++
    M23N 600 0.81 +
    M23R 3 0.02 −
    M23S 15 0.11 −
    V26D 747 0.75 +
    V26E 1021 1.37 +
    V26G 605 0.81 −
    V26K 0 0.00 −
    V26N 976 1.31 +
    V26S 6 0.01 −
    Q36E 7107 1.13 ++
    Q36N 1 0.00 −
    K39A 22724 3.61 +
    K39D 19 0.01
    K39E 1 0.00
    K39G 1 0.00
    K39N 69 0.04
    K39R 8376 1.33 +++
    K39S 23063 3.67 +
    K39T 19 0.01
    E42D 7307 1.16 +++
    E42Q 6702 1.07 +++
    E42R 583 0.58 −
    E42T 449 0.45 −
    Y44A 259 0.04 −
    Y44D 1 0.00
    Y44E 42 0.04 −
    Y44G 0 0.00
    Y44H 1 0.01
    Y44K 2 0.00 −
    Y44N 14 0.10 −
    Y44P 0 0.00
    Y44Q 19 0.02 −
    Y44S 1 0.00 −
    Y44T 21 0.15
    R48D 1 0.00
    R48E 74 0.04
    R48H 6063 0.96 −
    R48N 7100 1.13 −
    R48Q 743 0.42
    D49S 24 0.02 −
    W52A 38 0.27
    W52E 1 0.00
    W52K 0 0.00
    W52P 407 0.55
    W52Q 6 0.01 −
    W52T 5 0.03
    Q53A 251 0.04 −
    Q53D 6876 3.87 ++
    Q53E 1237 0.70
    Q53G 83 0.05 +
    Q53H 645 0.29 ++
    Q53K 6413 1.02 +
    Q53R 149 0.08
    Q53S 8530 1.36 +++
    Q53T 13237 2.10 ++
    D54K 10 0.01 −
    D54N 458 0.46 −
    D54S 38 0.01 −
    W55A 26 0.04
    W55E 2 0.00
    W55H 6 0.01
    W55K 10 0.07
    W55N 11 0.08
    W55P 0 0.00
    W55Q 10 0.07
    W55R 48 0.34 −
    W55T 0 0.00
    I57A 47 0.01 −
    I57D 0 0.00
    I57E 0 0.00
    I57H 8 0.06
    I57I 526 0.71 −
    I57K 9 0.06
    I57L 16106 2.56 0.63
    I57P 0 0.00
    I57Q 0 0.00
    I57T 1 0.00 −
    I57V 6 0.01
    E60H 129 0.07
    E60K 755 0.76 ++
    E60N 5 0.00
    E60P 145 0.08
    E60Q 3172 3.17 +
    E60R 2069 0.33 +
    E60S 97 0.05
    E60T 410 0.41 −
    A63E 4068 4.07 +
    A63Q 8577 8.58 ++
    A63R 3183 3.18 +
    A63S 8448 8.45 ++
    Y65D 18743 18.74 +++
    Y65E 382 0.38 −
    Y65N 11678 11.68 ++
    E70A 501 0.50 −
    E70Q 679 0.68 −
    A72D 5462 5.46 +
    A72E 3822 3.82 −
    A72H 3308 3.31 +
    A72K 3863 3.86 +
    A72N 1927 0.88 +
    A72R 491 0.49 −
    A72S 4784 2.17 ++
    F73A 153 1.10
    F73D 27 0.19
    F73E 138 0.99
    F73G 173 1.24
    F73H 5783 5.78 ++
    F73K 25 0.18
    F73N 321 0.43
    F73Q 75 0.54
    F73S 5159 0.82 ++
    F73T 193 1.38 −
    N76A 5570 3.14
    N76D 7534 4.24
    N76S 8816 4.97
    N76T 4576 2.58
    N76Y 814 0.46
    S77A 1194 0.67
    S77D 1 0.00
    S77E 46 0.03
    S77H 49 0.03
    S77K 1 0.00
    S77N 1 0.00
    S77P 1302 0.73
    S77Q 645 0.64 −
    S77T 1048 0.59
    Y78D 517 3.71 −
    Y78G 2 0.00
    Y78H 10102 1.61 +
    Y78N 5795 5.80 −
    Y78P 1249 1.68
    Y78R 264 1.89 −
    Y78S 9648 1.53 ++
    Y78T 714 5.12 −
    I86A 5635 5.64 ++
    I86D 3480 3.48 ++
    I86E 2556 3.43
    I86K 2214 2.97
    I86P 5 0.01
    I86Q 3008 4.04
    I86T 532 0.53 +
    Q88E 47 0.05 −
    L90E 235 0.32
    L90H 62 0.08
    L90H 62 0.08
    L90K 3 0.00 +
    L90N 200 0.09 +++
    L90P 109 0.15
    L90R 356 0.48
    L90S 5463 0.87 +++
    L90T 647 0.87
    F93A 12 0.02
    F93D 2346 0.37 ++
    F93E 646 0.87 ++
    F93G 24 0.03 ++
    F93H 16307 2.59 +++
    F93P 15 0.01 +++
    F93Q 279 0.13 +++
    F93R 38 0.02 ++
    F93S 2836 1.29 ++
    F93T 287 0.39 +
    I94A 2 0.00 +++
    I94E 1 0.00 −
    I94H 70 0.03 −
    I94K 0 0.00 −
    I94P 0 0.00
    I94Q 854 1.15
    I94R 0 0.00 +
    I94T 10 0.01 −
    N95D 18 0.02 −
    N95K 2 0.00 −
    N95Q 53 0.05 −
    N95R 1 0.00 −
    E97D 4784 2.17 −
    E97K 2936 1.33 −
    E97R 2113 0.96 −
    T98A 4208 1.91 −
    T98E 3064 1.39
    T98K 5464 2.48 −
    T98X 927 0.93 −
    A105V 440 0.44 −
    Q108D 4052 1.84 −
    Q108K 1 0.00 −
    Q108S 3529 1.60 −
    N110D 8591 3.91 −
    N110E 3020 1.37 −
    N110H 331 0.33 −
    A111D 2317 0.37 ++
    A111S 4358 4.36 −
    L115A 24 0.03
    L115E 1 0.00 −
    L115K 1 0.00 −
    L115Q 1 0.00 −
    L115T 0 0.00
    Y116A 0 0.00
    Y116D 1 0.00 −
    Y116E 0 0.00
    Y116H 16724 2.66 +
    Y116K 0 0.00
    Y116Q 0 0.00
    Y116S 34 0.01 −
    Y116T 2 0.00 −
    Y116Y 1922 2.58
    F117A 2 0.00 −
    F117D 0 0.00
    F117E 2407 0.38 −
    F117H 18720 2.98 ++
    F117K 329 0.44
    F117Q 3730 0.59 +
    F117R 604 0.81
    F117S 42 0.06
    F117Y 1682 2.26
    D119E 9669 1.54 ++
    D119N 2870 0.46 −
    D119S 4824 0.77 +
    D119T 2022 0.32 −
    S120D 21370 3.40 +++
    S120E 9259 1.47 ++
    S120N 11035 1.75 ++
    S120R 10544 1.68 ++
    S121D 9202 1.46 ++
    S121E 6098 0.97 +
    S121K 4793 0.76 −
    S121N 5161 0.82 −
    S121T 2204 0.35 −
    N122E 1 0.00 −
    N122Q 6 0.00 −
    N122R 63 0.01 −
    V123A 0 0.00
    V123D 1 0.00 −
    V123G 305 0.41
    V123N 0 0.00
    V123R 1 0.00 −
    V123T 1 0.00
    V123V 6 0.01
    L125A 1 0.00
    L125E 0 0.00
    L125K 1 0.00 −
    L125P 0 0.00
    L125Q 4 0.00 −
    L125T 0 0.00
    L125Y 3306 0.53 −
    K126D 4393 0.70 −
    K126E 24 0.01
    K126G 55 0.03
    K126Q 145 0.08
    K126R 10478 1.67 +
    K127A 1 0.00
    K127D 1 0.00
    K127E 3974 0.63 ++
    K127H 1 0.00
    K127N 1 0.00
    K127P 1 0.00
    K127Q 1 0.00
    K127S 1 0.00 −
    K127T 3 0.00
    K127Y 1 0.00
    Y128D 8948 1.42 ++
    Y128E 0 0.00
    Y128H 10887 1.73 ++
    Y128K 452 0.25
    Y128Q 11415 1.81 ++
    R129D 3093 0.49 +
    R129E 15209 2.42 +
    R129K 411 0.23
    R129N 573 0.32 +
    R129S 46 0.03
    N130D 18652 2.96 +
    R134D 1998 0.32 −
    R134E 21604 3.43 ++
    R134K 830 0.47
    R134L 9016 5.08 +
    R134P 125 0.07
    R134Q 1 0.00 −
    R134S 4314 2.43 ++
    A135D 5 0.00 −
    A135E 28974 4.61 ++
    A135S 29539 4.70 ++
    H139R 27483 4.37 +++
  • Preferred modifications include those modifications that increase the expression yield in 293T cells by at least 2-fold, including but not limited to L21N, K39A, K39S, Q53D, Q53T, I57L, E60Q, A63E, A63Q, A63R, A63S, Y65D, Y65N, A72D, A72E, A72H, A72K, A72S, F73H, N76A, N76D, N76S, N76T, Y78D, Y78N, Y78T, I86A, I86D, I86E, I86K, I86Q, F93H, E97D, T98K, N110D, A111S, Y116H, F117H, F117Y, S120D, R129D, N130D, R134E, R134L, R134S, A135E, A135S, and H139R. Especially preferred modifications include those modifications that increase the expression yield in 293T cells by at least 5-fold, including but not limited to A63Q, A63S, Y65D, Y65N, A72D, F73H, Y78N, Y78T, I86A, and R134L. Furthermore, a silent mutation at Y116 from codon TCA to codon TAT was observed to increase the expression yield in 293T cells by 2.6-fold.
  • Additional expression protocols were used for different scales (96-, 48-, 24-, 12-, or 6-well dishes as well as 10 cm or 15 cm plates), serum-free expression, and expression in alternate hosts (CHO and BRK-21).
  • Expression yields of selected Library 1 variants were determined for 293T, CHO, and BRK21 cells, as shown below. Expression of the wild type Image clone does vary between expression hosts. However, the relative expression yields for the different variants tend to be improved across hosts, indicating that a variant that improves expression yield in one host tends to improve expression yield in other hosts.
    TABLE 13
    Expression yields of selected Library 1 variants in different expression
    hosts
    Variant Variant Variant Variant
    Yield vs. Image Variant 23: 154: 249: 117: 80:
    Image in clone L21G Q53T Y65N Y78H F93H
    293T
    1 3.8 1.9 7.2 2.3 8.5
    CHO 1 0.9 1.4 6.8 1.1 6.5
    BRK21 1 1.0 1.4 10.2 1.3 5.8
  • Relative expression yield was also tested as a function of DNA dose (5.0, 2.5, and 1.0 ug were tested) and was found to be dose-independent.
    • Example 10 Characterization of the Receptor Binding Affinity of the BMP-7 Library 1 variants
  • The affinity of human and variant BMP-7 for several BMP receptors (ActRIa, BMPRIb, ActRIIa, and BMPRII) was measured using an ELISA-like assay, described below. 96-well plates were coated with a capture antibody (R&D Systems BMP-7 ELISA Duoset DY354, part # 840971) by diluting the antibody to 2 μg/mL in PBS, applying 50 μL/well, and incubating overnight or over the weekend at 4° C. in a humidified chamber. Excess liquid was removed from each plate. The plates were blocked by adding 175 μL blocking solution (1% BSA and 5% sucrose in PBS) to each well and incubating 1-2 hours at room temperature in a humidified chamber. The plates were then washed using an automated plate washer. 50 μL of BMP-7 containing solution (for example, diluted conditioned media obtained from the BMP-7 expression protocol above, or purified recombinant human BMP-7 of a known concentration) was added to each well and incubated 1.5-2 hours at room temperature in a humidified chamber. The plates were then washed using an automated plate washer. 50 μL of 5 μg/mL BMP receptor-Fc fusion in PBS was added to each well and incubated 1.5 hours at room temperature in a humidified chamber. The plates were then washed using an automated plate washer. 50 μL of 1:10,000 diluted anti-human IgG-HRP conjugate in secondary antibody dilution buffer (1% BSA in PBS, filtered through a 0.2 50 μm filter) was added to each well and incubated 30 minutes at room temperature in a humidified chamber. The plates were then washed using an automated plate washer. 50 μL of pre-mixed TMB substrate (BD Pharmingen # 555214) was added to each well and incubated for 10-20 minutes at room temperature in the dark. 25 μL of 2N H2SO4 was added to each well. Absorbance readings at 450 nm were taken using a 540 nm wavelength correction.
  • The table below shows the receptor binding affinity of a selection of BMP-7 variants relative to the wild type protein (normalized to 1.0). Note that the assays were performed using a fixed volume of conditioned media rather than a specific concentration of protein, so differences in expression levels as well as differences in receptor binding affinity may affect the results. Data is shown only for variants with expression yields greater than 10.0 ng/mL.
    TABLE 14
    Receptor binding affinity of BMP-7 Library 1 variants.
    ELISA Conc. BMPRIa BMPRIb
    wt res# variant (ng/mL) ActRIIa binding BMPRII binding binding binding
    M 23 S 15.20 2.20 2.41 0.88 1.09
    W 52 A 37.78 1.69 1.25 0.92 0.33
    W 55 N 10.93 0.41 0.82 0.35 0.00
    F 73 S 15.45 2.54 2.84 0.90 0.25
    F 73 D 26.89 2.50 3.05 0.33 0.64
    F 73 Q 74.76 1.87 2.85 1.05 1.71
    F 73 E 138.00 1.87 1.77 0.55 1.23
    F 73 A 153.25 1.13 0.82 0.55 1.05
    F 73 A 84.87 0.56 0.25 0.00 0.53
    Y 78 D 517.04 1.93 2.72 1.05 2.01
    Y 78 T 714.26 1.63 2.66 0.87 2.40
    Y 78 S 789.68 1.58 1.77 1.29 2.75
    L 21 N 414.21 1.03 1.73 1.57 2.81
    L 21 G 12.36 1.50 2.30 2.53 3.65
    Y 44 N 13.63 0.45 1.46 2.05 1.81
    F 73 T 192.64 2.29 3.41 2.04 2.86
    Y 44 T 21.46 0.36 0.25 1.09 1.33
    W 55 R 47.80 1.20 1.52 1.75 2.17
    F 73 G 22.42 1.41 1.55 1.36 1.64
    F 73 K 24.61 0.61 0.38 0.69 1.14
    F 73 G 172.77 1.73 1.26 1.16 1.53
    F 73 T 154.57 1.92 1.93 1.12 1.44
    Y 78 R 263.91 2.26 3.13 1.36 2.39
    Y 78 P 1249.23 0.92 0.85 0.75 0.69
    I 86 K 2214.38 0.97 1.02 0.81 0.69
    I 86 E 2555.62 1.00 1.13 0.66 0.69
    I 86 Q 3007.62 0.96 1.07 0.66 0.82
    L 90 R 338.46 0.47 0.13 0.29 0.32
    L 90 T 647.00 0.66 0.29 0.48 0.64
    L 90 E 234.92 0.24 0.18 0.20 0.27
    L 90 R 356.38 0.47 0.12 0.22 0.48
    F 93 A 11.61 0.11 0.09 0.10 0.24
    F 93 E 645.77 0.79 0.62 0.83 0.99
    F 93 D 52.77 0.80 0.62 0.96 0.91
    F 93 T 287.00 0.79 0.81 0.77 0.88
    L 115 A 24.24 0.01 −0.01 −0.02 0.17
    F 117 R 603.69 0.35 0.72 0.47 0.71
    F 117 K 329.23 0.34 0.20 0.43 0.62
    L 90 H 61.98 0.47 0.20 0.36 0.55
    L 90 P 109.40 0.75 0.17 0.46 0.52
    L 90 G 91.95 0.87 0.28 0.55 0.65
    F 93 H 233.85 0.98 1.20 1.03 1.04
    F 93 G 23.58 0.63 0.35 0.60 0.53
    Y 116 Y 1921.77 1.02 1.12 1.07 0.79
    F 117 S 42.22 0.11 −0.04 0.15 −0.08
    F 117 Y 1682.15 1.03 0.96 1.07 0.73
    V 123 G 304.85 0.53 0.22 0.67 0.17
    L 21 R 681.69 0.84 0.66 0.83 1.01
    L 21 E 332.00 0.25 0.07 0.12 0.16
    L 21 D 999.08 0.94 0.94 1.01 1.52
    M 23 N 600.08 0.94 0.90 0.98 1.36
    V 26 G 604.77 1.07 1.00 1.08 1.66
    V 26 N 976.38 1.00 0.97 1.14 1.43
    V 26 E 1020.54 1.02 0.73 1.02 1.38
    W 52 P 407.15 0.07 0.01 0.03 0.14
    W 55 A 26.22 0.09 0.03 0.10 0.23
    I 57 I 525.77 1.05 1.20 1.01 1.53
    I 57 L 23.04 0.90 0.40 0.92 1.17
    F 73 N 321.23 0.89 0.85 0.51 0.95
    Y 78 H 1489.38 1.07 1.47 1.36 1.34
    I 86 D 1703.85 1.09 1.31 1.03 1.18
    I 94 Q 854.46 1.10 1.32 0.74 0.74
    Y 128 K 452.40 1.11 1.78 1.40 1.57
    K 39 N 69.00 1.08 0.99 1.98 1.63
    K 39 A 8898.00 1.06 1.51 3.48 2.86
    K 39 S 7148.00 1.04 1.37 2.77 2.23
    R 48 E 73.90 0.34 −0.13 0.45 −0.51
    R 48 Q 743.20 0.80 0.15 1.06 0.85
    R 48 N 410.20 0.93 0.13 1.87 0.43
    R 48 H 42.82 1.02 0.58 3.15 3.58
    Q 53 G 82.88 0.99 1.37 3.70 3.95
    Q 53 R 149.28 0.81 0.96 1.26 1.41
    Q 53 E 1236.80 0.98 0.72 2.30 2.78
    Q 53 D 6876.00 0.89 1.01 2.20 3.74
    Q 53 K 485.40 0.73 0.14 0.70 2.03
    Q 53 T 5296.00 1.24 1.28 0.80 0.90
    Q 53 T 4072.00 1.14 1.23 0.73 0.85
    Q 53 S 5978.00 1.04 1.26 0.66 0.68
    E 60 R 122.78 0.68 0.77 0.35 0.23
    E 60 P 145.10 0.94 1.01 0.47 0.53
    E 60 H 128.78 0.86 1.25 0.34 0.42
    E 60 R 148.04 0.80 0.40 0.43 0.50
    N 76 T 4576.00 1.11 0.97 0.94 0.98
    N 76 D 7534.00 1.13 0.87 0.84 0.80
    N 76 Y 813.80 0.92 0.60 0.46 0.46
    N 76 N 4998.00 1.05 1.12 0.72 0.78
    N 76 A 5570.00 0.96 0.95 0.79 0.81
    N 76 S 8816.00 0.99 0.98 0.76 0.85
    S 77 A 24.84 0.91 0.80 0.55 0.76
    S 77 T 15.45 1.15 0.97 0.77 0.79
    S 77 E 45.54 1.17 0.98 0.81 0.94
    S 77 P 691.00 1.00 0.91 0.58 0.79
    S 77 A 1194.00 1.05 0.84 0.85 0.92
    S 77 H 48.80 0.42 0.08 0.29 0.30
    K 126 E 24.45 0.26 0.00 0.23 0.22
    K 126 Q 145.46 0.81 0.28 0.46 0.57
    R 129 N 573.40 1.10 1.40 0.89 1.03
    R 129 D 1305.00 1.13 1.86 0.93 1.16
    R 129 S 45.52 0.62 0.26 0.32 0.37
    R 129 K 410.80 1.12 0.78 0.69 0.77
    R 134 K 830.00 1.18 0.91 1.05 1.11
    R 134 R 249.28 1.09 0.81 0.87 0.90
    R 134 S 4314.00 1.17 1.07 1.10 1.15
    K 39 T 19.26 0.98 0.75 0.74 0.86
    K 39 D 18.87 0.88 0.72 0.67 0.82
    Q 53 A 27.33 0.84 0.26 0.54 0.65
    E 60 S 97.16 1.02 0.88 0.74 0.87
    S 77 T 1047.80 0.99 0.93 0.94 0.90
    S 77 P 1302.20 0.92 0.85 0.68 0.95
    K 126 G 55.32 0.53 0.12 0.30 0.35
    R 134 P 125.14 0.89 0.50 0.54 0.60
    R 134 R 927.00 1.11 1.02 0.86 0.98
    R 134 L 9016.00 0.99 1.00 1.03 1.02
  • To further characterize receptor binding, dose-response binding assays, using 12-point serial dilutions from conditioned media, were conducted for selected Library 1 variants.
  • Next, dissociation constants (KD below) were calculated for each variant using the nonlinear regression—one site hyperbolic binding model in Prism. Note that the experiment was repeated for the wild type protein. The relative binding constants may be compared to determine whether the specificity of each variant is appreciably different from wild type.
    TABLE 16
    Dissociation constants for BMP-7
    Library 1 variants
    ActRIIa BMPRII BMPRIa BMPRIb
    variant KD KD KD KD
    WT 0.40 1.28 1.61 1.77
    WT 0.28 0.98 1.53 0.33
    L21G 0.43 2.01 1.65 0.77
    L21K 0.84 3.09 2.92 1.75
    L21N 3.38 5.01 7.48 5.02
    L21R 0.31 2.14 3.32 1.60
    M23G 0.31 0.88 2.89 2.53
    M23N 0.06 0.99 1.79 1.07
    M23R 0.00 2.16 1.69 1.75
    M23S 0.58 3.03 2.77 1.39
    V26E 2.39 15.80 9.89 6.13
    V26G 1.71 3.93 5.76 12.74
    V26K 2.42 18.29 7.02 6.98
    V26N 1.88 9.33 7.94 5.45
    K39A 0.08 0.68 1.97 1.13
    K39S 0.12 0.88 1.65 1.11
    Y44A 1.57 4.27 5.54 2.39
    Y44D 2.08 44.04 3.71 2.18
    Y44G 1.10 21.39 4.98 2.56
    Y44N 0.80 3.34 2.92 2.63
    Y44P 0.80 11.56 6.46 1.67
    Y44S 0.53 6.26 3.48 1.82
    R48H 0.23 2.38 2.57 1.04
    R48N 0.26 3.14 2.78 1.10
    R48Q 1.42 5.37 5.17 5.16
    W52A 0.45 8.16 5.00 1.61
    Q53A 0.52 2.04 2.92 2.01
    Q53D 1.32 5.37 5.22 4.45
    Q53G 0.06 0.82 0.73 0.72
    Q53H 0.53 7.97 3.38 2.13
    Q53K 0.21 1.31 1.57 1.46
    Q53S 0.13 1.12 1.36 1.07
    Q53T 0.09 0.80 1.36 1.13
    W55N 0.55 5.52 5.99 1.99
    I57H 0.56 5.34 3.70 2.47
    I57I 0.13 1.23 1.36 0.67
    I57L 0.09 0.71 1.32 0.81
    E60K 0.70 3.71 4.03 3.25
    E60Q 0.49 2.32 2.93 2.11
    E60R 0.41 1.01 2.76 2.58
    A63Q 0.51 0.98 2.20 1.09
    A63S 0.61 2.29 2.90 1.30
    Y65D 0.45 1.11 2.19 1.11
    A72D 0.46 1.56 2.68 1.30
    A72H 0.54 2.55 1.98 1.71
    A72N 0.81 3.21 4.02 1.25
    A72S 0.35 1.50 2.48 1.04
    F73E 0.72 34.63 4.25 1.79
    F73S 0.18 1.72 2.33 1.08
    Y78H 0.10 1.05 1.46 1.12
    Y78R 0.94 11.65 3.90 1.68
    Y78S 0.19 1.10 1.40 0.98
    N83P 0.18 0.77 1.39 1.78
    I86A 0.16 1.12 3.55 1.12
    I86D 0.85 11.19 24.59 8.03
    Q88E 1.33 8.96 9.65 7.32
    L90N 1.11 12.59 7.26 5.23
    F93D 0.40 3.02 1.18 1.20
    F93E 0.73 17.88 3.57 1.33
    F93G 0.43 1.21 6.15 5.35
    F93H 0.14 0.84 1.35 0.71
    F93Q 0.94 4.44 6.25 3.46
    F93R 1.11 8.96 9.30 5.95
    F93S 0.61 1.89 1.11 1.37
    F93T 0.74 1.85 3.94 1.34
    I94E 3.02 9.73 14.20 8.08
    I94H 0.93 9.03 7.10 4.62
    I94K 1.07 1.07 4.74 3.05
    I94R 0.68 1.07 3.70 1.78
    N95K 2.13 1.49 8.31 1.46
    N95R 5.35 14.15 14.18 11.13
    E97D 0.38 1.27 3.35 1.40
    E97K 0.65 2.36 7.88 2.72
    E97R 0.24 1.38 2.22 0.31
    T98A 0.20 1.17 2.09 0.27
    T98E 0.14 1.41 1.95 0.35
    T98K 0.18 1.04 1.72 0.33
    T98X 0.15 1.32 1.60 0.34
    A105V 0.15 1.01 1.11 0.41
    Q108D 0.14 0.84 2.01 0.42
    Q108S 0.15 1.25 0.95 0.46
    N110D 0.20 0.35 0.62 0.34
    N110E 0.28 0.68 0.98 0.39
    Y116H 0.28 1.96 2.12 0.41
    Y116Y 0.25 1.06 2.20 0.93
    F117H 0.16 0.84 1.43 0.28
    F117R 0.65 5.54 4.17 1.17
    F117Y 1.26 5.15 5.11 6.81
    S120D 0.10 1.07 0.89 0.30
    R129D 0.26 0.43 2.22 1.40
    R129N 2.66 1.78 7.85 8.90
    R134E 0.31 1.07 2.43 0.55
    R134L 0.29 1.75 12.33 1.23
    R134R 0.39 6.16 4.26 2.72
    R134S 1.48 3.19 5.21 4.56
    A135E 0.08 1.22 0.99 0.38
    A135S 0.17 1.31 0.67 0.44
    H139R 0.15 1.41 1.00 0.37
  • Based on the above-described results, the vast majority of the variants have receptor binding affinities that are similar to wild type BMP-7. The following variants appear to have altered specificity for the type II receptors: M23N, Q53G, Q53H, and I86D. Q53H and I86D bind to ActRIIa with similar affinity to wild type, but bind BMPRII with approximately 10-fold reduced affinity relative to wild type. M23N and Q53G bind to ActRIIa with approximately 10-fold increased affinity relative to wild type, but bind BMPRII with similar affinity to wild type.
    • Example 11 Characterization of Library 1 BMP Variants Using the C2C12 Bioassay
  • The biological activity of human and variant BMP-7 molecules was measured using the C2C12 bioassay. C2C12 cells are a mouse myoblastic cell line that differentiates in response to BMPs such as BMP-7. C2C12 cells were trypsinized and diluted to approximately 60,000 cells/mL in C2C12 media (DMEM, 4 mM L-glutamine, 1.5 g/L sodium bicarbonate, 4.5 g/L glucose, 10% FBS, and antibiotics). 50 μL (3000 cells) were dispensed into each well of a 96-well plate and incubated overnight at 37° C. The next day, 50 μL of BMP-7 containing solution (for example, diluted conditioned media obtained from the BMP-7 expression protocol above, or purified recombinant human BMP-7 of a known concentration) was added to each well; each sample was tested in duplicate. The plates were incubated for 3 days at 37° C. The plates were then washed twice with 150 μL TBS (50 mM Tris pH 7.5, 150 mM NaCl). 25 μL TBS with 1% Triton-X100 was added to each well and the plate was incubated for 10-20 minutes at 4° C. 100-150 μL CSPD SapphireII luminescent alkaline phosphatase substrate (Applied Biosystems #T2210) was added to each well and incubated at room temperature in the dark. Luminescence readings were obtained for each well using the TopCount plate reader. Luminescence of the BMP-7 variants were compared to the luminescence of known quantities of recombinant human BMP-7 in order to determine the relative biological activity of the variants.
  • The table below shows the bioactivity of a selection of BMP-7 variants relative to the wild type protein (normalized to 1.0). Note that the assays were performed using a fixed volume of conditioned media rather than a specific concentration of protein, so differences in expression levels as well as differences in receptor binding affinity may affect the results. Data is shown only for variants with expression yields greater than 10.0 ng/mL.
    TABLE 17
    Bioactivity of BMP-7 Library 1 variants
    var# wt res # var ELISA Conc. (ng/mL) C2C12 Bioactivity
    1 M 23 S 15.20 8.65
    6 W 52 A 37.78 0.11
    9 W 55 N 10.93 0.06
    13 F 73 S 15.45 0.11
    14 F 73 D 26.89 0.03
    15 F 73 Q 74.76 0.20
    16 F 73 E 138.00 0.09
    17 F 73 A 153.25 0.18
    18 F 73 A 84.87 −0.08
    19 Y 78 D 517.04 0.13
    20 Y 78 T 714.26 0.17
    21 Y 78 S 789.68 0.09
    22 L 21 N 414.21 1.21
    23 L 21 G 12.36 4.34
    28 Y 44 N 13.63 0.11
    30 F 73 T 192.64 0.16
    31 Y 44 T 21.46 0.13
    33 W 55 R 47.80 0.51
    37 F 73 G 22.42 0.07
    39 F 73 K 24.61 0.11
    40 F 73 G 172.77 0.13
    41 F 73 T 154.57 0.17
    42 Y 78 R 263.91 2.50
    43 Y 78 P 1249.23 0.00
    49 I 86 K 2214.38 0.01
    50 I 86 E 2555.62 0.02
    51 I 86 Q 3007.62 0.05
    52 L 90 R 338.46 0.04
    53 L 90 T 647.00 0.01
    54 L 90 E 234.92 0.00
    55 L 90 R 356.38 0.00
    56 F 93 A 11.61 0.05
    57 F 93 E 645.77 6.14
    58 F 93 D 52.77 6.05
    59 F 93 T 287.00 5.61
    63 L 115 A 24.24 −0.01
    66 F 117 R 603.69 0.06
    67 F 117 K 329.23 0.08
    76 L 90 H 61.98 0.01
    77 L 90 P 109.40 −0.01
    78 L 90 G 91.95 −0.01
    80 F 93 H 233.85 5.78
    82 F 93 G 23.58 5.38
    85 Y 116 Y 1921.77 2.34
    86 F 117 S 42.22 0.00
    87 F 117 Y 1682.15 1.84
    88 V 123 G 304.85 0.31
    97 L 21 R 681.69 1.20
    98 L 21 E 332.00 0.00
    99 L 21 D 999.08 0.89
    100 M 23 N 600.08 1.54
    103 V 26 G 604.77 2.13
    104 V 26 N 976.38 2.75
    105 V 26 E 1020.54 0.97
    106 W 52 P 407.15 0.00
    109 W 55 A 26.22 −0.01
    111 I 57 I 525.77 1.66
    112 I 57 L 23.04 0.05
    116 F 73 N 321.23 −0.01
    117 Y 78 H 1489.38 2.67
    119 I 86 D 1703.85 0.20
    120 I 94 Q 854.46 0.00
    125 Y 128 K 452.40 0.12
    137 K 39 N 69.00 0.13
    140 K 39 A 8898.00 1.27
    141 K 39 S 7148.00 0.96
    143 R 48 E 73.90 0.00
    144 R 48 Q 743.20 0.10
    145 R 48 N 410.20 0.01
    147 R 48 H 42.82 0.33
    148 Q 53 G 82.88 1.00
    149 Q 53 R 149.28 0.02
    150 Q 53 E 1236.80 0.08
    151 Q 53 D 6876.00 1.67
    152 Q 53 K 485.40 0.04
    153 Q 53 T 5296.00 0.72
    154 Q 53 T 4072.00 1.20
    155 Q 53 S 5978.00 1.52
    156 E 60 R 122.78 0.17
    159 E 60 P 145.10 0.73
    160 E 60 H 128.78 0.32
    161 E 60 R 148.04 0.28
    162 N 76 T 4576.00 0.12
    163 N 76 D 7534.00 0.01
    164 N 76 Y 813.80 0.00
    165 N 76 N 4998.00 1.18
    166 N 76 A 5570.00 0.05
    167 N 76 S 8816.00 0.20
    168 S 77 A 24.84 0.32
    169 S 77 T 15.45 0.00
    170 S 77 E 45.54 −0.01
    171 S 77 P 691.00 −0.01
    172 S 77 A 1194.00 0.60
    173 S 77 H 48.80 0.01
    174 K 126 E 24.45 0.01
    175 K 126 Q 145.46 0.21
    182 R 129 N 573.40 1.50
    183 R 129 D 1305.00 3.96
    184 R 129 S 45.52 0.05
    185 R 129 K 410.80 0.01
    186 R 134 K 830.00 0.87
    187 R 134 R 249.28 0.50
    188 R 134 S 4314.00 3.76
    190 K 39 T 19.26 0.06
    191 K 39 D 18.87 0.01
    192 Q 53 A 27.33 0.02
    193 E 60 S 97.16 0.44
    197 S 77 T 1047.80 0.01
    199 S 77 P 1302.20 0.00
    200 K 126 G 55.32 0.00
    204 R 134 P 125.14 0.17
    205 R 134 R 927.00 3.57
    206 R 134 L 9016.00 3.76
  • Interestingly, a number of the library 1 variants have significantly greater bioactivity than the wild type Image clone. This observed increase in activity is likely due to increased expression yield, although additional factors including but not limited to altered stability, solubility, or receptor binding affinity may also influence the observed bioactivity. Substitutions that increase bioactivity by at least 2-fold relative to wild type include, but are not limited to, L21G, M23S, V26G, V26N, Y78H, Y78R, F93D, F93E, F93G, F93H, F93T, R129D, R134L, and R134S.
    • Example 12 Double Mutant Variants: BMP-7 Library 2
  • The point mutations from selected Library 1 variants were combined to yield a library of double mutants, referred to as Library 2. Methods for making and screening the Library 2 variants are as for the Library 1 variants described above. C2C12 bioassay data was determined at a single point by diluting conditioned media 1:66; due to the low expression yield of the Image clone, its bioassay signal is at background at this dilution.
    TABLE 18
    Expression yield and bioassay data, BMP-7 Library 2 variants.
    Western
    Blot
    293T Fold CHO Fold Band
    ELISA change: ELISA change: C2C12 Inten-
    Variant Name (ng/mL) 293T (ng/mL) CHO @ 1:66 sity
    L21G-Y65N 4261.8 2.1 73.7 3.6 0.09 ++
    L21G-F93H 23923.5 12.0 20.8 1.1 0.23 ++
    L21R-Y65N 4371.2 2.2 59.9 2.9 0.16 ++
    M23R-Y65N 5468.8 2.7 182.3 8.8 0.20 ++
    K39A-F93H 37258.8 18.6 222.5 10.8 0.66 ++
    K39S-Y65N 5259.4 2.6 39.4 1.9 0.13 ++
    K39S-A72D 3703.5 1.9 0.7 0.0 0.05 ++
    K39S-Y78H 18617.6 9.3 173.8 8.4 0.02 ++
    K39S-I86A 4231.2 2.1 16.3 0.8 0.05 ++
    K39S-I94R 4.9 0.0 0.3 0.0 0.04 ++
    K39S-F93S 3256.5 1.6 45.7 2.2 1.23 +++
    K39S-Q108D 5472.9 2.7 42.4 2.1 0.07 +++
    K39S-N110D 19964.7 10.0 171.8 8.3 0.49 ++
    K39S-S120D 21147.1 10.6 134.3 6.5 0.46 +++
    K39S-R129D 2048.8 1.0 34.0 1.6 0.28 ++
    K39S-N130D 3918.2 2.0 284.5 13.8 0.20 ++
    K39S-R134E 20564.7 10.3 6.2 0.3 0.28 ++
    K39S-R134S 18847.1 9.4 35.1 1.7 0.20 ++
    K39S-A135E 17694.1 8.8 159.9 7.8 0.03 ++
    K39S-A135S 2783.5 1.4 22.8 1.1 0.03 ++
    K39S-H139R 2868.8 1.4 37.2 1.8 0.03 ++
    Q53D-Y65N 22552.9 11.3 88.7 4.3 0.02 ++
    I57L-Y65N 18982.4 9.5 158.7 7.7 0.02 ++
    Y65N-Y78H 27923.5 14.0 197.3 9.6 0.13 ++
    Y65N-Y78R 20076.5 10.0 185.7 9.0 0.06 ++
    Y65N-S120D 23794.1 11.9 218.3 10.6 0.66 +++
    Y65N-A135S 22023.5 11.0 51.5 2.5 0.12 ++
    A72D-F93H 23329.4 11.7 369.2 17.9 0.17 ++
    Y78H-F93H 18117.6 9.1 395.7 20.5 0.36 ++
    Y78H-Q108D 35176.5 17.6 0.7 0.0 0.27 ++
    Y78H-Y116H 23688.2 11.8 70.8 3.2 0.01 +
    Y78H-F117Y 21794.1 10.9 62.3 5.5 0.07 ++
    Y78H-S120D 27864.7 13.9 179.6 12.5 0.34 ++
    Y78H-R134E 40129.4 20.1 410.1 21.6 0.72 ++
    Y78H-R134S 49617.6 24.8 36.3 2.4 0.68 ++
    Y78H-A135E 49729.4 24.9 167.6 9.6 0.03 ++
    Y78H-A135S 34458.8 17.2 43.4 2.2 0.05 ++
    Y78H-H139R 37770.6 18.9 40.5 2.1 0.14 ++
    F93H-F117Y 24747.1 12.4 296.0 14.4 0.40 ++
    F93H-S120D 35758.8 17.9 276.1 13.4 1.14 ++
    F93H-R134S 33800.0 16.9 378.7 18.4 1.21 ++
    F93H-H139R 39929.4 20.0 279.5 13.6 0.53 ++
  • As may be seen above, a number of the Library 2 variants have significantly increased expression yield, in both 293T and CHO cells, relative to the wild type Image clone. Preferred variants show at least a 10-fold increase in at least one expression host; examples of such variants include but are not limited to L21G/F93H, K39A/F93H, K39S/N110D, K39S/S120D, K39S/N130D, K39S/R134E, Q53D/Y65N, Y65N/Y78H, Y65N/Y78R, Y65N/S120D, Y65N/A135S, A72D/F93H, Y78H/F93H, Y78H/Q108D, Y78H/Y116H, Y78H/F117Y, Y78H/S120D, Y78H/R134E, Y78H/R134S, Y78H/A135E, Y78H/A135S, Y78H/H139R, F93H/F117Y, F93H/S120D, F93H/R134S, F93H/H139R. Especially preferred variants show at least a 10-fold increase in expression yield in both 293T and CHO cells; examples of such variants include but are not limited to K39A/F93H, Y65N/S120D, A72D/F93H, Y78H/S120D, Y78H/R134E, Y78H/A135E, F93H/F117Y, F93H/S120D, F93H/R134S, and F93H/H139R.
    • Example 13 Expression Yield of Triple, Quadruple, and Higher-Order Mutants
  • Triple, quadruple, and higher order mutants of BMP-7 were made and tested as described above. A number of these variants exhibit significantly increased expression yield or significantly increased bioactivity. Note that ELISA substantially underestimates the protein concentration of a substantial fraction of these variants due to decreased antibody binding affinity.
    TABLE 19
    Expression yield in 293T cells and bioactivity data for selected
    triple variants with high expression yield in 293T cells
    Fold Fold
    ELISA Increase Increase Western
    Conc. Expression C2C12 Blot Band
    Variant Name (ng/mL) Yield Bioactivity Intensity
    K39S/S120D/Y78H 50100.0 96.8 7.1 +++
    Y78H/F93H/F117H 43490.0 84.0 23.0 +++
    Y78H/F93H/Q108D 42880.0 82.8 21.6 +++
    Y78H/F93H/A72D 42590.0 82.3 14.6 +++
    K39S/S120D/Q108D 41170.0 79.5 15.6 +++
    Y78H/F93H/Y65N 34830.0 79.4 21.3 +++
    Y78H/F93H/S120D 40260.0 77.8 26.6 +++
    Y78H/R134E/Y65N 40210.0 77.7 42.2 ++++
    K39S/S120D/Y65N 34260.0 66.2 17.8 +++
    K39S/S120D/A72D 34070.0 65.8 25.9 +++
    K39S/S120D/R134E 32320.0 62.4 37.9 +++
    K39S/S120D/M23R 32060.0 61.9 14.3 +++
    K39S/S120D/H139R 29930.0 57.8 21.2 ++
    K39S/S120D/R129D 5910.0 11.4 22.7 +++
    Y78H/R134E/M23R 4775.0 9.2 27.7 ++
    Y78H/R134E/L21G 4763.0 9.2 28.4 ++
    Y78H/R134E/A72D 3269.0 6.3 43.6 ++++
    K39S/S120D/F93H 2950.0 5.7 2.1 +
    K39S/S120D/F93S 2031.0 4.6 45.3 +++
  • All of the above triples have expression yields that are at least 50-fold higher than wild type, and at least 2-fold higher than the best doubles. Furthermore, the majority of the above triples have significantly increased bioactivity relative to wild type and the best doubles. Triple variants with especially high bioactivity include, but are not limited to, K39S/F93S/S120D, K39S/S120D/R134E, Y65N/Y78H/R134E, and A72D/Y78H/R134E.
    TABLE 20
    Expression yield in CHO-K1 cells and bioactivity data for selected
    triple variants with high expression yield in CHO-K1 cells
    Fold Fold
    ELISA Increase Increase Western
    Conc. Expression C2C12 Blot Band
    Variant Name (ng/mL) Yield Bioactivity Intensity
    Y78H/R134E/Y65N 316.2 17.1 3.6 −
    Y78H/F93H/S120D 316.1 17.1 2.8 −
    K39S/S120D/R134E 245.7 13.3 21.8 +
    Y78H/R134E/A72D 232.1 12.5 14.7 +
    K39S/S120D/Q108D 219.8 11.9 2.4 −
    Y78H/F93H/Y65N 200.0 10.8 1.6 −
    Y78H/R134E/L21G 198.0 10.7 2.8 −
    Y78H/F93H/Q108D 115.3 6.2 2.9 −
    Y78H/F93H/A72D 107.1 5.8 2.0 −
    Y78H/R134E/M23R 78.8 4.3 6.4 −
    Y78H/F93H/F117H 58.7 3.2 1.0 −
    K39S/S120D/A72D 46.8 2.5 1.6 −
    K39S/S120D/R129D 42.9 2.3 28.0 +
    K39S/S120D/F93S 38.4 2.1 78.7 +
    K39S/S120D/H139R 33.8 1.8 1.5 −
  • Preferred variants with dramatic increases in CHO-K1 expression yield or C2C12 bioactivity include but are not limited to K39S/F93S/S120D, K39S/S120D/R129D, K39S/S120D/R134E, Y65N/Y78H/R134E, and Y78H/F93H/S120D.
  • Additional triple mutants were generated to determine the impact of different substitutions on receptor and inhibitor binding specificity. These variants included the Y65N and S120D substitutions, which confer increased expression yield and do not significantly affect receptor or inhibitor binding, and one additional substitution that may alter binding specificity. Triples comprising Y65N/S120D, and one of the following substitutions were made: M23R, R48H, R48N, R48Q, Q53G, Q53H, Q53K, Q53T, E60R, F73S, F73T, Y78D, Y78S, Y78T, 186D, K126R, Y128D, Y128H, and Y128Q.
    • Example 14 Purification of BMP-7 Variants
  • Y65N/S120D was partially purified using conventional chromatography. Heparin-sulphate sepharose (17-0407-01) was equilibrated in PBS. Conditioned media containing the Y65N/S120D variant was diluted 1:1 with 40 mM phosphate pH 6.5 filtered through a 0.45 micron filter, loaded onto the column, washed with 2-3 column volumes of PBS, and eluted in a single isocratic step with PBS/1M NaCl. The heparin bound fractions were dialyzed into 20 mM phosphate, 50 mM NaCl pH 7.0, loaded onto a SP-sepharose column, and eluted with a linear gradient (0-100% PBS/1M NaCl). A second purification protocol was used for larger scale purification of variants 457 (K39S/F93S), 471 (K39S/N130D), 492 (Y65N/Y78H), 504 (Y65N/S120D), 526 (K39S/S120D/R134E), and 565 (Y65N/F93T/R129D). Conditioned media was diluted 1:1 at neutral pH to lower the salt concentration to ˜75 mM and loaded onto a SP-sepharose column. The column was then washed in 75 mM salt and then 300 mM salt, and BMP-7 was eluted with 1M salt.
    • Example 15 Receptor, Antibody, and Inhibitor Binding of Selected Variants
  • The binding of selected variants to BMP receptors, antibodies, and inhibitors was characterized using a fluorescence binding assay and the AlphaScreen™ assay. BMP-7 variant Y65N/S120D, partially purified as described above, was labeled with the dye AlexaFluor 568 (Molecular Probes). Small-scale (25 uL) reactions were performed using 15 uM BMP-7 and dye concentrations ranging from 0.3 uM to 1000 uM. Reactions using 333 uM and 10 uM dye then were performed using 750 uL protein. The reaction was quenched with Tris pH 8.0 and cleaned up using a PD-10 desalt column; the second fraction was used in the experiments described below. BMP-7 was also labeled with C6-FXS, a FITC-derived fluorophore with a 6-carbon spacer between the fluor and the NHS group. Labeling conditions with various ratios of protein to dye were tested, in 20 mM PO4, 500 mM NaCl, pH 7 solution. After establishing labeling conditions, 500 ug Y65N/S120D was labeled. Excess dye was removed by centrifugation and a PD-10 desalt column.
  • The flourescently labeled BMP-7 was added to serial dilutions of receptor/Fc fusions of the BMP-7 receptors ActRIa, BMPRIa, BMPRIb, ActRIIa, ActRIIb, and BMPRII (R&D Systems). Experiments were also performed in which the fluorescently labeled BMP-7 was added to serial dilutions of noggin/Fc or gremlin (R&D Systems). The labeled BMP-7 and receptor or inhibitor was allowed to incubate, and the fluorescence polarization and intensity was measured using a TopCount plate reader. Significant changes in intensity or anisotropy were observed for all of the receptors and inhibitors tested, for at least one of the labeled BMP-7 molecules.
  • Binding affinity of different BMP variants to these receptors and inhibitors may be determined by performing competition experiments. To perform these experiments, labeled BMP-7 and receptor or inhibitor are combined in amounts that yield an appreciable change in anisotropy or intensity relative to free labeled BMP-7. Then, varying amounts of a second, unlabeled BMP-7 molecule are added and the change in anisotropy or polarization is measured. The EC50 is then given by the concentration of competitor when half of the labeled BMP-7 is bound and half is free.
  • The Y65N/S120D variant of BMP-7 was also biotinylated for use in AlphaScreen assays using NHS-biotin. Bioactivity of the biotinylated protein was confirmed. AlphaScreen assays were performed to determine the binding affinity of selected BMP-7 variants for Fc fusions of the receptors BMPRIa, BMPRIb, ActRIIa, and BMPRII and the inhibitor noggin (R&D Systems). AlphaScreen assays were also performed to determine the affinity of selected variants for an anti-BMP-7 monoclonal antibody (R&D Systems mAb 3541). In all cases, 12-point binding curves were obtained in triplicate. Each data point corresponds to the luminescence produced from a solution comprising 10 uL of serially diluted BMP-7 variant, 10 uL receptor, inhibitor, or antibody, 10 uL biotinylated BMP-7, 10 uL AlphaScreen™ acceptor beads, and 10 uL AlphaScreen™ donor beads. Prism was used to calculate EC50 values for selected experiments.
    TABLE 21
    EC50 of wild type human BMP-7 (R&D Systems) and BMP-7 variants 504, 526,
    and 565 for the BMP receptors BMPRIb, ActRIIa, and BMPRII and the BMP
    inhibitor noggin, as determined using AlphaScreen ™ assays.
    std. error
    BMP-7 Receptor or EC(50) EC50 log(EC50) log(EC50) (logEC50) Fold change
    variant inhibitor (ug/mL) (ng/mL) (ug/mL) (ng/mL) ug/mL vs. wt
    wt BMPRIb 0.0499 49.9 −1.30 1.70 0.136
    wt ActRIIa 0.107 107 −0.971 2.03 0.218
    wt BMPRII 0.230 230 −0.639 2.36 0.259
    wt noggin 2.85 2850 0.455 3.46 0.894
    v504 BMPRIb 0.0185 18.5 −1.73 1.27 0.190 0.371
    v504 ActRIIa 0.0475 47.5 −1.32 1.68 0.180 0.445
    v504 BMPRII 0.222 222 −0.653 2.35 0.567 0.969
    v504 noggin 3.40 3400 0.532 3.53 2.32 1.19
    v526 BMPRIb 0.0363 36.3 −1.44 1.56 0.172 0.727
    v526 ActRIIa 0.0445 44.5 −1.35 1.65 0.148 0.416
    v526 BMPRII 0.139 139.4 −0.856 2.14 0.394 0.607
    v526 noggin 16.7 16700 1.22 4.22 11.5 5.83
    v565 BMPRIb 0.0224 22.4 −1.65 1.35 0.121 0.448
    v565 ActRIIa 0.0424 42.4 −1.37 1.63 0.272 0.397
    v565 BMPRII 0.409 409 −0.388 2.61 1.02 1.78
    v565 noggin 0.392 392 −0.407 2.59 0.471 0.137
  • Overall, these three variants have binding affinities that are similar to wild type. Potentially significant differences include, but are not limited to, decreased noggin affinity of v526 and increased noggin affinity of v565.
    • Example 16 Concentration Determination
  • Some of the BMP-7 variants, especially those variants with two or more mutations, exhibit reduced antibody binding affinity. As a result, ELISA concentration determination systematically underestimates the concentration of these variants. In order to obtain more accurate concentrations for these variants, as well as correction factors for the concentrations determined using ELISA, multiple concentration determination measurements were performed. Following purification, the concentration of variants 457, 471, 492, 504, 526, and 565 was assessed using the BCA assay, densitometry analysis of Coomasie blue stained mature domain following SDS-PAGE, and Western blotting using a polyclonal antibody. Wild type BMP-7 (R&D Systems) was used as a standard.
    • Example 17 Specific Activity Determination
  • The specific activity of five especially preferred BMP-7 variants was determined and compared with the specific activity of recombinant human BMP-7 purchased from R&D Systems. Equal concentrations of each protein, as determined above, were tested in the C2C12 bioassay three times.
    TABLE 22
    Specific activity of selected BMP-7 variants.
    EC50: EC50: EC50: Avg
    Exp Exp Exp EC50 Std.
    Name # 1 #2 #3 (ug/mL) dev.
    Wild type (R&D 2.99 3.53 2.06 2.86 0.74
    Systems)
    565-Y65N/F93T/R129D 0.1 0.3 0.09 0.16 0.12
    526-K39S/S120D/R134E 0.58 1.69 0.49 0.92 0.67
    504-Y65N/S120D 2.91 nd 4.85 3.88 1.37
    492-Y65N/Y87H 5.91 nd 6.18 6.04 0.19
    471-K39S/N130D 1.38 nd 3.99 2.69 1.85
    457-K39S/F93S 0.37 1.1 nd 0.74 0.52
  • Variants with the F93S and F93T substitutions were found to have increased specific activity relative to the wild type protein.
    • Example 18 Specific Variant Designs
  • Quadruple mutant containing variants were designed to improve the proteins expression yields and ensure the highest biological activities. The mutant substitutions chosen for these variants comprise a subset of total variants that either singly, or in combination improve the properties of BMP-7. The stability and yield variants were chosen a subset of mutants that show beneficial protein properties and are located at amino acid residues that do not make receptor contacts. Furin optimization is defined as a set of mutant variants, built in either the native or Y65N/S120D background that have an engineered consensus site for the furin protease required for normal processing and secretion of BMP-7. Glycosylation removal variants are mutant BMP-7 proteins, built in either the native or F93H/R134S background that contain mutations in the consensus glycosylation site, these variants are predicted to be aglycosylated. The following table summaries specific variant BMP-7 proteins created to have the listed properties:
    TABLE 23
    Variant Property
    K39S_S120D_Q108D_F93S High activity and yield
    K39S_S120D_R129D_F93S High activity and yield
    K39S_S120D_Y65N_F93S High activity and yield
    K39S_S120D_A72D_F93S High activity and yield
    Y78H_R134E_Y65N_F93S High activity and yield
    Y78H_R134E_A72D_F93S High activity and yield
    K39S_S120D_Q108D_Q108D High activity and yield
    K39S_S120D_R129D_Q108D High activity and yield
    K39S_S120D_Y78H_Q108D High activity and yield
    K39S_S120D_R134E_Q108D High activity and yield
    K39S_S120D_A72D_Q108D High activity and yield
    Y78H_R134E_A72D_Q108D High activity and yield
    Y65N_R129D_M23R_Q108D High activity and yield
    K39S_S120D_Y65N_R129D High activity and yield
    K39S_S120D_Y78H_R129D High activity and yield
    K39S_S120D_A72D_R129D High activity and yield
    Y65N_R129D_M23R_S120D High activity and yield
    Y65N_R129D_Q108D_S120D High activity and yield
    K39S_S120D_Q108D_Y65N High activity and yield
    K39S_S120D_R129D_Y65N High activity and yield
    K39S_S120D_R134E_Y78H High activity and yield
    K39S_S120D_Q108D_R134E High activity and yield
    K39S_S120D_Y65N_R134E High activity and yield
    K39S_S120D_Y78H_R134E High activity and yield
    K39S_S120D_A72D_R134E High activity and yield
    K39S_S120D_Q108D_M23R High activity and yield
    K39S_S120D_R129D_M23R High activity and yield
    K39S_S120D_Y78H_M23R High activity and yield
    K39S_S120D_R134E_M23R High activity and yield
    K39S_S120D_A72D_M23R High activity and yield
    Y78H_R134E_Y65N_M23R High activity and yield
    Y78H_R134E_A72D_M23R High activity and yield
    Y65N_R129D_Q108D_M23R High activity and yield
    Q108D_A72D Stability and yield
    S120D_A72D Stability and yield
    R129D_A72D Stability and yield
    A135E_A72D Stability and yield
    A72D_Q108D Stability and yield
    S120D_Q108D Stability and yield
    Q108D_S120D Stability and yield
    A135E_S120D Stability and yield
    A72D_R129D Stability and yield
    Q108D_R129D Stability and yield
    S120D_R129D Stability and yield
    Q108D_A135E Stability and yield
    S120D_A135E Stability and yield
    A72D_F93S Stability and yield
    A72D_A105V Stability and yield
    A72D_N110D Stability and yield
    A72D_A135S Stability and yield
    A72D_H139R Stability and yield
    F93S_A105V Stability and yield
    F93S_Q108D Stability and yield
    F93S_N110D Stability and yield
    F93S_S120D Stability and yield
    F93S_R129D Stability and yield
    F93S_R134E Stability and yield
    F93S_A135S Stability and yield
    F93S_H139R Stability and yield
    A105V_S120D Stability and yield
    A105V_R129D Stability and yield
    A105V_R134E Stability and yield
    A105V_A135S Stability and yield
    A105V_H139R Stability and yield
    N110D_S120D Stability and yield
    N110D_R129D Stability and yield
    N110D_R134E Stability and yield
    N110D_A135S Stability and yield
    N110D_H139R Stability and yield
    Q108D_R134E Stability and yield
    Q108D_A135S Stability and yield
    Q108D_H139R Stability and yield
    F117Y_R129D Stability and yield
    F117Y_R134E Stability and yield
    S120D_R134E Stability and yield
    S120D_A135S Stability and yield
    S120D_H139R Stability and yield
    L21G_E42D Stability and yield
    L21G_T98K Stability and yield
    L21G_A105V Stability and yield
    L21G_S120D Stability and yield
    L21G_A135S Stability and yield
    L21G_A135E Stability and yield
    L21G_H139R Stability and yield
    M23R_E42D Stability and yield
    M23R_T98K Stability and yield
    M23R_A105V Stability and yield
    M23R_S120D Stability and yield
    M23R_A135S Stability and yield
    M23R_A135E Stability and yield
    M23R_H139R Stability and yield
    E42D_T98K Stability and yield
    E42D_A105V Stability and yield
    E42D_S120D Stability and yield
    E42D_A135S Stability and yield
    E42D_A135E Stability and yield
    E42D_H139R Stability and yield
    T98K_A105V Stability and yield
    T98K_S120D Stability and yield
    T98K_A135S Stability and yield
    T98K_A135E Stability and yield
    T98K_H139R Stability and yield
    A105V_S120D Stability and yield
    A105V_A135S Stability and yield
    A105V_A135E Stability and yield
    A105V_H139R Stability and yield
    S120D_A135S Stability and yield
    S120D_A135E Stability and yield
    S120D_H139R Stability and yield
    WT_P1_QVKKRSKR Furin optimization
    WT_P2_QVKKRSRR Furin optimization
    WT_P3_QVRKRSKR Furin optimization
    WT_P4_QVRKRSRR Furin optimization
    WT_P5_KVKKRSKR Funn optimization
    WT_P6_KVKKRSRR Furin optimization
    WT_P7_KVRKRSKR Furin optimization
    WT_P8_KVRKRSRR Furin optimization
    WT_P9_EVKLRSKR Furin optimization
    WT_P10_EVKLRSRR Furin optimization
    WT_P11_EVRLRSKR Furin optimization
    WT_P12_EVRLRSRR Furin optimization
    Y65N_S120D_QVKKRSKR Furin optimization
    Y65N_S120D_QVKKRSRR Furin optimization
    Y65N_S120D_QVRKRSKR Furin optimization
    Y65N_S120D_QVRKRSRR Furin optimization
    Y65N_S120D_KVKKRSKR Furin optimization
    Y65N_S120D_KVKKRSRR Furin optimization
    Y65N_S120D_KVRKRSKR Furin optimization
    Y65N_S120D_KVRKRSRR Furin optimization
    Y65N_S120D_EVKLRSKR Furin optimization
    Y65N_S120D_EVKLRSRR Furin optimization
    Y65N_S120D_EVRLRSKR Furin optimization
    Y65N_S120D_EVRLRSRR Furin optimization
    N80A Glycosylation removal
    N80C Glycosylation removal
    N80D Glycosylation removal
    N80E Glycosylation removal
    N80F Glycosylation removal
    N80G Glycosylation removal
    N80H Glycosylation removal
    N80I Glycosylation removal
    N80K Glycosylation removal
    N80L Glycosylation removal
    N80M Glycosylation removal
    N80P Glycosylation removal
    N80Q Glycosylation removal
    N80R Glycosylation removal
    N80S Glycosylation removal
    N80T Glycosylation removal
    N80V Glycosylation removal
    N80W Glycosylation removal
    N80Y Glycosylation removal
    A81P Glycosylation removal
    T82A Glycosylation removal
    T82D Glycosylation removal
    T82E Glycosylation removal
    T82F Glycosylation removal
    T82G Glycosylation removal
    T82H Glycosylation removal
    T82I Glycosylation removal
    T82K Glycosylation removal
    T82L Glycosylation removal
    T82M Glycosylation removal
    T82N Glycosylation removal
    T82P Glycosylation removal
    T82Q Glycosylation removal
    T82R Glycosylation removal
    T82V Glycosylation removal
    T82W Glycosylation removal
    T82Y Glycosylation removal
    F93H/R134S/N80A Glycosylation removal
    F93H/R134S/N80C Glycosylation removal
    F93H/R134S/N80D Glycosylation removal
    F93H/R134S/N80E Glycosylation removal
    F93H/R134S/N80F Glycosylation removal
    F93H/R134S/N80G Glycosylation removal
    F93H/R134S/N80H Glycosylation removal
    F93H/R134S/N80I Glycosylation removal
    F93H/R134S/N80K Glycosylation removal
    F93H/R134S/N80L Glycosylation removal
    F93H/R134S/N80M Glycosylation removal
    F93H/R134S/N80P Glycosylation removal
    F93H/R134S/N80Q Glycosylation removal
    F93H/R134S/N80R Glycosylation removal
    F93H/R134S/N80S Glycosylation removal
    F93H/R134S/N80T Glycosylation removal
    F93H/R134S/N80V Glycosylation removal
    F93H/R134S/N80W Glycosylation removal
    F93H/R134S/N80Y Glycosylation removal
    F93H/R134S/A81P Glycosylation removal
    F93H/R134S/T82A Glycosylation removal
    F93H/R134S/T82D Glycosylation removal
    F93H/R134S/T82E Glycosylation removal
    F93H/R134S/T82F Glycosylation removal
    F93H/R134S/T82G Glycosylation removal
    F93H/R134S/T82H Glycosylation removal
    F93H/R134S/T82I Glycosylation removal
    F93H/R134S/T82K Glycosylation removal
    F93H/R134S/T82L Glycosylation removal
    F93H/R134S/T82M Glycosylation removal
    F93H/R134S/T82N Glycosylation removal
    F93H/R134S/T82P Glycosylation removal
    F93H/R134S/T82Q Glycosylation removal
    F93H/R134S/T82R Glycosylation removal
    F93H/R134S/T82V Glycosylation removal
    F93H/R134S/T82W Glycosylation removal
    F93H/R134S/T82Y Glycosylation removal
    • Example 18 Variant Designs
  • In addition to the preferred embodiments disclosed in Table 23 above, the following variants are also preferred embodiments of the present invention:
    TABLE 24
    L21G_V26G
    L21G_V26N
    L21G_M23G
    L21N_M23G
    M23G_V26G
    M23G_V26N
    21N_23G_26G
    A105V
    A111D
    A111S
    A135D
    A135E
    A135S
    A37E
    A63E
    A63Q
    A63R
    A63S
    A72D
    A72E
    A72H
    A72K
    A72N
    A72R
    A72S
    A105V
    D119E
    D119N
    D119S
    D119T
    D49S
    D54K
    D54N
    D54S
    E42D
    E42Q
    E42R
    E42T
    E60H
    E60K
    E60N
    E60P
    E60Q
    E60R
    E60R
    E60R
    E60S
    E60T
    E70A
    E70Q
    E97D
    E97K
    E97R
    F117A
    F117D
    F117E
    F117H
    F117K
    F117Q
    F117R
    F117S
    F117Y
    F73A
    F73A
    F73D
    F73E
    F73G
    F73G
    F73H
    F73K
    F73N
    F73Q
    F73R
    F73S
    F73T
    F73T
    F93A
    F93D
    F93E
    F93G
    F93H
    F93H_A105V
    F93H_A135E
    F93H_A72D
    F93H_F117Y
    F93H_H139R
    F93H_I57L
    F93H_I94R
    F93H_K127E
    F93H_K39A
    F93H_K39S
    F93H_L21G
    F93H_L21R
    F93H_N130D
    F93H_Q108D
    F93H_R129D
    F93H_R134E
    F93H_R134S
    F93H_R48N
    F93H_S120D
    F93H_Y128D
    F93H_Y78R
    F93K
    F93P
    F93Q
    F93R
    F93S
    F93T
    H139R
    I124A
    I124D
    I124E
    I124K
    I124N
    I124Q
    I124R
    I124S
    I124T
    I124V
    I57A
    I57D
    I57E
    I57H
    I57I
    I57K
    I57L
    I57N
    I57P
    I57Q
    I57T
    I57V
    I86A
    I86D
    I86D
    I86E
    I86K
    I86P
    I86Q
    I86T
    I94A
    I94E
    I94H
    I94K
    I94K
    I94P
    I94Q
    I94R
    I94T
    K126D
    K126E
    K126G
    K126Q
    K126R
    K127A
    K127D
    K127E
    K127E
    K127H
    K127N
    K127P
    K127Q
    K127S
    K127T
    K127Y
    K39A
    K39A
    K39D
    K39E
    K39G
    K39N
    K39R
    K39S
    K39S_A135E
    K39S_A135S
    K39S_A72D
    K39S_F117H
    K39S_F117Y
    K39S_F93S
    K39S_H139R
    K39S_I57L
    K39S_I86A
    K39S_I94R
    K39S_L21G
    K39S_L21R
    K39S_M23R
    K39S_N110D
    K39S_N130D
    K39S_Q108D
    K39S_Q53G
    K39S_Q53T
    K39S_R129D
    K39S_R134E
    K39S_R134S
    K39S_R48N
    K39S_S120D
    K39S_S120D_A72D
    K39S_S120D_F93H
    K39S_S120D_F93S
    K39S_S120D_H139R
    K39S_S120D_L21G
    K39S_S120D_M23R
    K39S_S120D_Q108D
    K39S_S120D_R129D
    K39S_S120D_R134E
    K39S_S120D_Y65N
    K39S_S120D_Y78H
    K39S_Y116H
    K39S_Y128D
    K39S_Y65N
    K39S_Y78R
    K39T
    L115A
    L115E
    L115K
    L115Q
    L115T
    L125A
    L125E
    L125K
    L125P
    L125Q
    L125T
    L125Y
    L21D
    L21E
    L21G
    L21G
    L21H
    L21K
    L21N
    L21N_M23G_V26N
    L21R
    L21S
    L90A
    L90E
    L90G
    L90H
    L90K
    L90L
    L90N
    L90P
    L90P
    L90Q
    L90R
    L90R
    L90R
    L90S
    L90T
    M23D
    M23G
    M23K
    M23N
    M23R
    M23S
    N110D
    N110E
    N110H
    N122E
    N122Q
    N122R
    N130D
    N76A
    N76D
    N76N
    N76S
    N76T
    N76Y
    N83P
    N95D
    N95K
    N95Q
    N95R
    Q108D
    Q108K
    Q108S
    Q36E
    Q36N
    Q53A
    Q53D
    Q53E
    Q53G
    Q53H
    Q53K
    Q53R
    Q53S
    Q53T
    Q53T
    Q88E
    R129D
    R129E
    R129K
    R129N
    R129S
    R134D
    R134E
    R134K
    R134L
    R134P
    R134P
    R134Q
    R134R
    R134R
    R134S
    R48D
    R48E
    R48H
    R48N
    R48Q
    S113D
    S113E
    S120D
    S120E
    S120N
    S120R
    S121D
    S121E
    S121K
    S121N
    S121T
    S77A
    S77A
    S77A
    S77D
    S77E
    S77H
    S77K
    S77N
    S77P
    S77P
    S77Q
    S77T
    S77T
    T107D
    T107E
    T98A
    T98Del
    T98E
    T98E
    T98K
    V123A
    V123A
    V123D
    V123G
    V123G
    V123N
    V123N
    V123R
    V123T
    V123V
    V26D
    V26E
    V26G
    V26K
    V26K
    V26N
    V26S
    V26V
    W52A
    W52E
    W52K
    W52P
    W52Q
    W52T
    W55A
    W55A
    W55E
    W55H
    W55K
    W55N
    W55P
    W55Q
    W55R
    W55T
    Y116A
    Y116D
    Y116E
    Y116H
    Y116K
    Y116Q
    Y116S
    Y116T
    Y116Y
    Y128D
    Y128E
    Y128H
    Y128K
    Y128Q
    Y44A
    Y44D
    Y44E
    Y44G
    Y44H
    Y44K
    Y44N
    Y44P
    Y44Q
    Y44R
    Y44S
    Y44T
    Y65D
    Y65E
    Y65N
    Y65N_A105V
    Y65N_A135E
    Y65N_A135S
    Y65N_F117Y
    Y65N_F93H
    Y65N_F93T
    Y65N_H139R
    Y65N_I57L
    Y65N_I94R
    Y65N_K127E
    Y65N_K39A
    Y65N_K39S
    Y65N_L21G
    Y65N_L21R
    Y65N_M23N
    Y65N_M23R
    Y65N_Q108D
    Y65N_Q53D
    Y65N_Q53G
    Y65N_Q53S
    Y65N_Q53T
    Y65N_R129D
    Y65N_R129D_F117H
    Y65N_R129D_F117Y
    Y65N_R129D_F93H
    Y65N_R129D_F93S
    Y65N_R129D_F93T
    Y65N_R129D_K39A
    Y65N_R129D_K39S
    Y65N_R129D_L21G
    Y65N_R129D_M23R
    Y65N_R129D_Q108D
    Y65N_R129D_S120D
    Y65N_R129D_Y78H
    Y65N_R134E
    Y65N_R134S
    Y65N_S120D
    Y65N_Y128D
    Y65N_Y78H
    Y65N_Y78R
    Y78A
    Y78D
    Y78G
    Y78H
    Y78H_A105V
    Y78H_A135E
    Y78H_A135S
    Y78H_A63S
    Y78H_A72D
    Y78H_F117H
    Y78H_F117Y
    Y78H_F93H
    Y78H_F93H_A72D
    Y78H_F93H_F117H
    Y78H_F93H_F117Y
    Y78H_F93H_H139R
    Y78H_F93H_K39A
    Y78H_F93H_K39S
    Y78H_F93H_L21G
    Y78H_F93H_M23R
    Y78H_F93H_Q108D
    Y78H_F93H_R129D
    Y78H_F93H_R134S
    Y78H_F93H_S120D
    Y78H_F93H_Y65N
    Y78H_F93T
    Y78H_H139R
    Y78H_I57L
    Y78H_I94R
    Y78H_K127E
    Y78H_K39S
    Y78H_L21R
    Y78H_N110D
    Y78H_N130D
    Y78H_Q108D
    Y78H_Q53G
    Y78H_Q53S
    Y78H_R129D
    Y78H_R134E
    Y78H_R134E_A72D
    Y78H_R134E_F117Y
    Y78H_R134E_F93H
    Y78H_R134E_F93S
    Y78H_R134E_F93T
    Y78H_R134E_K39A
    Y78H_R134E_K39S
    Y78H_R134E_L21G
    Y78H_R134E_M23R
    Y78H_R134E_Q108D
    Y78H_R134E_S120D
    Y78H_R134E_Y65N
    Y78H_R134S
    Y78H_R48N
    Y78H_S120D
    Y78H_Y116H
    Y78H_Y128D
    Y78N
    Y78P
    Y78R
    Y78S
    Y78T
    Y78Y
  • While the foregoing invention has been described above, it will be clear to one skilled in the art that various changes and additional embodiments made be made without departing from the scope of the invention. All publications, patents, patent applications (provisional, utility and PCT) or other documents cited herein are incorporated by references in their entirety.

Claims (15)

1-27. (canceled)
28. A non-naturally occuring variant BMP-2 protein comprising at least one substitution as compared to an amino acid sequence comprising SEQ ID NO:1, said substitution selected from the group consisting of: S12E, S13K, K15D, P18R, P18T, S24N, S24Q, N29D, N29S, W31A, W31E, W31N, W31Q, P36K, P36Q, P36R, P36S, P36T, H39E, H39Q, F41D, F41N, E46Q, D53Q, D53T, Q64E, L66E, L66N, L66Q, S69A, S69D, S69R, S69F, V70E, V70K, V70Q, V70T, N71K, S72D, S85E, A86D, L90E, L90K, Y91D, Y91E, Y91K, Y91T, N95D, N95S, E96D, E96S, E96N, V98A, V98D, V98R, V98T, L100A, L100E, L100K, L100Q, Y103D, Q104D, and E109R.
29. A BMP-2 variant protein of claim 28, wherein a substitution is K15D.
30. A BMP-2 variant protein of claim 28, wherein a substitution is selected from the group consisting of F41D and F41N.
31. A BMP-2 variant protein of claim 28, wherein a substitution is selected from the group consisting of S69A, S69D, S69R, and S69F.
32. A BMP-2 variant protein of claim 28, wherein a substitution is selected from the group consisting of N95D and N95S.
33. A nucleic acid encoding the non-naturally occurring variant BMP-2 protein of claim 28.
34. An expression vector comprising the nucleic acid of claim 33.
35. A host cell comprising the nucleic acid of claim 33.
36. A host cell comprising the expression vector of claim 34.
37. A method of producing a non-naturally occurring BMP-2 protein comprising culturing the host cell of claim 35 under conditions suitable for expression of said nucleic acid.
38. The method according to claim 37 further comprising recovering said BMP-2 protein.
39. A pharmaceutical composition comprising the BMP-2 protein of claim 28, and a pharmaceutical carrier.
40. A method for treating a BMP-2 responsive disorder comprising administering the non-naturally occurring BMP-2 protein of claim 28 to a patient in need of said treatment.
41. The method according to claim 40, wherein said BMP-2 responsive disorder is selected from the group consisting of bone fractures, bone degeneration and spinal fusion.
US11/471,893 2004-03-31 2006-06-20 BMP-2 variants with improved properties Abandoned US20060235204A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/471,893 US20060235204A1 (en) 2004-03-31 2006-06-20 BMP-2 variants with improved properties

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US55818904P 2004-03-31 2004-03-31
US57052004P 2004-05-11 2004-05-11
US57843204P 2004-06-09 2004-06-09
US58746404P 2004-07-13 2004-07-13
US11/097,960 US7459527B2 (en) 2004-03-31 2005-03-31 BMP-7 variants with improved properties
US11/471,893 US20060235204A1 (en) 2004-03-31 2006-06-20 BMP-2 variants with improved properties

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/097,960 Continuation US7459527B2 (en) 2004-03-31 2005-03-31 BMP-7 variants with improved properties

Publications (1)

Publication Number Publication Date
US20060235204A1 true US20060235204A1 (en) 2006-10-19

Family

ID=34965017

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/097,960 Expired - Fee Related US7459527B2 (en) 2004-03-31 2005-03-31 BMP-7 variants with improved properties
US11/471,893 Abandoned US20060235204A1 (en) 2004-03-31 2006-06-20 BMP-2 variants with improved properties
US11/471,957 Abandoned US20080070837A1 (en) 2004-03-31 2006-06-20 BMP-4 variants with improved properties

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/097,960 Expired - Fee Related US7459527B2 (en) 2004-03-31 2005-03-31 BMP-7 variants with improved properties

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/471,957 Abandoned US20080070837A1 (en) 2004-03-31 2006-06-20 BMP-4 variants with improved properties

Country Status (6)

Country Link
US (3) US7459527B2 (en)
EP (1) EP1730186A2 (en)
JP (1) JP2008500816A (en)
AU (1) AU2005230854A1 (en)
CA (1) CA2561809A1 (en)
WO (1) WO2005097825A2 (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070056050A1 (en) * 2005-06-29 2007-03-08 Clokie Cameron M L PRODUCTION OF BONE MORPHOGENIC PROTEINS (BMPs) IN TRANSGENIC MAMMALS
WO2008082563A2 (en) 2006-12-21 2008-07-10 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
US20090087472A1 (en) * 2007-06-25 2009-04-02 Murphy William L Controlled release of biopharmaceutical growth factors from hydroxyapatite coating on bioresorbable interference screws used in cruciate ligament reconstruction surgery
US20100087625A1 (en) * 2007-05-25 2010-04-08 Peel Sean A F Method of enhancing recombinant protein production
WO2010093941A2 (en) 2009-02-12 2010-08-19 Stryker Corporation COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS
WO2010093925A2 (en) 2009-02-12 2010-08-19 Stryker Corporation PERIPHERAL ADMINISTRATION OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS FOR TREATMENT OF SYSTEMIC DISORDERS AND DISEASE
WO2010110974A1 (en) 2009-03-24 2010-09-30 Stryker Corporation Methods and compositions for tissue engineering
WO2011031856A1 (en) 2009-09-09 2011-03-17 Stryker Corporation Bmp -7 for use in treating pain induced by injuries and diseases of an articular joint
WO2011035094A1 (en) 2009-09-17 2011-03-24 Stryker Corporation Buffers for controlling the ph of bone morphogenetic proteins
WO2011087768A1 (en) 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
US20110182911A1 (en) * 2008-07-03 2011-07-28 Induce Biologics Inc. Use of immobilized antagonists for enhancing growth factor containing bioimplant effectiveness
RU2499048C1 (en) * 2012-09-24 2013-11-20 Российская Федерация, от имени которой выступает Министерство промышленности и торговли Российской Федерации (Минпромторг России) Recombinant plasmid, recombinant strain, recombinant protein bmp-2 and extraction method of recombinant protein in dimeric form
KR101767860B1 (en) * 2010-08-20 2017-08-14 와이어쓰 엘엘씨 Designer osteogenic proteins
WO2019246013A1 (en) * 2018-06-22 2019-12-26 The Children's Hospital Of Philadelphia Peptides to enhance bone growth, repair and cell function

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1677735T3 (en) 2003-10-17 2014-10-27 Joslin Diabetes Center Inc METHODS AND COMPOSITIONS FOR MODULATING ADIPOCYTE FUNCTION
WO2006012627A2 (en) 2004-07-23 2006-02-02 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US20100150885A1 (en) 2005-06-01 2010-06-17 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US20080199443A1 (en) * 2005-06-09 2008-08-21 The Govt. Of The U.S.A. As Represented By The Secretary, Dept. Of Health And Human Services Bone Morphogenetic Variants, Compositions and Methods of Treatment
JP2009515529A (en) * 2005-11-14 2009-04-16 メリアル リミテッド Gene therapy for renal failure
AU2015201033B2 (en) * 2005-11-23 2017-03-16 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
AU2012238197B2 (en) * 2005-11-23 2014-12-04 Acceleron Pharma Inc. Activin-ActRIIa antagonists and uses for promoting bone growth
JP5261187B2 (en) 2005-11-23 2013-08-14 アクセルロン ファーマ， インコーポレイテッド Activin-ActRIIa antagonist and use for promoting bone growth
JP5100662B2 (en) * 2005-12-22 2012-12-19 セントカー・インコーポレーテツド BMP-7 variant compositions, methods and uses
US7659250B2 (en) 2005-12-22 2010-02-09 Centocor, Inc. BMP-7 variant compositions, methods and uses
EP2056852A4 (en) * 2006-07-27 2010-01-13 Centocor Ortho Biotech Inc Bmp-7 variant compositions, methods and uses
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EA035911B1 (en) 2006-12-18 2020-08-31 Акселерон Фарма Инк. Use of polypeptide that inhibits activin-mediated signaling pathway as medicament
TWI480048B (en) 2007-02-01 2015-04-11 Acceleron Pharma Inc Activin-actriia antagonists and uses for treating or preventing breast cancer
TWI548647B (en) 2007-02-02 2016-09-11 艾瑟勒朗法瑪公司 Variants derived from actriib and uses therefor
CN104548056B (en) 2007-02-09 2022-09-09 阿塞勒隆制药公司 activin-ACTRIIA antagonists and uses for promoting bone growth in cancer patients
CN107412734A (en) 2007-09-18 2017-12-01 阿塞勒隆制药公司 Activin A CTRIIA antagonists and the purposes for reducing or suppressing FSH secretions
CA2708549C (en) * 2007-12-21 2014-04-01 Stryker Corporation Bmp mutants with decreased susceptibility to noggin
CA2725208A1 (en) * 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
PT3494986T (en) 2008-08-14 2020-07-14 Acceleron Pharma Inc Gdf traps for use to treat anemia
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
CA2749544A1 (en) 2009-01-13 2010-07-22 Acceleron Pharma Inc. Methods for increasing adiponectin
BRPI1010019B1 (en) * 2009-05-01 2019-02-05 Promega Corp modified luciferase polypeptide, vector and kit comprising the same
EP2440576A4 (en) 2009-06-08 2013-11-20 Acceleron Pharma Inc Methods for increasing thermogenic adipocytes
KR20120028358A (en) 2009-06-12 2012-03-22 악셀레론 파마 인코포레이티드 Truncated actriib-fc fusion proteins
EP2501400B1 (en) 2009-11-17 2017-11-01 Acceleron Pharma, Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
WO2011109245A1 (en) * 2010-03-03 2011-09-09 Wyatt Technology Corporation Method of characterizing interactions and screening for effectors
AU2011326586A1 (en) 2010-11-08 2013-05-30 Acceleron Pharma, Inc. ActRIIA binding agents and uses thereof
CN103649115B (en) * 2011-06-10 2016-01-20 诺沃—诺迪斯克有限公司 Polypeptide
WO2014071158A1 (en) 2012-11-02 2014-05-08 Celgene Corporation Activin-actrii antagonists and uses for treating bone and other disorders
EP2784083A1 (en) * 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
EP3154566B1 (en) 2014-06-13 2022-08-03 Acceleron Pharma Inc. Actrii antagonist for the treatment or prevention of a cutaneous ulcer in a subject that has anemia
MA41052A (en) 2014-10-09 2017-08-15 Celgene Corp TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS
PT3227675T (en) 2014-12-03 2023-05-30 Celgene Corp Activin-actrii antagonists and uses for treating anemia
JP2016204292A (en) * 2015-04-21 2016-12-08 国立大学法人 熊本大学 Bmp7 mutant-albumin cointegrate, and renal disease therapeutic agent containing the same
LT3288379T (en) 2015-05-01 2022-02-25 Onl Therapeutics, Inc. Peptide compositions and methods of use
AU2018258100B2 (en) 2017-04-27 2022-04-14 Eli Lilly And Company Variants of human BMP7 protein

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6949505B1 (en) * 1991-03-11 2005-09-27 Curis, Inc. Morphogen-induced dendritic growth
EP0661987B1 (en) * 1992-09-16 1998-01-14 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
US6273598B1 (en) * 1996-01-22 2001-08-14 Creative Biomolecules, Inc. Computer system and methods for producing morphogen analogs of human OP-1
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US6677432B1 (en) * 1998-10-07 2004-01-13 Stryker Corporation Mutations of the C-terminal portion of TGF-β superfamily proteins
CA2349038C (en) * 1998-11-13 2011-08-02 Curis, Inc. Methods of alleviating cancer symptoms

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070056050A1 (en) * 2005-06-29 2007-03-08 Clokie Cameron M L PRODUCTION OF BONE MORPHOGENIC PROTEINS (BMPs) IN TRANSGENIC MAMMALS
WO2008082563A2 (en) 2006-12-21 2008-07-10 Stryker Corporation Sustained-release formulations comprising crystals, macromolecular gels, and particulate suspensions of biologic agents
US20100087625A1 (en) * 2007-05-25 2010-04-08 Peel Sean A F Method of enhancing recombinant protein production
US8329429B2 (en) 2007-05-25 2012-12-11 Induce Biologics Inc. Method of enhancing recombinant protein production
US20090087472A1 (en) * 2007-06-25 2009-04-02 Murphy William L Controlled release of biopharmaceutical growth factors from hydroxyapatite coating on bioresorbable interference screws used in cruciate ligament reconstruction surgery
US8075562B2 (en) 2007-06-25 2011-12-13 Wisconsin Alumni Research Foundation Controlled release of biopharmaceutical growth factors from hydroxyapatite coating on bioresorbable interference screws used in cruciate ligament reconstruction surgery
US20110182911A1 (en) * 2008-07-03 2011-07-28 Induce Biologics Inc. Use of immobilized antagonists for enhancing growth factor containing bioimplant effectiveness
WO2010093941A2 (en) 2009-02-12 2010-08-19 Stryker Corporation COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS
WO2010093925A2 (en) 2009-02-12 2010-08-19 Stryker Corporation PERIPHERAL ADMINISTRATION OF PROTEINS INCLUDING TGF-β SUPERFAMILY MEMBERS FOR TREATMENT OF SYSTEMIC DISORDERS AND DISEASE
WO2010110974A1 (en) 2009-03-24 2010-09-30 Stryker Corporation Methods and compositions for tissue engineering
WO2011031856A1 (en) 2009-09-09 2011-03-17 Stryker Corporation Bmp -7 for use in treating pain induced by injuries and diseases of an articular joint
WO2011035094A1 (en) 2009-09-17 2011-03-24 Stryker Corporation Buffers for controlling the ph of bone morphogenetic proteins
WO2011087768A1 (en) 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
US20130190236A1 (en) * 2009-12-22 2013-07-25 Stryker Corporation BMP-7 Variants with Reduced Immunogenicity
KR101767860B1 (en) * 2010-08-20 2017-08-14 와이어쓰 엘엘씨 Designer osteogenic proteins
KR101800596B1 (en) 2010-08-20 2017-11-22 와이어쓰 엘엘씨 Designer osteogenic proteins
RU2499048C1 (en) * 2012-09-24 2013-11-20 Российская Федерация, от имени которой выступает Министерство промышленности и торговли Российской Федерации (Минпромторг России) Recombinant plasmid, recombinant strain, recombinant protein bmp-2 and extraction method of recombinant protein in dimeric form
WO2019246013A1 (en) * 2018-06-22 2019-12-26 The Children's Hospital Of Philadelphia Peptides to enhance bone growth, repair and cell function

Also Published As

Publication number Publication date
WO2005097825A3 (en) 2006-02-16
WO2005097825A2 (en) 2005-10-20
US7459527B2 (en) 2008-12-02
US20060058231A1 (en) 2006-03-16
US20080070837A1 (en) 2008-03-20
CA2561809A1 (en) 2005-10-20
EP1730186A2 (en) 2006-12-13
AU2005230854A1 (en) 2005-10-20
JP2008500816A (en) 2008-01-17

Similar Documents

Publication Publication Date Title
US7459527B2 (en) BMP-7 variants with improved properties
KR101558642B1 (en) Designer ligands of tgf-beta superfamily
US20090042780A1 (en) Modified TGF-Beta Superfamily Polypeptides and Related Methods
JP5529754B2 (en) BMP variant with reduced sensitivity to Noggin
EP3320913B1 (en) Designer osteogenic proteins
JP2006508049A (en) Peptides as solubilizing excipients for transforming growth factor beta protein
KR20190085132A (en) Compound for improving muscle performance
WO2008051526A9 (en) Bone morphogenetic proteins
US11512126B2 (en) AB6 family designer ligands of TGF-β superfamily
US11008373B2 (en) Designer osteogenic proteins
US20230050038A1 (en) Pdgf mutants and methods of use thereof
US20190135885A1 (en) Composition comprising an ab6 family designer ligand of tgf-beta superfamily for treating liver disease and use thereof
KR20190005240A (en) Compositions for Treating Bone and Cartilage Diseases Containing AB6 Family Designer Ligands of the TGF-Beta Super Family and Use Thereof

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION